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 i 
Abstract 
The proximicins are a family of three compounds – A-C – produced by two marine Actinomycete 
Verrucosispora strains – V. maris AB18-032 and V. sp. str. 37 - and are characterised by the 
presence of 2,4-disubstituted furan rings. Proximicins demonstrate cell-arresting and 
antimicrobial ability, making them interesting leads for clinical drug development. Proximicin 
research has been largely overshadowed by other Verrucosispora strain secondary metabolites 
(SM), and despite the publication of the V. maris AB18-032 draft, the enzymatic machinery 
responsible for their production has not been established. It has been noted in related research 
into a pyrrole-containing homolog – congocidine –due to the structural similarity exhibited, 
proximicins likely utilise a similar biosynthetic route.   
 
The initial aim of this research was to confirm the presumed pathway to proximicin biosynthesis. 
Following the sequencing, assembly and annotation of the second proximicin producer, 
Verrucosispora sp. str. MG37, and genome mining of V. maris AB18-032, no common clusters 
mimicked that of congocidine, casting doubt on the previously assumed analogous biosynthetic 
routes. A putative proximicin biosynthesis (ppb) cluster was identified, containing non-ribosomal 
peptide synthetase (NRPS) enzymes, exhibiting some homology with congocidine. NRPS-
systems represent a network of interacting proteins, which act as a SM assembly line: crucially, 
adenylation (A)- domain enzymes act as the ‘gate-keeper’, determining which precursors are 
included into the elongating peptide. To elucidate the route to proximicins, activity 
characterisation of the four A-domains present in ppb cluster was attempted. The A-domain 
Ppb120 was shown to possess novel activity, demonstrating a high promiscuity towards 
heterocycle containing precursors, in addition to the absence of an apparent essential domain. 
This discovery refutes previous work outlining the core residues which dictate A-domain activity, 
while also presenting a facile route to novel heterocycle-containing compounds. Despite 
extensive work, A-domains ppb195 and ppb210, were ineffectively purified in the active form – 
informing future work into A-domains activity characterisation. Finally, the ppb220 A-domain 
which lies at the border of ppb, was inactive suggesting over-estimation of the cluster margins. 
To confirm ppb220 redundancy and confirm ppb boundaries, CRISPR/Cas gene editing studies 
were done. The gene responsible for the orange pigment of Verrucosispora strains was initially 
targeted and successfully deleted, and ppb studies commenced.  
 
The research here refutes the previously presumed route to proximicin biosynthesis; the ppb 
cluster instead comprises enzymes exhibiting unique activity and structure. The findings 
represent the foundations for allowing exploitation of chemistry exhibited within the proximicin 
family. The novelty exhibited can be utilised in the search for antimicrobial clinical leads, by 
allowing the production of compounds containing previously inaccessible heterocycle chemistry.  
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Chapter 1. Introduction to Research  
 
1.1 Introduction  
                                                                                                                               
The unprecedented, large scale emergence of antimicrobial resistance, and 
depletion of antimicrobial leads, means we currently balance on the precipice of the 
post-antibiotic era (Willyard, 2017). The appearance of multi-drug resistant microbes 
continues to increase at an alarming rate, yet world-wide prevention programs 
continue to be of low-priority (WHO, 2017); thus, it is vital that we are united in this 
war. It has been demonstrated that some of the most effective antibiotics are those 
identified from microorganisms themselves; exploiting the millennia of evolution 
driven by microbe-on-microbe warfare. In the recent decades, misdirected efforts 
preoccupied with financial initiatives has led to a complete lack of novel antibiotic 
identification (Tegos et al., 2012). I propose that if we are to stall this impending 
catastrophe, we return to the previously fruitful pursuit of antibiotics of microbial 
origin, utilizing cheaply available scientific advances to result in a financially 
attractive research avenue, to propel the identification of a whole collection of novel 
antibiotic compounds.  
 
1.2 A Brief History of Drug Discovery  
 
The discovery and wide scale exploitation of antimicrobial compounds has been the 
singular most influential medicinal discovery of the twentieth century; revolutionizing 
healthcare, allowing treatment of infections that were once largely fatal and 
safeguarding procedures once unthinkable. The development of penicillin 
represented a tide-change in how life threatening infections were treated; due to the 
subsequent synthesis of other microbial agents, vaccines and antiseptics, victory 
against pathogens was declared (Sigerist, 1971). Convinced the arsenal of 
antimicrobial agents was well stocked, by the 1980’s research emphasis was poised 
to shift to other clinically relevant problems such as cancer, diabetes and heart 
disease, effectively closing the book on infectious diseases. However, after the 
introduction in the early 1940’s of the proclaimed ‘miracle drug’, penicillin-resistant 
Staphylococcus spp. were widespread by 1944 (Livermore, 2004). This was followed 
 2
by progressive ineffectiveness exhibited by every compound deployed in the fight 
against infectious disease; pathogenic microorganisms demonstrate a defiantly 
impressive ability to adapt and develop resistance. The optimistic mindset towards 
microbial control turned to skepticism as the chain of outbreaks and epidemics of 
new, re-emerging and resistant infections continued to appear. Giving rise to the 
term ‘super bugs’, these organisms dominated the scientific literature, commanding 
the attention of academics, governments, public health officials and the general 
public, alike. Focus shifted to quickly identifying new compounds to circumvent the 
requirement of those obsolete; the ‘Golden Era’ of antibiotic drug discovery ensued. 
The Golden Age of antimicrobial drug discovery was characterized by large scale 
screening of fermentation broths and extracts from microorganisms, with the aim of 
simply inhibiting the growth of bacterial organisms of interest, with little regard for 
the mechanism by which it exerts this action. This worked efficiently for a period, 
resulting in the discovery of the most common natural product antimicrobials (Fig. 
1); however, issues ensued regarding high rediscovery rates and in the 1960s 
methods of de-replication were developed. Traditional screening methods were 
modified to limit hits to detect inhibitors of a specific pathway, this lay the basis of 
what we consider today as target based screening. These focused pathway-
screens, resulted in the discovery of clinically useful classes such as carbapenems 
and fosfomycin, shown to target the bacterial cell wall (Silver, 2012). It was 
suggested towards the late 1970’s that all the low hanging fruit had been picked 
(Silver, 2012), and efforts were directed to increasingly intelligent screening designs, 
utilizing the growing ability to clone genes and manipulate bacterial strains, 
converting previously rudimentary approaches to enzyme specific target-directed 
screens (Kraus, 2008). As a result, a bottle neck toward chemical novelty began to 
form. Interest was awarded to compounds with identifiable targets with established 
amenability to downstream biochemical and physical analysis; this meant the 
perceived attractiveness of compounds with novel cellular targets was small, and 
they were hence given low priority. The diversity of natural compounds was limited 
further with steps being taken away from expensive crude microbial fermentation 
studies, with focus shifting to screening large libraries of compounds, especially 
those of combinatorial chemical origin (Demain, 1999; Kingston & Newman 2002). 
This concept of synthetically tailoring a small group of scaffolds to yield 
 3 
antimicrobials without resistance, as a drug discovery approach, was largely 
fruitless. However, the emergence of resistance and the propulsion of research 
specifically aimed at its avoidance only extended the futile implementation of this 
approach. Specific cellular targets would be selected by the relative ease a microbe 
could develop the ability to circumvent its necessity, and then large scale high 
throughput screens would be employed to find compounds which specifically inhibit 
this target. Much of the chemical diversity tested were of synthetic origin, groups of 
modified molecules with the aim of increasing target selectivity, potency and lesser 
off-target effect. This success of this approach was limited and marked the 
beginning of what is considered ‘the discovery void’ (Fig. 1) (Fischbach & Walsh, 
2009), which is typically greatly understated; some of the most recently registered 
representatives of novel drug classes were first reported in the latter half of the 
twentieth century but disregarded as poor leads, hence, to consider these as recent 
novelties, is tenuous at best (Silver, 2009). Despite creative, rational and 
technologically cutting edge screening approaches, innovation has failed to result in 
sufficient biologically active compounds. The current situation has been only 
exacerbated by the resilience of microbes, quickly acquiring resistance to the few 
compounds remaining in our repertoire; the full extent this threat poses to the 
societies of today is being modestly related to the mases, the crisis point looming 
being fundamentally dismissed (WHO, 2017). 
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1.3 Drug Resistance: the emerging threat  
It is estimated in the United Kingdom in the year of 2017, more people will die as a 
result of microbial infection causing sepsis, than the two leading cancers combined 
(Antibiotic Research UK, 2017). And yet, as cancer research continues to steadily 
decrease mortality associated with the disease, drug discovery pipelines remain 
eerily empty. When identifying emerging threats to public health, four main classes 
are typically highlighted (Tegos et al., 2012; WHO,2017):  
1. Methicillin resistant Staphylococcus aureus (MRSA) 
2. Multi-drug resistant (MDR) Gram-negative bacteria 
3. MDR and extensively drug-resistant Mycobacterium tuberculosis (TB) 
4. Candida species  
The major four classes are such as they result in the most deaths annually, due to 
typically affecting people with already compromised health, including the young, 
old, malnourished and immune-comprised (Tegos et al., 2012). The exact extent of 
mortality contributed to all resistant pathogens is undisclosed, Fig. 2 shows the 
numbers for 2015 combined from various sources reporting on singular infections. 
Each group is associated with specific characteristics facilitating their persistent 
pathogenicity, a niche they occupy in which they thrive; hindering their successful 
eradication. MRSA represents the only resistance level which has been steadily 
declining since the 1980’s, however, it remains such a threat as it increases the 
likelihood of vancomycin resistant S. aureus, increasing the difficulty associated with 
treating the infection (Chavers et al., 2003; Nordmann et al., 2007). Alternatively, the 
opportunistic health-care associated infections typical of resistant Gram-Negative 
bacteria are less prevalent, but are truly untreatable (McGowan, 2006; Dijkshoorn et 
al., 2007; Nordmann et al., 2007; Baldry, 2010; McKenna, 2011). These organisms 
have evolved the ability to modify the cellular targets of Gram-Negative specific 
antibiotics, intensified by the intrinsic difficulty associated with developing novel 
compounds to treat these pathogens attributed to their outer membrane preventing 
hydrophilic compound entry (Lee et al., 2000). Multi-Drug Resistant Mycobacterium 
tuberculosis (MDR-TB) poses an enormous threat to developing countries where 
healthcare access is low, as infections requires extensive treatment which is 
typically not administered leading to the associated high fatality rate (Dye, 2009; 
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Jassal & Bishai, 2009). Finally, resistant fungal infections are responsible for the 
most deaths associated of any catheter-related infection with the incredibility high 
mortality rates of ~15-49% (Crump & Collignon, 2000; Gudlaugsson et al., 2003). 
Each of these clinically prevalent pathogens pose the possibility of drastically 
increasing the risk associated with everyday procedures, such as hip replacements 
and appendectomies, or making them completely impossible, hurling our healthcare 
into an era distressingly similar to that before wide scale utilization of antimicrobials.  
These four groups stand as a conservative estimate of the groups which pose a 
major threat; a total of 18 were outlined by the US government, in a 2013 report with 
at least the hazard level: serious, requiring ‘prompt and sustained action’ (CDC, 
2017). It is becoming increasingly apparent that these infections are not only 
concerning the old, young or already unwell, resistant pathogen are spreading too 
amongst the healthy; one recently publicized example being MDR Nesisseria 
gonorrhoeae. It is responsible for the second most reported infection across 
developed countries, with current reports suggesting that as much as 30% of cases 
are due to pathogens resistant to typical treatment approaches (CDC, 2017). It is 
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Figure 2. Increasing prevalence of common antibiotic-resistant pathogens. A graph 
of combined data (WHO, 2017; McGowan, 2006; Dijkshoorn et al., 2007; Nordmann et 
al., 2007; Baldry, 2010; McKenna, 2011). All but MRSA is steadily increasing. VRE = 
Vancomycin resistant Enterococci; MRSA = Methicillin resistant S. aureus; TB = 
Resistant Mycobacterium tuberculosis; CRE = Carbapenem-resistant 
Enterobacteriaceae; ESBL = Extended spectrum beta-lactamases incidence; Salmonella 
NT = Non-typhoidal; Salmonella ST = Sequence Type 
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hence not difficult to imagine a time in the immediate future when it will be 
completely untreatable, as such, N. gonorrhoeae has been identified as a global 
health threat with intensive programs being put in place, poised to address the 
heavy burden resistant infections will exert on healthcare worldwide (CDC, 2017). 
Despite the evident threat these pathogenic microbes pose, along with the 
enormous costs associated with their treatment, they have garnered little re-
direction of funds from other research areas; a situation which must be resolved.   
The World Health Organization has recently proposed a multifaceted approach of 
resolution, summarized as (i) novel compound discovery, and (ii) curtailing 
resistance occurrence (Willyard, 2017). The latter has been extensively studied since 
its first report in the first half of the twentieth century. Put simply, drug resistance is 
the natural evolution of pathogens in response to a large selection pressure being 
Figure 3. Cellular targets of antibiotics and mechanisms utilised by pathogens for 
resistance. Antibiotics work by attacking an essential cellular target or process within a 
pathogenic microorganism, such as DNA synthesis or the cell membrane. Microbes 
evolve ways to circumvent their effect, primarily through excreting the antibiotic through 
efflux pumps, but other ways such as modifying the target so that the antibiotic can 
longer take effect on it, also exist.  
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exerted, exacerbated by the vast scale implementation, and irresponsible use, of 
antibiotics. How it arises can be typically categorized into either endogenously in the 
pathogen by mutation or selection, or exogenously, driven by horizontal gene 
transmission (HGT) (Bryan, 1989; D’Costa et al., 2006; Martinez et al., 2007). Just as 
the potential chemical scaffolds for antibiotics seems endless, so does the collective 
genomic repertoire of possible mechanisms within microbes to render them 
obsolete. This ability is often termed the antibiotic ‘resistome’ (D’Costa et al., 2006), 
and consists of mechanisms outlined in Fig. 3; regardless of cellular target, chemical 
modification or breakdown of antibiotics, target protection, efflux, or specific 
changes of the cellular target can prevent their activity (Woodford & Ellington, 2007) 
(Fig. 3). Crucially, the evolutionary event leading to endogenous resistance 
mechanism only need occur once, in a singular strain and it can then be propelled 
by HGT to any other bacterial strain. It is hence no surprise that exogenous 
resistance is responsible for some of the most clinically important resistance, 
inconspicuous strains act as reservoirs of resistance genes, acquired over years of 
challenges from other microbes (Courvalin, 2008; D’Costa et al., 2007; Martinez, 
2009). The prompt appearance of MDR microbes, evolving an array of efficient 
resistance mechanisms, demonstrates that the prospects for long term avoidance of 
resistance is poor and hence, the need for the large scale discovery of novel 
chemistry antimicrobials has never been greater. In this current predicament, all 
recent advances in scientific capability need to be redirected and repurposed with 
this aim, yielding not only novel compounds, but the refinement of discovery 
pipelines for optimal exploitation.  
1.4 Current Discovery Strategies: an evolving necessity  
 
The onset of the genomic era and the impending gene editing revolution may signify 
an end to the discovery hiatus, by accelerating the identification of novel 
compounds from microorganisms. Microbes possess an unparalleled ability to 
produce a wealth of structurally diverse metabolites which maintain a range of 
biological activity lending themselves to a wide variety of applications, crucially, in 
the treatment of infectious disease (Fowler et al., 2006; Demain & Sanchez, 2009; 
Louie et al., 2011). Compounds of microbial origin, and their semisynthetic 
derivatives, provide the basis for much of the healthcare of today, and contain 
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chemical scaffolds far more complex than combinatorial approaches could feasibly 
yield (Demain & Sanchez, 2009). Hence, it is no surprise that recent research has 
returned to microorganisms for help tackling the current resistance crisis. This has 
been propelled by the onset of the genomic era over the last decade, resulting in the 
wide scale implementation of sequencing technologies; in doing this, one fact 
became increasingly apparent: microorganisms have far greater potential to 
produce specialized metabolites, than what was revealed by traditional bioactive 
screens (Omura et al., 2001; Bentley et al., 2002; Backhage et al., 2011). Whole 
genome sequencing (WGS) and improved bioinformatical abilities has led to the 
discovery of many silent or cryptic biosynthetic gene clusters, the products of 
which, were never realized during prior screens. Demonstrating the extent of this, 
the soil bacterium Streptomyces coelicolor A3(2), an organism which has been 
extensively studied for more than five decades and regarded as a model antibiotic 
producing Actinobacteria, was shown to contain the biosynthetic gene clusters 
(BGCs) for 22 distinct specialized metabolites compared to the previously identified 
6 (Challis, 2011). This was a trend not limited to the actinobacteria but also genomes 
of fungi such as Aspergillus, and Gram-Negative bacteria Pseudomonas and 
Clostridium, which were also demonstrated to be promising reservoirs of novel 
secondary metabolite gene clusters (SMC’s) (Keller et al., 2005; Donadio et al., 
2007; Letzel et al., 2013; Wilson et al., 2014). This has stimulated the development 
of a range of experimental pipelines for identifying these clusters (Fig. 4), and 
predicting their products, giving rise to the new field of genomic-driven natural 
product discovery.  
It is tempting to envision a time in which next generation sequencing (NGS)-based 
approaches would allow the identification of the full complement of putative SMC’s 
within the DNA of any given microorganism. The genomic revolution, leading to the 
full comprehension of what microbes have to offer, has started a renaissance in 
antibiotic identification (Zerikly & Challis, 2009; Weber et al., 2015). When novel 
product discovery began to dwindle towards the end of the 20th century, so did 
interest in the industry; big pharma redirected funds to areas of research more 
financially fruitful. This desertion of drug discovery is further exacerbated by the 
unattractive long term prospects of any identified novel drugs; they are only used  
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short term, unlike some of the cancer and HIV drugs and importantly, in the aim to 
avoid resistance they are not used in such high quantities, primarily as a last resort. 
This makes the prospect of large scale financial investment less than alluring, and so 
steps are required to lower the financial burden associated with novel compound 
generation. The advent, and continual refinement, of next generation sequencing 
approaches offers an unparalleled potential resolution; they possess the ability to 
rapidly and cheaply identify multiple potentially profitable gene clusters and lend 
themselves to high throughput approaches (Metzker, 2010; Gomez-Escribano et al., 
2012; Izawa et al., 2013; Schorn et al., 2013). Unlike costs and efforts associated 
with whole genome sequencing (WGS) at its conception, drastic improvements have 
greatly accelerated the rate and reduced cost of genomic acquisition, making it 
commonplace for draft genomes of organisms of interest to be generated and 
utilized as an investigative tool (Medema et al., 2011; Blin et al., 2013; Blin et al., 
2014). The result is that the SMCs, and large-scale production, of novel compounds 
can be done in a matter of weeks with relatively low associated costs. This has 
resulted in well-established frameworks for novel compound exploration utilizing 
genome mining approaches (Fig. 4). Bioinformatical programs, despite lagging 
behind NGS technologies which continue to surge ahead, possess the ability to 
identify common biosynthetic cluster types present in bacteria which may contain 
novel compound chemistry, and hence, potential antimicrobial leads. One area of 
particular interest, owed to their highly conserved domain structure permitting easy 
identification and exploitation, are compounds produced via non-ribosomal peptide 
synthases; these systems are responsible for the biosynthesis of clinically important 
compounds such as daptomycin, and NGS has allowed the unveiling of the true 
breadth and potential these systems encompass (Felnagle et al., 2008).  
 
Figure 4. Typical pipeline for genome mining approaches to novel compound 
discovery. Research into identifying novel biologically active compounds via genome 
mining typically occurs in the four steps outlined resulting in the discovery of not only 
novel compounds but also their pathways which aids large scale production.  
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1.5 Importance of Non-Ribosomal Peptide Synthetase Enzymes  
 
Non-ribosomal peptide synthesis represents a complex ribosomal-independent 
mechanism utilised by microorganisms to produce a large array of chemically and 
structurally diverse and clinically important secondary metabolites. They represent a 
network of interacting proteins, which act as an enzymatic assembly line: accepting 
precursor molecules, catalysing peptide bond formation before shuttling 
intermediates down the Non-Ribosomal Peptide Synthases (NRPS) system for the 
next addition. The ability NRPS systems possess to introduce novel chemistry, in a 
highly predictable and exploitable manner, dictated by their characteristic domain 
arrangements, make them an alluring target for novel antibiotic compound 
discovery. 
 
Non-ribosomal peptide synthetase (NRPS) systems are not a recent discovery; 
Alexander Fleming’s detection of penicillin in the late 1920’s unwittingly initiated the 
scrutiny of these large enzyme complexes. Non-ribosomal peptides (NRPs) 
comprise a group of some of our most important antibacterial, antifungal and 
anticancer drugs, ensuring their continual garnering of significant interest in areas of 
drug development. Research has been steadily building on these complex systems 
for decades; commencing with Mach et al., (1963) in the demonstration that a 
mechanism independent of the ribosome was responsible for biosynthesis of the 
cyclic decapeptide, tyrocidine. This work was further confirmed by investigation into 
gramicidin S and ediene, showing that addition of ribosome inhibitors or RNase 
enzymes did not abolish their production (Berg et al., 1965; Yukioka et al., 1965; 
Fujikawa et a., 1966; Borowska et al., 1966; Spaeren et al., 1967; Tomino et al., 
1967). As the ability to manipulate DNA progressed, so did the insight into these 
systems. Gevers et al., (1968) executed an array of elegant experiments, culminating 
in the exposure of mechanisms responsible; initially utilising partially purified 
enzymes known to be involved in gramicidin biosynthesis, it was revealed that the 
ATP-dependent reaction catalysed, occurs in two steps. The first step involves the 
release of PPi and the second, the release of AMP, resulting in an amino acid being 
covalently tethered to the NRPS machinery (Gevers et al., 1968; Kleinkauf et al., 
1969). This evidence established the presence of an amino acid ‘carrier’, furthered 
by the finding that it occurs as a progressive synthesis of enzyme-linked peptides, 
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one amino acid added at a time (Froshov et al., 1970; Lipmann et al., 1970). Analysis 
of the chemical stability of the covalent linkages present, suggested a thioester 
bond between the NRPS enzyme and amino acid (Gevers et al., 1969).  This work 
was propelled by that being done simultaneously on fatty acid biosynthesis, in 
which it was established that intermediates were thioesterfied to a 4’-
phosphopantetheinyl (4’-Ppant) cofactor (Bremer, 1968). Once confirmed the 
involvement of 4’-PPant (Gilhuus-Moe et al., 1970; Kleinkauf et al., 1970; Lee et al., 
1973), it was initially hypothesised that this was done on a single molecule of 4’-
Ppant through a series of thiol exchange reactions. This research led to the initial 
‘thiotemplate mechanism’ for NRPS enzymology, proposed by various groups 
concurrently (Lipmann et al., 1971; Laland & Zimmer, 1973; Kurahashi, 1974); this 
system was modified slightly, with the advent of NGS, which revealed that each 
module of catalytic domains involved the activation of an amino acid, contained its 
own 4’-Ppant cofactor (Felnagle et al., 1998). This subtle revision led to the ‘multiple 
carrier model’ we use today (Schlumbohm et al., 1991; Stein et al., 1994; Stein et al., 
1996); each amino acid is activated as an aminoacyl-AMP intermediate and 
subsequently tethered to their individual 4’-Ppant cofactor as an aminoacylthioester. 
The transthiolation reactions proposed in the initial mechanism, were made 
redundant, as biosynthesis proceeds via head-to-tail condensations of the amino 
acids by transpeptidation reactions. The characteristic modularity of NRPS systems 
was noted very early in the research, with the observation of ~70-75 kDa of protein 
existed per amino acid activated (Lee et al., 1973; Lipmann et al., 1973). It is 
typically noted that there are a single set of enzymatic domains or modules 
associated with each incorporated amino acid. These repeating modules catalyse 
the actions of three core domains: the adenylation, thiolation and condensation 
domains which together comprise a minimal NRPS module. They are typically 
arranged chronologically, dictating the peptide sequence; ending at the C-terminal 
end with a thioesterase domain which catalyses the termination of NRP synthesis, 
marked by the release of the peptide from the enzyme complex. As with any 
naturally occurring scheme, the multiple carrier model does not encompass the 
enzymology utilised in all NRPS systems; for the purpose of clarity, however, it is the 
only one discussed here.  
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The repeating steps, and distinctive domain nature of NRPS systems, conveys a 
simplicity in determining the product they are responsible for producing; by 
understanding the roles of enzymatic machineries present, it allows the route to 
potentially novel compounds to be established and exploited.  
 
1.5.1 Adenylation domain (A-domain) 
Arguably the most important component of the NRPS system, the A-domain acts as 
the ‘gate-keeper’ to peptide elongation, determining the chemistry of the next 
building block added (Haese et al., 1994; Diechmann et al., 1995). They do this by 
catalysing a two-step, ATP dependent reaction which involves the activation of the 
carboxylate group of a specific substrate as an aminoacyl-AMP intermediate and 
subsequent transfer onto the 4’-Ppant arm of the neighbouring thiolation domain 
(Fig. 6a). Raised as early as 1967, Plant et al., (1967) noted the functional similarities 
exhibited by NRPS A-domains, with Acyl-CoA synthetases and firefly luciferases. All 
members of these groups, although catalysing distinct reactions utilise a two-step 
reaction: first activating a carboxylate substrate by reacting with ATP for form the 
acyladenylate and inorganic PPi which provides the energy for the second partial 
reaction which differs depending on subfamily. This diverse group of adenylating 
enzymes has since been termed the ANL superfamily, of which NRPS A-domains 
have recently been classified (Gulick, 2009). 
 
A-domains represent the first level of substrate selectively, and are responsible for 
the huge chemical diversity exhibited by NRPS as they are not limited to 
proteogenic amino acids, but have been shown to have activity towards hundreds of 
substrates (Von Dohren, 1990). Because of this, extensive research efforts have 
been dedicated to understanding how these enzymes elicit this selectivity, with aim 
of modifying and exploiting it for novel compound production (Strieker et al., 2010; 
Thrilway et al., 2012). Traditional work, supported by recent crystal structures of A-
domains, either alone or co-crystallised with a known substrate, has led to some 
fundamental findings. Key residues involved in substrate specificity and catalytic 
activity have been revealed culminating in the bioinformatical ability to establish an 
A-domains substrate pool with the amino acid sequence (Challis et al., 2000; 
Schwarzer et al., 2003; Rausch et al., 2005; Tanovic et al., 2008). The basis of much 
of what we know is built on innovative works done by Marahiel et al., (1997) and 
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Shachelhaus et al., (1999) (Fig. 5a), in which ten core sequence motifs were 
identified (A1-A10) shown to be important for structural, catalytic and substrate 
selectively roles. The latter of these was furthered by the identification of 10 
substrate selectivity conferring motifs, shown to occupy vital positions within the 
substrate binding pocket located between A4 and A5, whose chemistry dictates the 
potential substrate pool (Shachelhaus et al., 1999) (Fig. 5b). This information has 
been supported by numerous gene editing studies in the model A-domain – the 
phenylalanine activating GrsA involved in gramicidin synthesis, to confirm the role of 
each of these domains in which substrate selectively has been relaxed or altered 
entirely (Shachelhaus et al., 1999; Challis et al., 2000). Some of this work is shown in 
Fig. 5c, in which specificity towards phenylalanine of GrsA was altered to allow the 
activation of other precursors by mutating single residues (shown in pink) present 
within the binding pocket defined by Shachelhaus et al., (1999). Further, extensive 
specificity conferring residues mutational studies have shown some residues are 
more resistant to change than others; for example, Asp235 and Lys517 are always 
invariant, and have been shown to stabilise the α-amino acid group and to interact 
with the α-carboxylate, present on the substrate, respectively (Shachelhaus et al., 
1999). Other positions are very tolerant of variation, leading to relaxation or 
complete changes in specificity (Shachelhaus et al., 1999). Garnering information 
regarding the components which determines an A-domains activity is vital in the 
continual expansion of the pool of potential compounds, possessing biological 
activity, which can be produced. Understanding the mechanism for catalytic activity 
exhibited by adenylation domains has permitted the development of many 
bioinformatical tools which identify substrates by the residues which line the binding 
pocket (Medema et al., 2011; Rottig et al., 2011). These applications allow the 
identification of potentially novel BGCs, propelling the detection of novel 
compounds for medicinal exploitation. 
 
 
 
 
 
 
 
 15 
 
Figure 5. Important Adenylation domain active site residues, and research into 
their manipulation. (a) A typical NRPS-adenylating domain contains 10 well conserved 
motifs outlined by Marahiel et al., (1997) demonstrated to be important in structure 
(pink), catalytic (grey) activity and substrate selection (blue); located between domain A4 
and A5 sits the active site of the A-domain which is responsible for substrate binding. 
Shachelhaus et al., (1999) outlines these 9 core specificity conferring residues shown in 
yellow. (b) the GrsA adenylation domain binding pocket with the phenylalanine 
substrate present outlined by Shachelhaus et al., (1999). Different shade of yellow 
denotes the chemical nature of the largest proportion of residues noted at this position: 
White – Basic amino acids; light yellow: hydrophobic; medium yellow: acidic and dark 
yellow: hydrophobic/polar. (c) the mutations to single amino acids known to sit within 
the GrsA binding pocket, and the alteration from phenylalanine substrate selectivity to 
other substrates located to the side of the mutated binding pocket, outlined by 
Shachelhaus et al., (1999). Binding pockets shown in the style of Challis et al., (2000).  
(a) 
(b) 
(c) 
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1.5.2 Thiolation domain (T-domain) 
T-domains, sometimes referred to as PCP domains, work in conjunction with A-
domains once the aminoacyl-AMP intermediate has been formed (Fig. 6b). T-
domains and acyl carrier proteins (ACP) involved in fatty acid and polyketide 
biosynthesis belong to the same superfamily, and share a conserved four-helix 
bundle structure Weber et al., 2000; Samel et al., 2007). Similar to ACPs, T-domains 
are required to be post-translationally modified with the addition of a 4’-Ppant group 
on a conserved seryl residue located at the centre of the T-domain by a 4’-Ppant 
transferase; this results in the change into its holo-form, and activation of the T-
domain (Quadri et al., 1998). The T-domain has been shown to be the location of the 
aminoacylthioester formation noted by initial researchers in the early 1970’s 
(Lipmann et al., 1971; Laland & Zimmer, 1973; Kurahashi, 1974), as the newly 
acquired 4’-Ppant arm attacks the carboxyl group of the aminoacyl-AMP 
intermediate yielding the aminoacylthioester (fig. 6b) 
 
T-domains play a central role in NRP synthesis, as they are responsible for a variety 
of reactions with many partners, which must be conducted in an exquisitely timed 
sequence. Understanding how T-domain enzymes achieved this was the focus of 
much research (Koglin et al., 2006), and it was determined that they can maintain 
three different conformations and transitioning between these requires significant 
repositioning of the 4’-Ppant arm; this gave the first detailed evidence of the 4’-
Ppant ‘swinging arm’ motion required for shuttling peptide intermediates down the 
NRPS assembly line and established a structural basis for the differential 
interactions exhibited.  
 
1.5.3 Condensation domain (C-domain) 
As the name suggests, C-domains are responsible for a condensation reaction, and 
are typically situated between consecutive pairs of A and T domains – precisely 
positioned for catalysing peptide bond formation between two tethered substrates. 
This results in the linkage of the upstream and downstream building blocks which 
surround them. The currently accepted model of C-domain activity suggests they 
possess two distinct substrate binding sites: one binding the preceding and the 
other, the proceeding amino acid, denoted the accepter and donor site, respectively 
(Fig. 6c). As there are only two crystal structures solved of C-domains (Keating et al., 
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2002; Samel et al., 2007), neither with the substrate bound, the mechanism of 
substrate recognition remains elusive; however, it has been determined that, 
similarly to A-domains, they contain a core motif (HHxxxxDG) that is essential for 
catalysis (Stachelhaus et al., 1998; Keating et al., 2002). The mechanism they utilise 
is thought to be similar to that of ribosome-catalysed peptide bond formation, in 
which ionic interactions stabilise catalytic intermediates, as opposed to acid-base 
catalysis as previously thought (Bieling et al., 2006; Samel et al., 2007).  
 
1.5.4 Thioesterase Domains (Te domain)  
The Te-domain works to release the now fully synthetized tethered peptide, and 
hence, is typically located as part of the final C-domain. This enzyme can catalyse 
either (i) the hydrolysis of the peptide (Fig. 6d (a)), or (ii) intramolecular cyclization 
either by amide or ester bond formation (Fig. 6d (b)), both of which result in the 
release of the peptide from the assembly line. They do this by catalysing the 
formation of an ester-linked intermediate the terminal carboxyl group located on the 
peptide with a conserved seryl residue within the Te domain, resulting in the 
cleavage of the peptide from the final 4’-Ppant arm. Te domains represent another 
barrier of substrate specificity as it has been shown that selectivity is limited to the 
NRP residues which bind at or near the site of the conserved seryl residue. Further, 
domains which catalyse cyclisation reactions have a larger substrate pool, with 
some selectively being based on the size of the resultant cyclic peptide and the 
secondary structure it forms. (Trauger et al., 2000; Trauger et al., 2001; Kohli et al., 
2002; Tseng et al., 2002). As with A-domains, the specificity conferring nature and 
the ability to induce increased substrate flexibility has been investigated, generating 
cyclic peptide libraries resulting in novel derivatives of daptomycin and cryptophycin 
(Kohli et al., 2002; Beck et al., 2005; Kopp et al., 2006).  
 
In addition to these core domains comprising the minimal requirement for NRPS 
activity, other strategically embedded auxiliary domains can be present, serving to 
further increase the structural diversity and functional groups present. Normally 
located between core motifs A8 and A9, these can include cyclization, 
methyltransferase, monooxygenases, oxidases and reductase domains (Labby et 
al., 2015). Further, it has recently been seen that these additional domains can sit 
within A-domains; initially thought to be inactivated by this interruption, it is 
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Figure 6. Schematic representation of the reactions catalysed by each NRPS 
module. The domain involved in each reaction is that of the same colour box which 
surrounds the reaction. (a) The reversible A-domain adenylation reaction in which 
catalyses aminoacyl-AMP formation. (b) transfer of the activated substrate to the T-
domain releasing AMP, and the formation of the aminoacyl thioester. (c) The 
condensation domain then forms the peptide bond between two aminoacyl thioester 
substrates. In the schematic, T1 and T2 denote the T domains from neighbouring NRPS 
modules. And on the condensation enzyme, the ‘a’ and ‘d’ denote the donor and 
acceptor sites, respectively. (d) release of the substrate by the Te domain, first by 
aminoacylester formation on the Te domain then either by hydrolysis of the peptide (a) 
or cyclization (b). The X represents either a nitrogen or oxygen. The 4’Ppant co-factor is 
represented by the SH bonded to each T domain. Adapted from Felnagle et al., (2008). 
(c) 
(a) 
(b) 
(d) 
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increasingly becoming clear that these A-domains maintain activity, and take an 
active role in the biosynthesis of many natural products such as thiocoraline and 
cereulide (Magarvey et al., 2006; Zolova et al., 2014). The incorporation of an 
auxiliary domain within an A-domain has been demonstrated to allow successive 
adenylating then auxiliary action, further increasing the already colossal potential 
product structures (Labby et al., 2015). NRPS systems possess, acquired by 
millennia of evolution, a largely unexploited reservoir of compounds exhibiting 
chemical and structural diversity. This untapped potential could harbour the answer 
to stalling the ever impending post-antibiotic era; research efforts need to be 
redirected towards these systems with aim of (i) novel compound production, and (ii) 
low cost yet efficient and profitable discovery pipelines to entice interest back into 
the largely deserted antibiotic drug discovery industry.  
 
1.6 Introduction to Proximicins  
 
 As previously discussed, the necessity for antimicrobial and anticancer with novel 
chemistry and mode of action has never been greater: proximicins represent a 
group of compounds which meet this demand. Proximicins are a family of three 
molecules (A-C) (Fig. 7), each consisting of two distinctive 2,4-disubstituted furan 
groups differing in what appears to be an additional tryptophan or tyrosine group 
being present on B and C, respectively. Proximicin A was first discovered in the 
Figure 7. The Proximicin family of compounds, and the similar congocidine 
molecule. (a) Proximicins A-C (left to right) showing the core 2,4-disubstituted furan 
group highlighted in light blue and the unique groups to B and C highlighted in pink. (b) 
Congocidine molecule with core pyrrole groups highlighted in dark blue. 
(a) (b) 
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marine Actinomycete species, V. maris AB18-032 followed by that of A-C in 
Verrucosispora sp. str. MG37 (Fiedler et al., 2008). The research into proximicins is 
limited, however it has been shown that proximicins have the ability to arrest the cell 
cycle, although the mechanism of this remains elusive (Schneider et al., 2008). 
Schneider et al., (2008) demonstrated that they cause an upregulation of p53 and 
cyclin kinase inhibitor p21 - regulatory proteins involved in the transition from the G1 
to the S phase of the cell cycle, suggesting a related cellular target, although this 
remains unverified. Other than their likely production via an NRPS system, little is 
also known about the by which proximicins are synthesised in the producing 
organism; interest has been largely directed towards other potential drug leads 
produced by Verrucosispora strains, such as the abyssomicin antimicrobial family 
(Fiedler et al., 2008). It has been suggested in passing by Lautru et al., (2012), that 
proximicins are likely biosynthesised via an NRPS assembly line mimicking that of 
the pyrrole containing analogue produced by Streptomyces netropsis (Finlay et al., 
1954) congocidine (Fig. 7). It was noted that a simple replacement of the reductive 
amination step with a ketoreduction, could repurpose the congocidine pathway for 
proximicin biosynthesis (Lautru et al., 2012). However, despite the continual 
garnering of research interest directed to abyssomicin (Nicolaou et al., 2006; Keller 
et al. 2007a; Keller et al., 2007b; Gottardi et al., 2011; Goodfellow et al., 2012; Savic 
et al., 2013; Vieweg et al., 2014, Hashimoto et al., 2015), and congocidine (Juguet et 
al., 2009; Lipfert et al., 2010; Lautru et al., 2012; Al-Mestarihi et al., 2015), enabling 
the discovery and exploitation of their biosynthetic routes, information concerning 
proximicin biosynthesis remains largely elusive.  
 
Proximicins present an exciting research opportunity for novel compound 
identification, for two principal reasons: (i) heterocycle containing compounds have 
previously been shown to possess anticancer and antimicrobial properties 
(Dmiitrienko et al., 2007; Wetzler et al., 2007; Arora et al., 2012; Mazimba et al., 
2015), and it has been demonstrated that furans specifically alter the cellular target 
(Schneider et al., 2008); leading on to, (ii) 2,4-disubstituted furans preparation 
methods are rare, and typically low yielding and expensive (Lautru et al., 2012), 
hence, a cheap and rapid route to 2,4-disubstituted furan production would be 
advantageous to novel compound elucidation. 
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1.6.1 Proximicins as a scaffold of novel cell arresting drugs 
In the quest for novel antibacterial compounds, the presence or addition of many 
chemical groups has been assessed for the activities they contribute, underlining 
the principle of combinatorial chemistry approaches to novel compound discovery. 
It was identified that compounds containing heterocycle groups possessed DNA 
binding activity; two compounds widely studied of note here are congocidine and 
distamycin produced by S. netropsis (Finlay et al., 1954) and S. distallicus 
(Arcamone et al., 1964), respectively. These compounds have a similar structure to 
that of the proximicin family, distinct by the presence of a N-methyl-pyrrole 
heterocycle, opposed to the furan of proximicins. These pyrrole analogues possess 
the ability to bind to the minor groove of DNA, representing the first compounds to 
demonstrate AT-selective DNA binding. This ability has made them good targets for 
the production of synthetic derivatives capable of binding to a specific sequence for 
use as antitumor agents (Kopka et al., 1985a; Kopka et al., 1985b; Schneider et al., 
2008; Ganji et al., 2016). This interest has led to the refinement of the route 
responsible for congocidine biosynthesis in S. netropsis, outlining the enzymes 
responsible for incorporation of the activity-conferring N-methyl-pyrrole ring (Juguet 
et al., 2009; Al-Mestarihi et al.,2015). How this occurs was of specific interest as no 
adenylation domain has previously been shown to have specificity towards 
precursors containing this chemistry. Due to the high level of homology exhibited by 
proximicins and congocidine, it was suggested that their synthesis routes route be 
analogous. This led to the enzymatic machinery responsible for proximicin 
biosynthesis in Verrucosispora strains being considered established, and focus 
quickly progressed to other attractive metabolite investigation (Lautru et al., 2012). 
The differing mode of actions exhibited conferring the antitumor activity by 
congocidine and proximicin - DNA binding and interrupting the cell cycle 
independent of DNA binding respectively – was investigated, leading to an array of 
hybrid molecules being synthesised (Schneider et al., 2008; Wolter et al., 2009). 
Derivatives varied by the nature of terminal modifications, and the central 
furan/pyrrole groups were not altered. These apparently minor alterations resulted in 
an array of altered activities including improved antitumor activity compared to 
original compounds (Wolter et al., 2009). A change in mode of action was also 
shown, with furan containing homologs of congocidine exhibiting the ability to bind 
to the minor groove of DNA – a capability not displayed by proximicins (Wolter et al., 
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2009). Interestingly, furan containing derivatives of congocidine, maintain higher 
levels of antitumor activity (Schneider et al., 2008; Wolter et al., 2009); this is likely 
due to the increased polarity of the molecules, and additional hydrogen-bond 
acceptors conferred by the oxygens of the furan group. The novel cell arrest activity 
demonstrated, and the presence of the novel, activity conferring chemistry, make it 
difficult to believe that the proximicin family of molecules have been overlooked to 
such an extent.  
 
1.6.2 A simple source of novel chemistry 
Heterocycles are an abundant structural element of natural products of almost every 
class and they typically contribute significantly to their biological activity (Pozharskii 
et al., 2011; Taylor et al., 2014). Despite nature providing many routes to their 
incorporation into biological molecules, reproducing this in a lab setting is extremely 
difficult. This is true for proximicins, resulting in the distinctive 2,4-disubstituted 
furan group of proximicins which makes them an alluring drug discovery target, also 
being responsible for the lack of research interest surrounding them. Excluding their 
initial discovery, all proximicin research has relied entirely on chemical synthesis of 
the 2,4-disubstituted group (Schneider et al., 2008; Wolter et al., 2009); as the 
biosynthetic pathway responsible in the producing organism has not been outlined, 
preventing its exploitation. The route to total synthesis of proximicin is extremely 
time consuming and financially expensive, typically resulting in low yields and over 
substitution of the furan ring (Wolter et al., 2009); this hinders the ability to 
investigate them, lowering their perceived attractiveness to large scale research 
investment. An inexpensive route amenable to scaling-up, resulting in 2,4-
disubstiuted furan production would negate this problem; one approach would be to 
exploit the natural route to furan production in Verrucosispora strains, enabling their 
industrial scale recombinant production. To allow this, the biosynthetic route would 
have to be elucidated; a complex task considering only a singular Verrucosispora 
strain has a genome draft published (Roh et al., 2011), no biosynthetic clusters have 
been identified and, current work is minimal. Despite these barriers, the potential 
which 2,4-disubstituted furan exploitation poses is huge, not only for the 
construction of libraries of pyrrole/furan hybrid for novel DNA binding agents, but 
the ability to easily access 2,4-disubstituted furan chemistry, would allow its 
exploitation in small molecule libraries. The modular nature of the NRPS system 
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responsible for proximicin synthesis lends itself to this application. Analysis of the 
proximicin family of molecules, shows the repeating 2,4-disubstituted furan group, 
suggesting that it is formed from iterative activation of two furan containing 
precursors. The machinery which produces these compounds, and the unique 
enzymes responsible for their incorporation into the peptide backbone, provide 
extremely attractive targets to exploit for novel compound production. If these 
enzymes could be identified and characterised, it would represent an important 
milestone on the way to using these enzymes as a chemo-enzymatic tool in novel 
natural product synthesis, similar to previous work done (Friedrich et al., 2015; 
Schmidt et al., 2016). Effectively unlocking the potential this chemistry contains, 
allowing the production of the much needed novel antimicrobial, anticancer and 
antifungal compounds.  
 
Proximicins present such an exciting lead for novel compound production as both a 
family of compounds and a potential source of novel chemistry for introduction into 
other families. To facilitate this, the gene cluster responsible for proximicin 
production was identified in both producers V. maris AB18-032 and V. sp. str. 
MG37; done by the sequencing, assembly and annotation of the V. sp. str. MG37 
genome. Large scale genome comparison studies followed, allowing the 
identification of a common secondary metabolite gene cluster encoding NRPS 
enzyme machinery exhibiting the predicted similarities to that of congocidine. Large 
scale recombinant protein production and A-domain activity assays revealed the A-
domain responsible for 2,4-disubstitued furan incorporation and allowed the 
outlining of the putative proximicin biosynthetic route. Preliminary studies utilising 
CRISPR/Cas technologies for gene editing were done in the proximicin producing 
organism, resulting in a phenotypical variant, paving the way for future work into 
proximicin cluster deletion and re-complementation studies.  
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Chapter 2. Genome sequencing, assembly, annotation of 
Verrucosispora sp. str. MG37, and identification of putative 
proximicin cluster 
 
2.1 Introduction 
 
2.1.1 Overview of Proximicins  
Proximicins are a family of heterocycle containing compounds, shown to possess 
the ability to arrest the cell cycle, in addition to slight antimicrobial activity (Wolter et 
al., 2009). They are produced by two species of marine Actinomycete 
Verrucosispora – maris AB18-032 and sp. str. MG37– first discovered in sediments 
isolated from the Sea of Japan and Raune Fjord, Norway, respectively (Fiedler et al., 
2008). Fiedler et al., (2008) used HPLC-diode array to monitor extracts from the 
isolated Verrucosispora species, which led to the identification of the secondary 
metabolites (SM) – specifically proximicins – from the two producers. Proximicins 
show high structural similarity with characterised pyrrolamidone antibiotics – 
congocidine and distamycin – produced by S. netropsis (Finlay et al., 1954) and S. 
distallicus (Arcamone et al., 1964), respectively. These γ-peptide antibiotics have a 
characteristic structural element – an N-methyl-pyrrole ring, conferring antitumor 
activity caused by their ability to selectively bind to the AT-rich sequences found in 
the minor groove of DNA (Bailly et al., 1998). Distinct from the pyrrole-amides, 
proximicins have been shown to have a different mode of anti-tumour action not 
reliant on DNA binding (Fiedler et al., 2008). The ability to produce biologically active 
compounds produced by Verrucosispora strains pose the possibility of novel 
clinically relevant molecule characterisation. V. maris AB18-032 was the subject of 
much research, resulting in its genome being sequenced, assembled and annotated 
(Roh et al., 2011) – due to its ability to produce the abyssomicin family of 
compounds. Abyssomicin’s are polycyclic polyketide natural products with 
impressive biological activity and present a substantial potential clinical lead 
(Nicolaou & Harrison, 2006); this family of compounds are not produced by V. sp. 
str. MG37 (Fiedler et al., 2008). Due to the combination of structural novelty and 
activity of the abyssomicin family, proximicins have largely been overlooked. What is 
known is that there are three proximicin members: A, B and C (Fig. 7); all contain 
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two 2,4-disubstitued furan groups, with B and C having what appears to be an 
additional tyrosine or tryptophan moiety present, respectively. Only B exhibited 
moderate growth inhibition of Gram-Positive bacteria, whereas C showed only slight 
inhibition against Brevibaccillus brevis DSM30 (Fiedler et al., 2008). All Gram-
Negative and fungi tested by Fiedler et al., (2008) where shown to be insensitive to 
all proximicins; however, substantial inhibition of tumour cell line growth was 
demonstrated. Despite their novel chemistry and activity, little is known about the 
enzymatic machinery responsible for proximicin biosynthesis. To harness the novel 
chemistry and activity exhibited by this family, whole genome sequencing (WGS) 
and annotation studies must be done to: (i) identify a putative proximicin 
biosynthesis (ppb) cluster present in both producers; (ii) identify the route to 
proximicin synthesis and, (iii) determine the genetic basis for the discrepancies in 
proximicin production between the two Verrucosispora species.  
 
2.1.2 Pre-genomic era SBC identification 
Secondary metabolites isolated from microbes have had an unparalleled impact on 
modern-day medicine. These small molecule natural products, which include 
important clinical drugs, such as: antibiotics (Kardos & Demain et al., 2011); 
cholesterol-lowering compounds (Endo, 2010); antifungals, and immunosuppressive 
cyclosporins (Britton & Palacios, 1982), have revolutionised the treatment and 
prevention of illness and infection. Despite the plethora of compounds identified and 
in current use, microbial secondary metabolites continue to be an important source 
of molecules for drug discovery. Many initial insights into SM biosynthetic pathways 
came during the early 1950’s, and were obtained by organic chemists using isotopic 
tracers (Bentley, 1999). The research methods quickly shifted to investigate the 
molecular biology with the advent of DNA cloning and sequencing tools; this 
culminated in many landmark papers, which described the molecular cloning of 
entire secondary metabolite clusters (SMC) from Actinomycete bacteria (Malpartida 
& Hopwood, 1984; Cortes et al., 1990; Donadio et al., 1991). After preliminary 
identification of genes involved in SM biosynthesis, the hallmark trait of gene 
clustering was quickly observed in both fungi and bacteria; this tendency of genes 
to cluster on a chromosomal locus greatly accelerated the elucidation of enzymatic 
steps involved in the biosynthesis of compounds. In the pre-genomic era, 
identification of SMC was a laborious, and time consuming task. It was done 
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traditionally by either complementation of blocked mutants by cosmid libraries or 
insertional mutagenesis followed by plasmid rescue (Mayorga & Timberlake, 1990; 
Hendrickson et al., 1999); both of these approaches rely on extensive screening, 
which is simply not a feasible response to increasing incidence of bacterial multiple-
resistance (Yang et al., 1996). Other approaches, such as the genome scanning 
method described by Zazopoulos et al., (2003) in which the enediyne antitumor 
antimitotic pathways were characterised offered other approaches; however, the 
introduction of low cost, rapid sequencing platforms and the genomic revolution it 
triggered completely transformed SMC elucidation.   
 
The introduction of DNA sequencing, bypassed the necessity for these cumbersome 
SMC identification methods, by revealing the inventory of all the SMC present in the 
producing organism. This paradigm shift led to some renaissance of natural product 
research in academia and industry. This was reinforced when the first genome 
sequence of the model organism Streptomyces coelicolor A3(2) (Bentley et al., 2002) 
and the avermectin producing strain S. avermitilis (Omura et al., 2001; Ikeda et al., 
2003) were both found to possess more SMC than previously estimated. This was 
especially remarkable as these strains both served as model organisms and 
industrial production strains, and so it was widely presumed that all was already 
known about the SM’s they are capable of producing. As sequencing ability and 
applicability increased, high numbers of cryptic or silent secondary biosynthetic 
cluster (SBC) – especially in the Actinomycetes (Weber et al., 2015), became a 
common feature. Table 1 shows novel compound discoveries solely from gene 
mining approaches. This has been further propelled by the rapid improvement in 
NGS technologies in the last decade, dramatically lowering the cost of DNA 
sequencing, putting the power of bacterial WGS in the hand of individual 
laboratories.  
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2.1.3 Advent and impact of Whole Genome Sequencing  
The information of biochemical and hereditary properties conferred by the DNA 
sequence of an organism underpins much of today’s scientific knowledge; this is 
due to the advent of relatively cheap and fast DNA sequencing technologies. The 
primary break-through came with the introduction of Sanger Sequencing in 1977, 
and served as the blue print for today’s technologies. Sanger Sequencing utilises 
the classical chain-termination method; put simply, the DNA code is read by 
identifying the incorporation of a modified fluorescent ddNTPs, which has blocked 
the DNA polymerase extension of the DNA strand. This led on to the development 
and implementation of increasingly automated approaches, leading to the first crop 
of commercial DNA sequencing machines. The advent of Sanger Sequencing was 
undoubtedly revolutionary; however, limitations arose, specifically related to the time 
consuming and tedious cloning steps necessary. The year of 2006 marked a turning 
point in sequencing abilities; an explosion of new methods, techniques and 
protocols were revealed with the arrival of Next Generation Sequencing (NGS) 
technologies which quickly overcame previously encountered issues. Typical 
approaches of NGS are: sequencing by synthesis (Illumina, Pacific Biosciences, Ion 
Torrent); Nanopore (Oxford Nanopore); Pyrophosphorolysis (Base4), and 
Sequencing by ligation (SOLiD, Complete Genomics). There are many excellent 
reviews (Levy & Myers, 2016) which explain each sequencing methodology in detail, 
and so this will not be discussed here. However, it should be noted that NGS 
platforms can be divided by three axes of sequencing approach: (i) single molecule 
detection per reaction, well or sensor (Pacific Biosciences) or detection of clonally 
amplified DNA (Illumina, Ion Torrent); (ii) the use of optical detection to make the 
sequencing base calls (Illumina, Pacific Biosciences, Ion Torrent and Oxford 
Nanopore), and (iii) the use of polymerase or ligation process to drive a sequencing 
by synthesis reaction (Illumina, Ion Torrent, Pacific Biosciences and Roche 454). 
Each approach has similarities and distinctions relative to the others depending on 
the chemistry and detection method utilised; these lead to a spectrum of capabilities 
and applications. The differences in each platform has resulted in much research 
into their comparison under similar conditions. Comparisons are typically done using 
two specifications: the number of reads produced in a single run, and the length of 
those reads; with other metrics such as sample preparation time and cost, being 
much harder to compare between platforms. Table 2 Shows the currently marketed 
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NGS compared by these specifications. The application of the sequencing data 
dictates which approach is best suited; for example, sequencing by ligation (SOLiD) 
struggles to resolve areas of palindromic repeats and would be a poor choice for 
bacterial genomes which are known to contain these complex regions (Utturkar et 
al., 2014). Further, sequence by synthesis methods, such as Illumina, require large 
amounts of DNA template and so are not well suited for metagenomic analysis. 
Recently, deviation of sequencing approaches can be seen as platforms become 
specialised and tailored, to a given purpose. Despite this diversification, all share 
one major limitation: due to a reduction in read length from ~1 to 0.3 Kb, the sheer 
volume of reads produced per run has increased dramatically. This imposes a 
progressively high demand on the bioinformatical capabilities responsible for 
processing the raw data into clinically actionable knowledge. The computational 
ability to analyse the data generated from NGS platforms is advancing; however, it 
remains largely over eclipsed by the ability of NGS machines. To challenge this 
bottle-neck, just as sequencing approaches are becoming increasingly purpose-
designed, it is vital to test and compare bioinformatical approaches in an 
application-specific manner to produce refined pipelines.  
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2.1.4 Next generation bacterial sequencing and assembly  
The introduction of second-generation sequencing technologies has resolved the 
traditional Sanger sequencing paradigm. However, the intrinsic complexity of 
genomes, even that of small microbes, means it remains a challenge to generate 
complete assemblies without laborious laboratory work, such as PCR gap closing 
(Finotello et al., 2011; Quail et al., 2012). The incidence of long repeat regions and 
short read length characteristic of bacterial genomes and NGS platforms 
respectively, often lead to assemblies being left as unfinished, fragmented drafts 
(Ferrarini et al., 2013; Koren et al., 2013). Attempts to resolve these issues have 
been made, principally with the introduction of so-called ‘third generation’ 
sequencing – such as PacBio – which have significantly longer read length; 
however, these too have inherent shortcomings such as low accuracy (~15% error 
rate) (Eid et al., 2009). This has led to production of hybrid approaches combining 
reads from two or more sequencing platforms to allow optimal sequence assembly; 
these reads are combined using hybrid programs such as ALLPATHS-LG (Ribeiro et 
al., 2012), PacBio correct reads (PBcR) pipeline (Bashir et al., 2012) and SPAdes 
(Prjibelski et al., 2014). For example, the authors of ALLPATHS-LC (Ribeiro et al., 
2012), proposed a unique methodology which is incorporated into ALLPATHS-LG to 
use Illumina paired-end reads of two libraries, in addition to PacBio long reads. It 
was demonstrated by Ribeiro et al., (2012) that this pipeline was able to produce 
nearly perfect bacterial assembly; despite this, few bacterial genomes have been 
assembled in this way likely owing to the cost associated with a such an extensive 
sequencing approach (Shibata et al., 2013; Ku et al., 2012).  
 
To circumvent costly multiple platform implementation, work is also focusing on 
improving bioinformatical capabilities and specifically the intelligent treatment of 
reads to allow optimal data extraction. Review of previous assembly pipelines and 
the quality of the resulting assemblies, allows the effectiveness of each program in a 
bacterial genome application to be evaluated, hence, enlightening future work. To 
aid in pipeline selection here, recent work which utilised the Illumina MiSeq platform 
specifically was reviewed and is summarised in Fig.8. In line with the typical NGS 
output, raw data from Illumina Miseq is two collections of reads – the paired-end 
(PE) and mate-pair (MP) library; the two are not compatible with each other and 
require different pre-processing treatments. Pre-processing typically involves quality 
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control of reads and trimming of adapter content; many programs are available for 
PE processing, with less emphasis been put on MP read processing. This is due to 
MP’s being harder to utilise, and has resulted in previous research largely 
disregarding the library, or incorporating it at the very end of assembly. The wealth 
of information held within the MP reads has recently been realised, and a tide-
change in pipeline has resulted in additional effort into producing programs which 
can utilise the data. Taking advantage of this sequence information, many programs 
– such as SPAdes 3.5 (Bankevich et al., 2012) – are incorporating MP libraries much 
earlier in the assembly process. All assemblers differ in intensiveness and assembly 
speed but typically all use de Bruijn graph algorithms. Put simply, de Bruijn graphs 
are directed graphs representing overlaps between sequences; to be generated, the 
amount of overlap between reads must be dictated – this is set by the k-mer length, 
to result in the production of a vertex by reconstructing a string from the set of k-
mers. Recently, advances have been made into producing algorithms which uses a 
set of pairs of k-mers (k-bimers), utilising the data present in the MP library. As 
mentioned, the potential of this approach is arguably the most poorly explored stage 
of assembly; this was due to programmers aiming to have a fixed distance between 
reads –  unrealistic due to the variation in the read length characteristic of NGS 
machines. This made bridging the gap between theoretical idea to practical 
implementation difficult; this was resolved with the introduction of SPAdes which 
uses k-bimer adjustment which reveals exact distances for the vast majority of the 
adjusted k-bimers. It has been demonstrated that this type of approach, utilising the 
MP libraries can help close gaps, resolve palindromic regions, and increase contig 
length threefold (Greninger et al., 2017). The final task is locating the target SMC 
which is typically done by either directly searching (TBLASTN search against a 
database generated from the assembled genome scaffolds) or using a SMC 
searching program (Prokka (Seeman, 2014), RAST (Aziz et al., 2008), AntiSMASH 
(Medema et al., 2012)) to identify genes which encode backbone enzymes that 
synthesise the specific class of compounds which correspond to the target SM. As 
shown in Fig. 8 there are many programs which use different algorithmic 
approaches for bacterial genome assembly; if the potential of NGS platforms is to 
avoid bottleneck, the applicability of these programs in non-specialised settings 
must be scrutinised.   

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Here, using the Verrucosispora sp. str. MG37 genome as an example, we test and 
compare many leading bioinformatical programs to describe the most efficient 
pipeline for microbial genome assembly and annotation, major issues encountered 
and how they were resolved. The principal objective was to identify the ppb cluster 
and outline the biosynthetic route resulting in proximicin, and different SMC 
searching programs were used and compared; in addition to this, the applicability of 
NGS genome assembly and annotation programs to be utilised in non-centralised, 
individual laboratory was assessed. 
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Chapter 2. Sequencing, assembly & annotation of Verrucosispora 
sp. str. MG37, and identification of the biosynthetic gene cluster 
responsible for proximicin biosynthesis 
 
2.2 Materials and Methods 
 
2.2.1 Media and Reagents   
GYM Streptomyces medium was used for routine growth of Verrucosispora strains: 
4.0 g Glucose, 4.0 g Yeast extract, 10.0 g Malt extract, 2.0 g CaCO3, 12 g Agar 
(optional) and 1L distilled water. The pH was adjusted to 7.2 prior to addition of 
agar, and CaCO3 excluded if medium was used, followed by autoclaving. All DNA 
fragments were visualised by running on 2% agarose gels stained with ethidium 
bromide, unless otherwise stated. Explanation of output terms is explained in 
Appendix B.  
 
2.2.2 Identification of putative proximicin biosynthetic (ppb) gene cluster in 
Verrucosispora species and initial investigation into adenylation 
domains. 
Identifying likely genes to be present in the ppb cluster 
The component chemistry of proximicins A, B and C was analyzed, common 
structures identified, and differences highlighted. Possible biosynthetic routes were 
hypothesized and genes which would be required predicted – this information was 
used to identify gene cluster characteristics that should be prioritized. This was 
done manually, with support from previous di-substituted heterocycle biosynthesis 
research (c.f. congocidine biosynthesis).  
 
Identifying the ppb cluster 
Mining of the published V. maris AB18-032 genome using a secondary metabolite 
gene cluster analyzer – antiSMASH (Blin et al., 2013) – was done to reveal NRPS-
containing biosynthetic gene clusters. Clusters with the characteristics previously 
identified to be likely present for proximicin production were prioritized, with those 
likely to produce a compound of similar size to proximicin. Prediction of adenylation 
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domain substrates was done using Maryland NRPS analyzer (Bachmann & Ravel, 
2009) and the function of non-NRPS proteins by BLAST (Altschu et al., 1990) and 
HHPred (Söding et al., 2005). Finally, 3D protein prediction was done using iTASSER 
(Zhang, 2008) and PyMOL (DeLano, 2002).  
 
Initial bioinformatic analysis of ppb cluster adenylation domains 
Adenylation domains were initially analysed using Bioedit (Hall, 1991) to identify core 
domains required for adenylation domain function. This was done by sequence 
alignment with 11 described functional A-domains. Core consensus sequences 
were highlighted, and their presence / absence / modifications from consensus, 
were noted and potential enzymatic outcomes from these deviations hypothesised.  
 
Analyzing adenylation domain activity  
Programs were used to initially identify potential substrates of the adenylation 
domains identified in the ppb cluster; these programs include: Maryland PKS/NRPS 
analysis (Bachmann et al., 2009); NRPSpredictor2 (Röttig et al., 2011) and Prism 
(Tunchag et al., 2011; Baspinar et al., 2014); this was also done by comparing 
known a selection of 10 known adenylation domains to identify present/absent core 
sequence domains.  
 
Route to proximicin biosynthesis outlined 
From the proposed functions of the genes within the putative proximicin cluster, 
various biosynthetic routes were outlined. This was done manually, using the 
similarities the genes in ppb have to give potential routes to a 2,4-disubstituted 
heterocycle containing compound.  
 
2.2.3 Genomic sequencing of Verrucosispora sp. str. MG37  
Genomic DNA extraction  
Genomic DNA was extracted from Verrucosispora sp. str. MG37 using the 
cetyltrimethyl ammonium bromide (CTAB) method. 30 mL cultures were grown up in 
GYM media for 16 hours and harvested at 16,000 X g and re-suspended in 5 mL 
TE25S buffer (25 mM Tris-HCl pH. 8; 25 mM EDTA pH. 8 and 0.3 M sucrose) 
lysozyme added to final concentration 2 mg/mL and incubated for 1 hr at 37°C. 
Proteinase K and SDS added to final concentration 0.18 mg/mL and 0.5 % 
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respectively, and incubated for 1 hr with occasional inversion at 55°C. NaCl was 
added to final concentration of 0.8 M and mixed; CTAB/NaCl (10 %CTAB in 0.7 M 
NaCl) was added and the mixture was incubated at 55°C for 10 mins followed by 
cooling to 37°C. Chloroform/isoamyl alcohol added and mixed by inversion for 30 
min then centrifuged at 13,500 X g at 20°C for 15 mins. The supernatant was 
decanted and 0.6 volumes of isopropanol added and mixed; after 3 min DNA was 
spooled, rinsed in ethanol and air dried before being dissolved in 1 mL TE buffer 
(1mM Tris-HCl; 1 mM EDTA pH. 8) at 55°C. Successful gDNA extraction was 
confirmed by agarose gel electrophoresis. 
 
Checking presence of ppb genes 
HPLC-purified primers were designed to amplify ppb genes chosen to span the 
entire cluster identified in V. maris AB18-032: ppb genes ppb090 (Primer #: 1 & 2); 
ppb110 (Primer #: 3 & 4); ppb120 (Primer #: 5 & 6); ppb155 (Primer #: 7 & 8) and 
ppb180 (Primer #: 9 & 10). The extracted gDNA was used in a PCR mixture (25 μL) 
contained 2XMyfiTM High-Fidelity polymerase master-mix (Bioline), primers (0.5 μM 
each), template DNA (25ng) and DMSO (3%). The PCR was performed using a 
specified MyFiTM Thermal Cycling Procedure: 1 cycle, 95°C for 60 s; 30 cycles, 95°C 
for 15 s, 71°C for 15 s and 72°C for 3:00 min; and 1 cycle 72°C for 15 min. PCR was 
checked using gel electrophoresis, 4 μL of reaction mix was ran on a 1% agarose 
gel. Products were E-Gel purified and quantified using Nanodrop.  
 
Genome sequencing of Verrucosispora sp. str MG37  
For shotgun sequencing (Paired End) libraries, DNA was sheared into 100 - 1500 bp 
range in a microTUBE using a focused-ultrasonicator (Covaris, USA) and quantified 
on a Qubit instrument (Thermofisher, USA). Sheared DNA was end-repaired, A-
tailed, adapter ligated and amplified with a Kapa Hyper library construction kit (Kapa 
Biosystem, USA). For Mate-Pair libraries, DNA was tagmented, circularized, 
fragmented, enriched and adapter ligated using a Nextera Mate Pair sample 
preparation kit (Illumina, USA). The circularization adaptor for mate-pair library was 
5’-CTGTCTCTTATACACATCT-3’. Adapters for sequencing both paired end and 
mate pair libraries were: read 1: 5’-
AGATCGGAAGAGCACACGTCTGAACTCCAGTCACNNNNNNATCTCGTATGCCGTC
TTCTGCTTG-3’ where (NNNNNN = 6 nt index) and 5’- 
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AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGCCGTATC
AT-3’.  Index sequences for the paired end library was GCCAAT, and ACAGTG for 
the Mate Pair library. The libraries were pooled and quantified by qPCR prior to 
sequencing on a MiSeq DNA instrument; one MiSeq V3 flowcell for 311 cycles and a 
MiSeq 600-cycle sequencing kit, was used to generate sequences from each end of 
the fragments. Fastq files were generated and demultiplexed with bcl2fastq v1.8.4 
conversion software (Illumina, USA). All the above steps were done by the High-
Throughput Sequencing and Genotyping Unit at the Roy J. Carver Biotechnology 
Centre, University of Illinois. 
 
2.2.4 Verrucosispora sp. str MG37 genome assembly and annotation 
A bioinformatics pipeline was employed based on previous work in de novo 
microbial genome assembly and annotation, and is outlined in Fig. 9. 
 
Quality check of raw sequencing data 
Both Mate-Pair and Paired-End read libraries were checked using FastQC (Andrews, 
2010), this program analyses the sequencing to give an output file detailing: total 
sequence length, flagged poor quality sequences, average sequence length, GC 
percentage, at what point in the reads the phred score drops below 20, adapter and 
Kmer content.  
 
Trimming of Paired-End library 
Trimmomatic (Bolger et al., 2014) and Cutadapt (Martin, 2011) were used to trim the 
paired end library. Trimmomatic is a command line tool used to trim and crop 
Illumina data, as well as remove sequencing adapters. Paired end mode was used 
to maintain correspondence of read pairs and to utilize the additional information 
contained in paired reads to better find adaptors and DNA fragments introduced by 
the library preparation process. Within the Trimmomatic program there is an array of 
steps (Appendix C). Four output files were created: Forward Reads which remained 
Paired; Reverse Reads that remained Paired; Forward Reads which are Unpaired 
and Reverse Reads which are Unpaired. The unpaired reads are due to one out of 
the pair being removed. Reads which failed to meet the specified criteria, were 
deleted; no library was made with them. Cutadapt is a command line program which 
finds and removes adapter sequences, primers, poly-A tails and 

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other unwanted sequences. Cutadapt searches for multiple adapters in a single run, 
either discarding or trimming reads where adapters are found. Low quality ends of 
reads are trimmed. The programs used within Trimmomatic are outlined in Appendix 
C.  
 
Trimming of Mate-Pair library 
 NxTrim (O’Connel et al., 2014) is an optimized trimming program designed 
specifically for Mate-Pair reads. It can interpret each potential scenario resulting 
from the fragmentation of the 6-8 Kb fragments produced during Illumina Mate-pair 
sequencing, and splits these into four libraries: Mate-pair; UNKNOWN; Paired-end 
and a set of single reads. This allows the use of not just the typical Mate-pair reads 
(as is the case with other trimming software), but also reads which are Paired-end 
and singletons. This tool allows more information to be retained from the trimming 
steps to aid assembly. The four output files are the standard Mate-Pair, Unknown, 
Paired Ends and a set of single reads, and how each is created is outlined in Fig. 14.   
 
Quality check after trimming steps  
FastQC was again used, to determine the quality of the reads after the trimming 
steps. Primarily to ensure all adapter sequences have been removed and all 
sequences with a low quality (Phred score >20) has been removed, this should 
increase the average quality of reads but lower the number of reads.  
 
Assembly of reads 
SPAdes 3.5.0 (Bankevich at al., 2012), an iterative short read genome assembly 
program, was chosen as the assembly tool, this has the error correcting program 
BayesHammer (Nikolenko et al., 2013) within it. BayesHammer and SPAdes, 
although possible to run together, were run separately (Appendix D). As the input 
data was a multi-cell data set with read length for each pair >250, K-mer lengths 
were altered to take advantage of the long read length. SPAdes works iteratively to 
calculate the optimal read length from a set specified; for this genome assembly K-
mer lengths:  21, 33, 55, 77 and 127 were chosen. Increasing the K-mer length 
increases the chances of mismatches and so SPAdes was run in the ‘careful’ mode 
to reduce the number of mismatches in the final contig.  For both, Paired end, Mate-
pair and single reads are the input files, accounting for orientation in the command 
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line. The output files are five directories: reads corrected by BayesHammer; resulting 
contigs; resulting contigs in FASTG format; resulting scaffolds and resulting 
scaffolds in FASTG format. The workflow of SPAdes is summarized in Appendix D.  
 
Assessment of assembly quality 
QUAST (Gurevich et al., 2013) is a command line program that evaluates the 
assemblies of genomes by comparing it against a known and annotated genome. 
Both the assembled Verrucosispora sp. str. MG37 and V. maris AB18-032 genomes 
were input as FASTA files. The output is an output report in a .html file with 
interactive plots on quality. All inputs were left as default. 
 
Contig ordering 
MAUVE (Darling et al., 2004) uses highly similar sub-sequences to employ an anchor 
alignment approach, which only requires modest computational resources. To avoid 
problems encountered with highly repetitive regions and contig ordering, Mauve 
employs multiple maximal unique matches (MUMs) of some minimal length k as 
alignment anchors. These ‘MUM’s’ are exactly matching subsequences shared by 
two or more genomes that occur only a single time in each genome and are 
bounded either side by mismatched nucleotides. Mauve then uses a recursive 
anchoring strategy that progressively reduces k, searching for smaller anchors in the 
remaining unmatched regions. Input files were Verrucosispora sp. str, MG37 
genome scaffolds and the V. maris AB18-032 genome. The output is an interactive 
graphical platform, allowing manual rearrangement of contigs. The rearranged 
contigs were output as a .fasta file.  
 
Genome annotation and identification of secondary metabolite gene clusters 
Four programs – RAST (Aziz et al., 2004), Prokka (Seeman, 2014), antiSMASH (Blin 
et al., 2013) and Prism (Tunchag et al., 2011; Baspinar et al., 2014); - were used to 
allow comparison of results:  
 
RAST identifies protein encoding, rRNA and tRNA genes, attempts to assign 
function, and to reconstruct the metabolic network of the given genome. RAST uses 
the data and procedures established with the SEED framework to allow high quality 
gene calling annotation (Overbeek et al., 2005). The SEED project is an open source 
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resource which focus is to develop curated genomic data. The annotation is done 
via subsystems – functional roles that an annotator has decided should be thought 
of as related, e.g. functional roles or a class of proteins. This allows high quality 
gene calling and functional annotation. The annotated genome can be downloaded 
in GenBank or Fasta format, or browse the genome in the comparative environment 
of SEED-viewer.  
 
Prokka uses external feature prediction tools to identify the coordinates of genomic 
features within contigs. Within Prokka five tools are used which predicts different 
features: Prodigal (coding sequence); RNAmmer (ribosomal RNA genes); Aragorn 
(transfer RNA genes); SignalP (signal leader peptides) and infernal (non-coding 
RNA). Protein coding regions are identified in two stages: Prodigal identifies the 
region and coordinates of the candidate gene, however, instead of using the 
traditional method of comparing this sequence to a large database of known 
sequences and finding the most closely matched, Prodigal uses a hierarchal method 
to start comparison with a small, trustworthy database, moving onto domain 
specific and then curated models of protein families. The antiSMASH program is a 
genome mining tool specifically designed to identify antibiotic and secondary 
metabolite gene clusters.  
 
Prism is a computational resource for the identification of biosynthetic gene cluster, 
along with the predication of genetically encoded NRP’s; it implements novel 
algorithms which render it uniquely capable of making comprehensive genome 
guided chemical structure predictions.  
 
Comparative genomics 
The draft genomes of Verrucosispora sp. str. MG37 and the whole genome of V. 
maris AB18-032 were aligned using ACT (Carver et al., 2005) software after running 
a pairwise blastn search. Mauve (Darling et al., 2004); was used to reorder the 
contigs of Verrucosispora sp. str. MG37 using V. maris AB18-032 as the reference 
genome. Regions of difference were manually identified. The ppb cluster was 
examined to identify any genetic differences which could account for differential 
production of proximicins observed between the strains. Genome illustrations were 
done using Circos (Krzywinski et al., 2009). Species identification based on genome 
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sequence was done as defined by the average nucleotide identity between 
Verrucosispora sp. str. MG37 and Verrucosispora maris AB18-032 (Goris et al., 
2007) and by Genome-to-Genome distance calculation (Auch et al., 2010) 
 
2.2.5 Confirming the ppb cluster 
Identifying potential proximicin biosynthetic cluster 
Of the clusters present in both Verrucosispora sp. str. MG37 and V. maris AB18-032, 
any clusters not common to both were excluded, then any which did not contain 
NRPS-adenylating proteins.  The remaining clusters were ranked depending on their 
similarity to the predicted proximicin clusters previously outlined. This was done to 
confirm that the previously determined ppb is the most likely candidate in both 
producers.   
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Chapter 2. Sequencing, assembly & annotation of Verrucosispora 
sp. str. MG37 and identification of the biosynthetic gene cluster 
responsible for proximicin biosynthesis 
 
2.3 Results   
 
2.3.1 Putative proximicin cluster in V. maris AB18-032 
Identifying genes likely to be present in the ppb cluster 
Proximicins all contain a two 2,4-disubstituted furans, with B and C containing a 
tyramide and tryptamine (likely to be of tyrosine or tryptophan origin), respectively. 
They are likely synthesized by an NRPS route (amide bond between non-
proteogenic amino acids), and it is possible that the two furan groups are added 
iteratively by a single A-domain (c.f. congocidine biosynthesis); also, if an A-domain 
does activate furan containing precursors, it would have non-canonical  active site 
residues – as furans are not α-amino acids. If this is the similar to the biosynthetic 
route to congocidine, genes likely to be included in the cluster are: at least two 
NRPS adenylating enzymes, at least one having a non-canonical active site 
sequence (depending on whether the furan group is added iteratively or by two 
separate A-domains). This would be accompanied by a tryptophan and/or tyrosine 
activating A-domain, as well as the cognate T-domains and a TE domain to release 
the peptide. If this is the route utilized, it is likely the cluster will have similarities to 
congocidine biosynthetic cluster, as it is responsible for the production of a similarly 
structured compound. An alternative hypothesis is that a linear molecule could be 
initially activated and condensed, with cyclization to form the furan moieties 
occurring post peptide formation; this would negate the requirement for furan 
precursor synthesis. In this case, it would be a linear residue accepting A-domain, 
still accompanied by the tryptophan and/or tyrosine activating A-domain(s), but with 
the presence of a singular or multiple cyclizing enzymes. It is also likely that an 
MbtH-like protein will be present, as these proteins are often required for correct 
functioning of NRPS enzymes.  
 
 
 
 55 
Genome mining of Verrucosispora maris AB18-032 
Genome mining of V. maris AB18-032 showed many biosynthetic gene clusters (19 
in total), five of which are NRPS systems (Table 3). Different prediction programs 
gave different outputs for the boundaries of the clusters, for example antiSMASH 
suggested a single cluster, whereas PRISM suggested two individual smaller 
clusters. This highlights the necessity for hand curation. Consequently, one cluster 
was identified as the putative proximicin biosynthetic cluster. This cluster was one 
that was predicted to be part of a larger cluster by antiSMASH, however, annotation 
of this cluster (see below) showed similarities to the gene clusters responsible for 
congocidine (Al-Mestarihi et al., 2015) and pacidamycins (Rackham et al., 2010, 
Zhang et al., 2010) biosynthesis – specifically all having dissociated atypical NRPS 
module systems – and so its prediction as one cluster (containing multiple NRPS 
genes) is likely due to its proximity to a second NRPS gene cluster (PRISM identified 
them as separate gene clusters). One similarity between the ppb cluster and the 
congocidine gene cluster is the presence of an adenylation domain with an unusual 
amino acid substitution in the residues comprising the substrate-recognition motif – 
Ser235 to Asp235 in Ppb120 and Cgc18, respectively. Ser235 is invariant in adenylation 
domains that select and activate α-amino acids making it highly likely that both 
activate a non-proteogenic amino acid; at the time of analysis, Cgc18 was predicted 
to activate a heterocyclic γ-amino acid (4-aminopyrrole-2-carboxylate) a substrate 
differing from the predicted proximicin precursor by the presence of a pyrrole, rather 
than furan, ring. This further supported the identification of ppb as the proximicin 
biosynthetic gene cluster. The components of the putative proximicin gene cluster 
and their predicted function are given in Table 4 and the genetic organization is 
shown in Figure 10. 
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* As defined by Cimermancic et al. 2014, NRPS = Non-ribosomal peptide synthetase, T1pks 
= Type 1 Polyketide synthase, T2pks = Type 2 Polyketide synthase. Putative proximicin 
biosynthetic gene cluster (ppb) is shown in blue. 
 
 
 
 
 
 
Cluster Type* Genome location 
(bases) 
Most similar known cluster biosynthetic 
gene cluster 
 start end  
Terpene 191982 212893 Sioxanthin 
Terpene 278534 299589 Phosphonoglycans 
NRPS-fatty acid-
Arylpolyene 489000 581354 Kedarcidin 
T1pks-fatty acid 2554963 2631233 Abyssomicin 
T1pks 2679427 2778878 Streptazone E 
T2pks 2948612 3007502 Xantholipin 
NRPS-T1pks 3021143 3109012 Sporolide 
NRPS 3194386 3247461 Arsenopolyketides 
Bacteriocin-
Lantipeptide 3439443 3502185 Desferrioxamine B 
Terpene-
Thiopeptide-
Lantipeptide 
3630549 3691043 n/a 
NRPS 3894106 3992199 Pacidamycin 
Lantipeptide-
saccharide 4044111 4086687 SapB 
T2pks 4255327 4299256 Spore pigment 
T1pks-NRPS-fatty 
acid 4459178 4574561 Maduropeptin 
Terpene-Bacteriocin 4750901 4778203 Lymphostin 
Terpene 4913335 4934267 n/a 
T3pks 6212354 6253403 Alkyl-O-Dihydrogeranyl-Methoxyhydroquinones 
Table 3. Major natural product gene clusters of Verrucosispora AB18-032 
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Gene 
Product 
size (aa) 
Identity Function 
Present in 
both strains 
ppb055 1951 99% Short chain alcohol dehydrogenase Y
ppb060 184 99% Transcriptional regulator Y 
ppb065 323 100% Hydrolase/ reductase N 
ppb070 211 64% Integral membrane protein Y 
ppb075 337 99% Membrane protein Y 
ppb080 319 98% Transcriptional regulator Y 
ppb085 942 99% DNA binding transcriptional activator of the SARP family Y 
ppb090 206 100% Cyclodehydratase Y
ppb095 340 99% Transcriptional regulator Y 
ppb100 342 99% DNA binding protein Y 
ppb105 442 100% Transcriptional regulator Y 
ppb110 596 99% NRPS module Y
ppb115 342 100% DAHP synthase Y 
ppb120 764 99% NRPS module Y 
ppb125 72 100% MbtH protein Y 
ppb130 240 99% Hydrolase Y 
ppb135 286 100% Orotidine-5’-phosphate decarboxylase Y 
ppb140 1160 99% NRPS modules Y 
ppb145 123 99% SAM-dependent methyl-transferase Y
ppb150 437 100% Permeases of the major facilitator family Y 
ppb155 353 99% Carbomoyl-phosphate synthase large subunit Y 
ppb160 422 99% Pyridoxal phosphate-dependent aminotransferase Y 
ppb165 247 99% Thioesterase in NRPSynthesis Y 
ppb170 316 99% Nonheme iron dioxygenase Y 
ppb175 344 99% Threonin aldolase Y 
ppb180 757 99% Cysteine synthase Y 
ppb185 299 99% Protein involved in propanediol utilization and related proteins Y 
ppb190 512 99% Argininosuccinate lyase Y 
ppb195 938 99% NRPS module Y 
ppb200 258 99% SAM-dependent methyl transferase Y 
ppb205 409 99% Cytochrome P450 Y 
ppb210 836 99% NRPS module Y 
ppb215 305 99% Transcriptional regulator Y 
ppb220 622 99% NRPS module Y
Table 4. Genes present in the putative proximicin biosynthetic cluster. NRPS and 
related proteins are shown in blue; regulatory genes in pink and other genes of interest 
in light blue.   
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Confirmation of ppb cluster presence in V. sp. str. MG37 by PCR 
If the ppb cluster was correct, it would also need to be present in the genome of 
Verrucosispora sp. str. MG37. This was successfully confirmed using V. maris AB18-
032 as the control (Fig. 11). Genes ppb genes ppb090; ppb110; ppb120; ppb115 
and ppb180 with the respective expected base pair fragment sizes: 528bp; 993bp; 
774bp; 1008bp and 1008bp were shown to be present in both proximicin 
producers.  
 
 
 
 
 
 
 
 
 
Figure 11. PCR amplicons of ppb cluster spanning genes in Verrucosispora strains. 
1% agarose gel showing PCR products spanning of ppb genes first in V. sp. st. MG37 and 
then V. maris AB18-032 1. Generuler 1Kb 2 & 3 ppb090 4 & 5 ppb110 6 & 7 ppb120 8 & 9 
ppb155 10 & 11 ppb190 11.  
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2.3.2 Genome sequencing, assembly and annotation of Verrucosispora sp. str. 
MG37 
Genome sequencing 
To recover the whole ppb cluster from Verrucosispora sp. str. MG37, a whole 
genome sequence approach was used. This approach also allowed for comparative 
genomics; other biosynthetic gene clusters present in both strains of Verrucosispora 
were identified (see below) in case the ppb cluster was later experimentally rejected.  
 
Trimming libraries and quality control of sequence reads 
For the paired end library, both Trimmomatic and TrimAdapt programs were used to 
trim adapter sequences and any reads of low quality. The FastQC report before 
(raw) and after processing are shown in Table 5. Although both programs use the 
paired end information (using both reads) to identify where the sequences fall below 
a quality threshold, and to remove adaptor sequences, TrimAdapt left almost 60,000 
more reads available to use in assembly. This is likely due to Trimmomatic only 
keeping sequences with both a Phred score >20 and a length of >304 bp, where 
TrimAdapt keeps any sequence of Phred score >20, with a less stringent 
requirement for length of read.  Despite the difference in read number between 
programs, both very similar outcomes according to FastQC – maintaining a mean 
quality score >30, and removing 100% of the adapter content. Because of this, the 
TrimAdapt reads were used for assembly. Nxtrim was successfully used to trim the 
adapter sequences from the mate pair library and remove any low-quality reads.  
 
Genome assembly of Verrucosispora sp. str. MG37 
The genome was successfully assembled into 6 major scaffolds, with the largest 
contig spanning half the genome (3.01Mb), followed by two slightly smaller contigs 
at 2.1Mb and 1.2Mb. The quality of assembly was assessed using QUAST, it 
showed that 6.75Mb (>99%) of DNA could be mapped to the V. maris AB18-032 
genome, with a low number of miss-assemblies (<200). The majority of these miss-
assemblies were matches to entirely different species – and so were considered 
contamination from either the genome extraction or sequencing process. 
Verrucosispora sp. str. MG37 assembled contigs were successfully reordered 
according to the reference genome V. maris AB18-032 using MAUVE.  

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Annotation of Verrucosispora sp. str. MG37 genome 
Bacterial genome annotation and secondary metabolite cluster finding programs 
were used for annotation and mining of the Verrucosispora sp. str. MG37 genome. 
These included: Prokka, RAST, antiSMASH and Prism. After manual rearrangement 
of the large contigs, the two Verrucosispora strains had very similar genomic 
arrangement, as expected with two such closely related organisms. Indeed, 
Verrucosispora sp. str. MG37 very likely belongs to the species maris AB18-032, as 
the average nucleotide identity (ANI) between the two strains is > 97% (suggested 
cut-off for placing two strains in the same species is 95%). Furthermore, the 
genome-to-genome comparison, that is considered more reliable than ANI, gave a > 
80% probability that both strains belong to the same species. The secondary 
metabolite biosynthetic clusters identified in Verrucosispora sp. str. MG37 were then 
compared to those in V. maris AB18-032, and corresponding clusters matched 
(Table 6), in total 21 common clusters were found, with 4 additional undescribed 
clusters being present in Verrucosispora sp. str. MG37. Importantly, there were four 
NRPS-containing clusters common to both proximicin producers, including the ppb 
cluster identified in V. maris AB18-032. Although largely similar in the secondary 
metabolite clusters present in both, some cluster differences between the two 
proximicin producers are of note: the abyssomicin cluster present in V. maris AB18-
032 is identified as not being present in Verrucosispora sp. str. MG37 – close 
inspection of the cluster shows a very low retained similarity with the abyssomicin in 
V. maris AB18-032. This supported previous metabolite studies noting that 
Verrucosispora sp. str. MG37 doesn’t produce this compound; and gave confidence 
the genome assembly was of high quality. Whole genome sequences and their 
annotated features are given in Fig. 12 and 13 and genome alignment of the two 
strains in Fig. 13. Alignment of the two genomes suggests a reason for strain 
differences: there is a large (ca. 700 kb) genome inversion region (red links in center 
circle Fig. 14), this inversion and subsequent repair is likely responsible for the loss 
of the abyssomicin gene cluster from Verrucosispora sp. str. MG37 (center of 
inversion). 
 
 
 
 

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Figure 12. V. maris AB18-032 genome. Rings (outer to inner) represent: a) scale (kb), b) 
size and location of NP clusters as predicted by antiSMASH, c) RAST predicted genes 
positive strand, d) predicted genes negative strand, e) %G+C (red ≥ 66%, blue ≤ 66%; 
max = 76%, min = 57%), f) GC skew (green ≥ 0.287, purple ≤ 0.287; max = 5.5, min = -
6.12), g) RNAs: black = tRNAs, bold italics = other none-coding small RNAs, red italics = 
ribosomal RNA operons, orange = CRISPR arrays and blue = regulatory RNAs. 
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Figure 13. Verrucosispora sp. str. MG37 genome. Rings (outer to inner) represent: a) 
scale (kb), b) size and location of NP clusters as predicted by antiSMASH, c) RAST 
predicted genes positive strand, d) predicted genes negative strand, e) %G+C (red ≥ 68%, 
blue ≤ 68%; max = 76%, min = 60%), f) GC skew (green ≥ 0.202, purple ≤ 0.202; max = 
5.5, min = -6.12), g) RNAs: black = tRNAs, bold italics = other none-coding small RNAs, 
red italics = ribosomal RNA operons, orange = CRISPR arrays and blue = regulatory RNAs. 
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Figure 14. Genomic comparison of Verrucosispora sp. str. MG37 and V. maris AB18-
032. Rings (outer to inner) represent: a) scale (kb), b) RAST predicted genes positive 
strand, d) predicted genes negative strand, c) %G+C, d) GC skew, e) shared NP clusters, f) 
NP non-shared NP clusters. The links in the centre of the figure show regions of DNA with 
>97% similarity over 10 kb, red lines show regions that are inverted relative to one another. 
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2.3.3 Analysis of ppb cluster in Verrucosispora sp. str. MG37 
Confirmation of ppb cluster in Verrucosispora sp. str. MG37   
To ensure the correct cluster is identified, all Verrucosispora sp. str. MG37 clusters 
were analyzed independently of the ppb cluster in V. maris AB18-032, with the hope 
that it would result in the same cluster being identified in both producers. All SBC 
were analyzed to determine their predicted products and it was found that the most 
likely candidate cluster present in Verrucosispora sp. str. MG37 was homologous 
with the ppb cluster identified in V. maris AB18-032. There were no other common 
SBCs identified in Verrucosispora sp. str. MG37 that were thought to produce a 
molecule similar in chemistry to proximicin, defined by constraints previously 
outlined to likely be present in ppb; this further confirmed our hypothesis that the 
ppb identified in V. maris AB18-032 is correct. 
 
Alignment of ppb cluster in both strains 
ACT was used to align both genomes to highlight regions of similarity and looking 
specifically at the ppb region in both producers. If ppb is the biosynthetic cluster 
responsible for proximicin production, then it should be present in its entirety in both 
strains. This was effectively shown using ACT, showing large regions of similarity 
with the only difference apparent being the lack of a reductase gene (ppb065) in 
Verrucosispora sp. str. MG37 which is present in V. maris AB18-032. No other 
secondary biosynthetic clusters identified in Verrucosispora sp. str. MG37 were 
determined to be likely candidates for proximicin biosynthesis, (using constraints 
previously outlined above)  
 
Analysis of ppb genes  
As the ppb cluster has been identified as being present in both proximicin 
producers, and it appears to be the only likely candidate for proximicin production, 
the genes present were analyzed for likely function. From this six NRPS-like proteins 
were present, all with >99% amino acid identity with V. maris AB18-032; in addition, 
there were a selection of regulatory proteins as well as a cyclodehydratase. Also 
present is an MbtH-like protein, which most likely has a role in adenylation activity.  
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Analysis of A-domains present in the putative proximicin biosynthetic cluster 
Of the six NRPS-like proteins present in ppb, four contain adenylation domains; the 
other two contain only condensation and thiolation domains. The A-domains were 
examined for potential substrates they activate, and these results given from the 
NRPS-predictor programs were further elaborated by looking at the core motifs 
manually. Ppb120 was shown to be very atypical in a specific core residue – a 
change serine to aspartate at the Asp235 position. It also had a very minimally 
conserved A3 and A5 domains, 50% and 33%, respectively. Ppb210 was predicted 
to activate either tryptophan or tyrosine consistently by all predication programs, 
and was shown to contain all core motifs indicative of an active A-domain. No 
substrates could be predicted for Ppb220 and Ppb195; Ppb195 contains all 
conserved core residues which would imply activity, Ppb220 however, has a 
completely absent A1 domain, suggesting that the protein would be inactive.  
 
 
 Ppb120 Ppb195 Ppb210 Ppb220 
Domains present ** A-T A-T-Te A-T A 
Residues in binding pocket SYGXlVXX DIWQCTAD DAWTVAAV DILTFALM 
Maryland NRPS analyzer 
(Bachmann & Ravel, 2009) 
No-
prediction 
No-
prediction Phe 
No-
prediction 
NRPS predictor2 
(Röttig et al., 2011) 
No-
Prediction Gln, Arg Phe, Trp Gly, Ala 
A1 100% 83% 33% 0% 
A2 50% 66% 75% 100% 
A3 61% 83% 100% 92% 
A4 75% 100% 100% 100% 
A5 33% 83% 100% 83% 
A6 81% 36% 72% 90% 
A7 100% 33% 100% 83% 
A8 75% 85% 100% 100% 
A9 85% 100% 100% 80% 
A10 100% 83% 83% 83% 
**A-Adenylation T = Thiolation Te = Thioesterase 
Table 7. Summary of adenylation domains found in ppb cluster. Domains present, 
residues which line the binding pocket and predictions show. Also, the percentage each 
residue conforms to known boundaries as determined by Stachelhaus et al., (1999). Blue 
represents known regions to be involved in substrate binding, and any very poorly 
conserved regions (<40%) are highlighted in bold. The unique serine residue mutation 
observed in ppb120, is highlighted in pink.  
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Chapter 2. Genome sequencing, assembly, annotation of 
Verrucosispora sp. str. MG37, and identification of putative 
proximicin cluster 
 
2.4 Discussion  
  
2.4.1 Overview of Findings  
Whole genome sequencing and assembly of the second proximicin producer - 
Verrucosispora sp. str. MG37 – was reported here for the first time, using a next 
generation sequencing (NGS) platform. By using comparative bioinformatical 
analysis of both proximicin producing Verrucosispora species, a putative proximicin 
biosynthetic cluster was identified, and was shown to present and complete in both, 
with largely >99% identity. Extensive bioinformatical analysis of the cluster allowed 
the outlining of two opposing potential proximicin biosynthetic routes, detailing the 
incorporation of the 2,4-disubstitued furan group. 
 
2.4.2 Assembly and annotation of Verrucosispora sp. str. MG37 
In the research described here, Illumina MiSeq was chosen to sequence the genome 
of V. sp. str. MG37. This platform was selected for many reasons, principally, the 
high speed and coverage, and low relative cost associated with Illumina sequencing 
approaches in comparison to other NGS platforms. Illumina MiSeq harnesses 
sequencing by synthesis (SBS) technology – the reversible terminator method, with 
fluorescently labelled nucleotides to detect single bases as they are incorporated 
into the growing DNA strands - to allow the delivery of highly accurate and robust 
performance. As with the typical cyclic array sequencing workflow, the library was 
prepared by adding sequencing adapters and the libraries transferred to the flow 
cells and sequenced. This allows the output of 2 X 300 bp read lengths, 25 million 
reads per run and a run time of 4-55 hours to run a maximum of 15 Gb. The output 
format of the data is FASTQ, which was developed from the original FASTA format 
to allow the incorporation of Phred-scaled base quality scores to facilitate the 
assessment of sequence quality. Phred score aids in the determination of accurate, 
quality based assemblies and, despite increasing computational complexity to the 
sequencing output, should be retained. This vast amount of resulting data from NGS 
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platforms, and the continual adaptation of bioinformatical programs to process it, 
make deciding on an assembly pipeline difficult. Here I briefly discuss issues 
encountered in read treatments, assembly and SMC identification, and programs 
used to minimise their influence; this will hopefully give insight for future researchers 
attempting assembly and annotation of bacterial genomes. 
 
Quality assessment & treatment of raw reads 
The output given from the Illumina MiSeq sequencing technology is four read 
libraries: Mate-Pair (MP); Single Read (SE); Paired End (PE), and UNKNOWN; how 
each of these are generated from the sequencing reaction is shown in Fig. 15. As 
each library contains different information – determined from where the ligated 
adaptor is located – they each have to be processed differently, in order to most 
efficiently use the information contained. The first step in genome assembly involves 
checking the quality of the reads produced and pre-processing of reads – to make 
Figure 15. How each read library is produced during Illumina MiSeq sequencing 
depending on where reads are taken. (A) shows each read on circular DNA produced 
by adapter arms attached to each end of the DNA fragment then annealed. (B) once 
linearized, reads are taken and they are sorted depending on where the adapter is in the 
read. Looking just at the 5’ read: If the adapter is not encountered at all, it is a standard 
MP (i); if the start of the read is adapter then native DNA, it is a shortened alignment MP, 
and pooled with the MP’s (ii). If the read contains only adapter content, then the 3’ read 
is a single read (iii). If the read contains adapter content, then native DNA it is a paired 
end read (iv) and if the read contains no adapter content, due to incomplete enrichment 
of adapters, it is put into the UNKNOWN library.  
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them compatible with one another. Several tools have been developed for quality 
control (QC) of raw NGS data; these include FastQC (Andrews, 2010) and PRINSEQ 
(Schmieder et al., 2011). The first of these – FastQC – was used here; it is a java 
application that generates many useful data diagnostics, such as the Phred score 
distribution along the reads, GC content and sequence duplication level – this 
information enables what future steps are required prior to alignment. Standard pre-
processing steps include adapter removal and trimming reads identified by QC 
programs. Removal of adaptor sequences is important to prevent alignment errors 
and an increased number of unaligned of reads, yet preserving the maximum of 
useful sequencing data. Most trimming tools available provide this generic 
functions, along with their own custom feature; for example, CutAdapt (Martin et al., 
2011) specifically allows detection of adaptor sequences anywhere in the read, 
whereas Trimmomatic is tailored to process PE reads. Both of these programs were 
analysed to identify which was best to use for Illumina MiSeq data processing, with 
FastQC was used after each program to identify which gave the highest quality 
reads after trimming steps. Although both programs successfully trimmed reads of 
adapter sequences, TrimAdapt left more reads for subsequent assembly while still 
removing adapter and low quality sequences. Trimmomatic removed an additional 
~60,000 sequences, leaving a large amount of ‘orphaned’ reads; for this reason, it 
was excluded from the computational pipeline, and replaced by the more 
conservative trimmer – CutAdapt, in an effort to retain the largest potential amount 
of information available.  
 
Assembly of Verrucosispora sp. str. MG37 
Much research has focused on determining how genome assemblers compare, for 
example the original GAGE assembly comparison (Genome Assembly Gold-
standard Evaluation) (Salzberg et al., 2012) which led to GAGE-B (Genome 
Assembly Gold-standard Evaluation for Bacteria). These large scale program 
evaluations were deigned to answer key questions, such as which program 
generates the best assemblies? and what depth of coverage and software 
parameters should be used to produce the optimal assemblies? This research 
demonstrated that the relatively new genome assembly programme – SPAdes 
(Bankevich et al., 2012) – was the best for microbial genomes, and hence, utilised 
here (Utturkar et al., 2014). One key advantage of SPAdes is the use of paired de 
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Bruijn graphs which allow the integration of read-pair information at a much earlier 
stage of assembly than most other assemblers which employ approach. This results 
in an improvement in contig length by incorporating MP information into the graph 
structure itself, in comparison to other programs which typically ignoring available 
MP information until post-processing steps. The Verrucosispora sp. str. MG37 
genome was successfully assembled into 6 major scaffolds, with the largest three 
spanning >98% of V. maris AB18-032 genome. The availability of this assembled 
closely related genome allows it to be utilised as a high quality reference, and so 
laborious de novo assembly was not necessary. This also meant we were able to 
bypass many issues regarding assessing the quality of our assembly, as this could 
be judged largely by the amount which matched with the reference genome. 
However, to validate the assembly pipeline employed here, results were compared 
to that of other, similarly assembled genomes (Fig. 8). Where miss-assemblies were 
found, further analysis proved that these were not of Verrucosispora strain origin, 
and so are likely an artefact of contamination during the sequencing process. These 
miss-assemblies were disregarded and not included in further steps involving 
genome annotation, and ppb cluster identification.  
 
Identification of Secondary Metabolite Clusters (SMC) 
Despite the chemical diversity of small molecule natural products, the biosynthetic 
principles that govern their production are highly conserved. Enzyme families are 
typically associated with specific production of SM production classes; this 
information can be used to mine genomes for the presence of SMC. There are two 
principal strategies implemented by bioinformatical tools: (i) rule based approaches 
in which specific enzymatic domains are searched for, and then predefined rules are 
used to associate the presence of such hits with defined classes of SM. Such rule 
based strategies can easily detect clusters with well-defined domains, such as 
NRPS or polyketide synthetase (PKS) systems, and is implemented in such 
programs as antiSMASH (Medema et al., 2011), PRISM (Skinnider et al., 2015), and 
NP.searcher (Li et al., 2009). One major issue with this search tool is that it requires 
rules, and hence, cannot uncover SBC’s with novel enzymology. This limitation was 
circumvented by the introduction of (ii) rule independent approaches, used in 
programs such as ClusterFinder (Cimermancic et al., 2014) and EvoMining (Weber et 
al., 2016), which utilises machine based learning or automated phylogenics analyses 
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to make predictions. As we predicted that proximicin is produced by a NRPS, we 
were confident that rule based programs would successfully identify the ppb cluster; 
three programs were used: antiSMASH (Medema et al., 2011), RAST (Aziz et al., 
2008) and Prism (Skinnider et al., (2015). AntiSMASH (antibiotics and Secondary 
Metabolite Analysis Shell) can detect 44 different classes of SMC’s, especially 
clusters containing modular enzymes such as PKS and NRPS genes. It also 
provides detailed annotation of the domain structure of NRPS, substrate prediction, 
genome-scale metabolic modelling and comparative genomic tools, making it the 
most comprehensive software for mining genomes. AntiSMASH is hence referred to 
as the ‘gold-standard’ of annotation tools, and was used here to allow the 
comparison of capabilities of less exploited programs – Prism and RAST. RAST – 
rapid annotation subsystem technology - identified the fewest number of SMC. 
RAST utilises the SEED project of annotation integration (Overbeek et al., 2013), to 
identify genes by comparison to the SEED collection. Continual addition of new 
subsystems into the SEED database will likely lead to the increase in unannotated 
regions of the Verrucosispora sp. str. MG37 genome. Prism made some important 
distinctions in comparison to antiSMASH. Prism is a web based tool specifically 
designed to mine for and analyse PKS and NRPS pathways; it includes the 
identification of similar known pathways. And, unlike antiSMASH – although not 
utilised in this research - is closely connected with the metabolomics platform 
iSNAP (Ibrahim et al., 2012), which can exploit liquid chromatography/tandem mass 
spectrometry (LC-MS/MS) data to identify peaks based on the predicted products. 
Similar to antiSMASH, PRISM identified the ppb cluster; however, interestingly it 
was a smaller cluster containing only six NRPS-proteins consisting of four A-
domains, in comparison to the large SMC identified by antiSMASH. PRISM 
identified the same cluster boundaries as what was predicted by hand curation of 
the antiSMASH report; a small SBC with only four A-domains. AntiSMASH predicted 
that the ppb cluster was part of a larger NRPS cluster, including four other NRPS 
genes which lie upstream, responsible for producing a much larger SM. The 
connecting A-domain-containing protein Ppb220 – is likely inactive, supported by 
research discussed later, as many of its domains are incomplete; antiSMASH, using 
the rule-based approach, was unable to discern that although domains were 
present, they did not retain enough homology in core residues to allow activity. This 
is demonstrated in Table 7, were the presence of core residues was curated by 
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hand, and given as a percentage. As PRISM is a NRPS-specific annotator it was 
able to resolve this ambiguity; this demonstrates that even the ‘gold standard’ of 
annotation programs still requires support, either by hand curation or a specified 
program – if available.  
 
Using the SBC annotation reports from all three discussed programs, identified 
clusters for both V. maris AB18-032 and Verrucosispora sp. str. MG37 were 
compared (Table 6). There were some important differences to note between the 
two Verrucosispora species: primarily, only V. maris AB18-032 contained the 
abyssomicin cluster which supports previous metabolite work suggesting 
Verrucosispora sp. str. MG37 does not produce this compound. Clusters which had 
characteristics previously identified to be required for proximicin biosynthesis were 
identified; primarily we expected to find (i) an NRPS-system cluster which (ii) 
contains an A-domain with a novel active site, capable of accepting a 2,4-
disubstituted containing precursor, (iii) which may have likeness to that seen in 
congocidine biosynthesis. Clusters were systematically excluded or prioritised 
depending on their likeness to these three criteria. Only one common cluster with 
the required components was found; this was given the denotation of ppb – putative 
proximicin cluster. 
 
2.4.3 Analysis of genes present in the ppb cluster 
The ppb cluster contains a total 32 genes, composed of the expected regulatory, 
transportation and proximicin biosynthesis proteins (Fig. 10). Six were identified as 
NRPS-related modules, four of which contain a singular adenylation domain – 
ppb120, ppb195, ppb210 and ppb220. To confirm that it is this cluster that is 
responsible for proximicin biosynthesis, the proteins it encodes, and in particular the 
structure of the adenylation domains present were further investigated.  
 
Adenylation domains determine the chemistry of the amino acid incorporated next 
along the NRPS assembly line, and hence, are responsible for the structure of the 
final SM produced. Through crystal structure analysis, much has been learnt about 
the formation and configuration of these proteins; they are made up of three 
domains: a large N-terminus, a smaller C-terminus and an ATP binding site situated 
between. By investigating the sequence of an A-domain it can be determined (i) 
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whether it is likely that the enzyme is active and (ii) the potential precursor it is likely 
to activate. This is important for resolving the proximicin biosynthetic pathway, as by 
identifying the activity of the A-domains, we can determine chemistry, and the order, 
in which substrates are incorporated. There are many programs dedicated to A-
domain characterisation which is typically a two-fold endeavour: (i) A-domain 
proteins are initially identified by well conserved domains – denoted as A1-A10 
which are involved in both structural and catalytic roles established by Marahiel et 
al., (1997) summarised in Table 8; (ii) A-domain substrate selectivity is then analysed 
by a 10 residue code located at specific positions in the protein located between A4 
and A5, resulting in them being present in the active site – and hence involved in 
substrate coordination and catalysis (Stachelhaus et al., 1999) (Table 8, pink). 
Adenylation domain core motifs are mentioned here only to aid understanding of the 
bioinformatical programs implemented; the origin and specific roles of each, as well 
as their organization in ppb genes, will be evaluated extensively in a later chapter. 
Programs PRISM, NRPSpredictor2 and PKS/NRPS Analysis Web-site exploit this 
well characterised, conserved structure-function relationship for substrate 
recruitment to allow prediction of potential substrate pools. The computational basis 
of these predictions are reliant on the prerequisite that the substrate of a given A-
domain can be deciphered by specificity conferring code. PKS/NRPS Analysis Web-
site delivers predictions based on BLAST analysis against the signatures determined 
by Challis et al., (2000) with more recent tools such as PRISM and NRPSpredictor2 
introducing the use of profile Hidden Markov Models (HMM) and machine learning, 
respectively. As expected by the complexity of the algorithms they utilise, these 
programs were able to match substrates to three out of the four of the A-domains 
tested in this study. The less extensive analysis used in Maryland PKS/NRPS 
Analysis Web-site was reflected in its ability to only predict a singular A-domain 
substrate profile – for Ppb210 – which has an extremely conventional A-domain 
structure (Table 7). Other approaches for A-domain prediction are available, for 
example, there have been many successful reports of using structural models 
consisting of crystal or homology models, as well as docking analysis with putative 
substrates. This was not utilised here, despite being shown to contribute greatly to 
predicting substrate specificity, due in part to the lack of automated tools meaning it 
remains very computer intensive. But primarily due to the key A-domain of interest – 
Ppb120 or whichever is shown to be responsible for incorporating the furan- 
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containing precursor – being novel, and so there would be no homology or crystal 
structures available, preventing comparison affording useful information.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Aromatic residue ** GrsA numbering  
 
 
 
 
 
 
Core Consensus sequence Role 
A1 L(T/S)YxEL Structural; at N-terminus of domain 
A2 LKAGxAYL(V/L)P(L/I)D Structural; properly aligns Gly78 
A3 LAYxxYTSG(S/T)TGxPKG Substrate binding; acts as a loop
A4 *DxS 
Substrate binding; aromatic residue terminates 
an A-helix that forms side of the acyl-binding 
pocket. 
D235  A236  W239  T278  I299  A301  A322  I330  C331  K517 ** 
A5 NxYGPTE 
Structural and substrate binding; invariant 
glutamic acid coordinates Mg2+ ion 
A6 GELxIGx(V/L)ARGYL 
Structural; stabilizes distorted beta sheets in the 
N-terminus domain 
A7 Y(R/K)TGDL 
Substrate binding and catalytic; aspartic residue 
is 100% conserved 
A8 GRxDxxxKxxGxxxELxxxE Structural and substrate binding 
A9 (L/V)Px*M(L/V/I)P Catalytic 
A10 NGK(V/L)DR Catalytic 
Table 8. Core domains present in NRPS-adenylation domains. Core domains 
present in A-domains first outlined by Marahiel et al., (1997), shown to have roles in 
structure, substrate binding and catalytic activity. Consensus sequence of each 
domain shown to be present. The substrate specificity conferring residues located 
between motifs A4 and A5 for model A-domain GrsA outlined by Stachelhaus et al., 
(1999) shown in pink. X denotes any amino acid residue.    
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Identifying the substrates of each present A-domain in the ppb cluster was the initial 
approach utilised in attempting to identifying a potential biosynthetic route to 
proximicin. As discussed, it was predicted that at least one of the adenylation 
domains present in the ppb cluster would have a unique structure, as it is required 
to activate the non α-amino acid group of a 2,4-disubstitued furan. It was also 
hypothesised that it would possess similarity with the A-domain responsible for 
pyrrole incorporation in congocidine biosynthesis – which at the time of the research 
was Cgc18. Cgc18 has been shown to be unique – it possesses a mutation at the 
core residue Asp235, known to be responsible for the alignment of the amino group 
of the substrate in the active site. The idea that this substitution made the enzyme a 
good candidate for a protein which would be able to activate a heterocycle 
precursor was shared by Juguet et al. (2009). However, the congocidine 
biosynthesis pathway has since been revised and it has been shown that it is 
actually another protein – Cgc13* - which is responsible for pyrrole activation. 
Although discussed at length in future chapters, it should be noted that the Asp235 
mutation exhibited in Cgc18, although proven to not be indicative of a heterocycle 
precursor specifically, is suggestive of a non α-amino acid being accepted. One 
such similar A-domain was identified – Ppb120 – which conformed to both of these 
initial predictions; it was unique in its predicted structure, no precursor predictor 
programs could determine its substrate and it possess the same Asp235 mutation. As 
Ppb120 was the singular unique A-domain present in the ppb cluster, we suggest 
that it works in an iterative manner to load precursors (see below). This repetitive 
activation, loading and trans-adenylation activity of A-domains been shown in other 
NRPS synthesis pathways, for example in yersiniabactin biosynthesis, a single 
adenylation domains loads three T domains (Keating et al., 2000) and also, more 
specifically in the revised congocidine pathway, a pyrrole molecule is added 
iteratively by a single A-domain to two different T-domains.  
 
The adenylation domain of Ppb210 contains all the required domains for activity, 
and is predicated to activate a tyrosine or tryptophan like molecule; this prediction 
was shared by all utilised A-domain substrate prediction programs utilised, with a 
high likelihood. The A-domain of Ppb195 is also likely to be active as it contains all 
domains known to be required for activity, however, a likely substrate could not be 
predicted. The final A-domain present in the enzymes of the ppb cluster, located on 
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the boundary of the cluster - Ppb220 - is most likely completely inactive due to 
many of its crucial activity core domains being mutated or completely absent. This 
was supported by in the inability of any of the NRPS-predictor programs to predict 
potential substrates. The inactivity of Ppb220 makes sense as it is the last 
adenylation domain in the gene cluster; as noted, the proximicin gene cluster is 
interpreted by some secondary metabolite clusters finding programs as being part 
of another cluster which lies further along the 3’ end of the DNA. If experimental 
work supports the bioinformatical analysis, and Ppb220 is in fact inactive, it could 
mark the end of the proximicin cluster, and may suggests that previously a larger 
compound was made but inactivity of Ppb220 lead to disconnection of the two 
halves of the cluster, resulting in proximicin production. There are many 
characteristics of Ppb220 which make it extremely unlikely that it would be active, 
many of the core domains vary a lot from the known core consensus sequences, or 
are entirely absent. From the A-domains identified and characterised, along with 
other genes present in ppb cluster, two potentially conflicting routes for proximicin 
biosynthesis were outlined.  
 
2.4.4 Discrepancies in proximicin production   
It has been demonstrated that members of the proximicin family are produced by 
two Verrucosispora species, however they differ in which they produce; 
Verrucosispora sp. str. MG37 can produce all three – A, B and C- and V. maris 
AB18-032 has only been shown to produce A. It was previously thought that some 
mutational event led to this discrepancy exhibited in production. A diversion event 
pushed by differing conditions – potentially limited carbon sources – leading to V. 
maris AB18-032 only producing proximicin A most likely because it is a smaller 
molecule and doesn’t require the addition of the tryptophan or tyrosine moiety. A 
selection event which was not imposed on Verrucosispora sp. str. MG37, and so it 
continued on producing all three. Or perhaps, as V. maris AB18-032 has the ability 
to produce abyssomicin compounds – another family of antimicrobials – proximicins 
were made surplus. Alternatively, Verrucosispora sp. str. MG37 may have been 
under selection pressure by competing bacteria – an evolutionary arms race – 
leading to it retaining the ability to produce proximicins B and C. Abyssomicin 
biosynthesis involves the biosynthesis of a three-carbon unit derived from fructose-
6-phosphate, this is also a key intermediate in the biosynthesis of aromatic amino 
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acids. Thus, during secondary metabolism there may be competition for precursor 
molecules required for the biosynthesis of both abyssomicin and proximicins B and 
C, but not for proximicin A. The absence of the abyssomicin gene cluster in 
Verrucosispora sp. str. MG37 removes this competition resulting in the biosynthesis 
of all proximicins. This hypothesis could be tested by deleting the abyssomicin gene 
cluster in V. maris AB18-032 and observing whether or not proximicins B and C are 
produced. Whatever the driving force, the differences in production presented 
potential insight into the divergence of these two closely related species. However, 
analysis of the two producers and the ppb cluster – shows that there is no genetic 
basis which would result in V. maris AB18-032 only being able to produce 
proximicin A. The ppb cluster has over >99% identity between the two producers, 
and the only difference is the absence of Ppb065 – a hydrolase/reductase – in 
Verrucosispora sp. str. MG37. which would not account for the apparent differences 
in production of proximicins. Both proximicin producers are genetically capable of 
producing the entire family of proximicins, but only one does; this means the genes 
must be under some type of regulatory control preventing expression of certain 
compounds. Regulatory control of gene expression, and hence metabolite 
production, is extremely complex; and so further analysis of proteins governing 
proximicin production is required. It is extremely difficult to determine the regulatory 
control of a biosynthetic cluster, as proteins controlling production may be located 
distantly on the genome to the SBC they control; and typically, many proteins work 
in parallel in a complex homeostasis. One simpler approach would be growing V. 
maris AB18-032 in different media and determine whether it – when exposed to 
differing stresses - begins to produce other proximicins. Alternatively, by alleviating 
potential stresses - such as limited nutrient resources or microbial competition 
leading to the high production of other costly compounds – its metabolic profile may 
change. V. maris AB18-032 and Verrucosispora sp. str. MG37 are both marine 
organisms but were isolated from different locations and at different depths, the Sea 
of Japan at 289 M and Raune Fjord, Norwary at 250 M, respectively. Fiedler et al., 
(2008) when describing the differing production ability of the two species uses a 
singular growth media for metabolite studies: SSG media. Although this is known to 
be a good media for growth of Streptomyces, it is not discussed to what extent this 
media is similar to that of which the bacteria have been extracted. It would be 
interesting to determine whether, if put in an environment similar to that of 
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Verrucosispora sp. str. MG37’s isolation, V. maris AB18-032 would produce all three 
proximicins. Or whether, by adding excess tryptophan or tyrosine – the component 
differences between proximicin A, B and C – would induce production, meaning 
amino acid concentration is the limiting step to proximicins production in V. maris 
AB18-032. If this was successful, a transcriptomics approach could be used to 
determine genes with differing regulation in the new conditions resulting in 
proximicin production – and hence, gain insight into the regulatory control of the 
proximicins.  
 
2.4.5 Conflicting biosynthetic route proposals  
Preliminary review of the ppb gene cluster revealed that it resembles that of 
congocidine, and hence, it was initially presumed that a similar biosynthetic route 
was shared by both enzyme clusters. The biosynthesis of the 2,4-disubstitute 
pyrrole that forms the core dipeptide of congocidine has been determined (Fig. 16a); 
it is derived from fructose-6-phosphate (Lautru et al., 2012). The authors also 
predicted that a similar route would yield the 2,4-disubstituted furan of the 
proximicins; the difference being that a key reductive amination reaction in the 
formation of the pyrrole, would be replaced by a ketoreduction to form the furan 
(Fig. 16b). However, searches of the Verrucosispora genomes using the key 
congocidine biosynthetic genes involved in the formation of the pyrrole (Cgc8, 9, 10 
and 11) failed to identify any homologues. This indicates that the furan moiety of the 
proximicins has a distinct biosynthetic origin. Also, on further analysis of the ppb 
gene cluster, it was shown that it contained many genes which would not be 
required in the initially outlined biosynthetic route; raising the questions – why are 
they present? What is their role? Of these proteins, one of particular interest is 
Ppb090, which shares high sequence similarity with cyclodehydratase enzymes 
responsible for cyclization of linear peptides into heterocycle containing 
compounds, specifically seen in secondary metabolite activation. This led to the 
proposal of a second potential biosynthetic route leading to proximicin biosynthesis, 
in which an unusual linear molecule is accepted by an A-domain and cyclised while 
on the NRPS assembly line by the cyclodehydratases ppb090. The support for both 
these potential routes is outlined below.  
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4-aminofuran-2-carboxylic acid route 
In the first route predicted route a 2,4-disubstituted furan (4-aminofuran-2-
carboxylic or a derivative thereof) is selected and activated by Ppb120 (its activity 
dependent on the MbtH protein Ppb125), Ppb110 loads the adenylated 2,4-
disubstitued furan on to its cognate T domain, and also loads the T domain of 
Ppb140 (a C-T domain protein). Formation of the core proximicin structure 
(dipeptide of 4-aminofuran-2-carboxylic) is achieved through peptide bond 
formation using the two furan aminoacyls as substrates. Ppb165 then catalyzes 
release of the dipeptide from the T domain of Ppb110. Tailoring steps would include 
Ppb155 (carboxyaminoimidazole synthase-like protein) and Ppb145 (a 
methyltransferase) forming the N-terminal methyl carbamate. This route would yield 
proximicin A (Fig. 16b). Biosynthesis of proximicins B and C would be very similar 
except that Ppb120 would load itself and Ppb140 (a C-T-C domain protein) (Fig. 
16b). The domain organization of Ppb140 is very unusual in having two 
condensation domains and no adenylation domains, but it makes sense from the 
perspective of the proposed proximicin biosynthesis pathway: the first condensation 
domain would form the peptide bond as for Ppb110 above; the second would then 
form a peptide bond between peptidyl-S-T of Ppb140 and the aminoacyl-S-T of 
Ppb210, ultimately yielding proximicin B if tyrosine is selected and loaded by 
Ppb210, or proximicin C if tryptophan is selected. Ppb165 would catalyze release of 
the tripeptide from Ppb140 (premature release of the dipeptide would lead to 
proximicin A biosynthesis). The N-terminal modifications would occur as above. The 
C-terminal tyramine in the case of proximicin B and of tryptamine of proximicin C 
are predicted to come from the decarboxylation of tyrosine and tryptophan, 
respectively. The most likely candidate enzyme for this decarboxylation reaction is 
Ppb135 (decarboxylase), but Ppb205 (cytochrome P450) and Ppb130 (hydroloase) 
could feasibly play a role in decarboxylation (Fig. 16b). 
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Cyclohydratase-mediated formation of heterocycles 
Adenylation domains present in the ppb cluster support the route outlined above; 
however, other genes present in ppb cluster introduce potential ambiguity. The 
cyclodehydratases present within the cluster make it unclear at what point the di-
substituted heterocycle is formed: pre- or post-amide bond formation. If it occurred 
post amide bond formation, it would require a heterocyclase to catalyse this 
reaction. Peptide-based biologically active natural products produced by bacteria 
which contain heterocyclic rings are common (Arnison et al., 2013); the presence of 
thiazolines and oxazolines in a variety of approved and potential drugs, has made 
them the focus of much research (Jin et al., 2011). Of particular note here, are three 
homologous systems – the Sag, Mcb and Tru pathways – responsible for the 
production of the antimicrobials streptolysin, microcin B17 and macrocyclic 
cyanobactins, respectively. These are of interest as each pathway involves the 
cyclisation of residues – normally the amino acid cysteine, serine or threonine – on 
the precursor molecule to produce the biologically active final compound. This post-
transcriptional modification of inactive compounds to active toxins – suggests that it 
is a method utilised by microorganisms to prevent self- damage. This class of 
ribosomally synthesized and post- translationally modified peptides (RiPPS) is 
rapidly growing, as research continues into biologically active molecules. Peptide 
residues which are cyclised share some commonalities in their genetic organisation 
and enzyme requirements (Fig. 17a), such as (i) precursor peptide to be modified, 
which contains a conserved N-terminal leader and protease, micro-cyclisation 
domain and the peptide to be processed; (ii) cyclodehydratase enzyme; (iii) 
dehydrogenase enzyme and, (iv) a docking protein. This collection of enzymes 
typically appears next to one another in the genome and are co-transcribed to 
produce a trimeric synthetase complex, and through the action of this complex, 
oxazole and thiazole heterocycles are incorporated into the peptide scaffold. Using 
the biosynthesis of microcins as an example, it has been shown that heterocycles 
are installed through a two-step process: a cyclodehydration to generate an azoline 
heterocycle and a subsequent Flavin mononucleotide (FMN)-dependent 
dehydrogenation to give the aromatic azole (Fig.17b) (Li et al., 1996; Lee et al., 2008; 
McIntosh et al., 2010). It has been shown that these enzymes work in a systematic  
manner to cyclise the precursor molecule, and that the cyclodehydratases enzymes 
exhibit a high level promiscuity, meaning that chemical versatility exists in relation to
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which can be processed. Further work has shown regions of invariantly conserved 
residues are present within both the cyclodehydratase and dehydrogenase which 
are indicative of activity. Multiple sequence alignment of these enzymes families 
previously done shows two almost invariant CXXC motifs in the cyclodehydratases 
thought to be involved in the structural coordination of a Zn2+ molecule – shown to 
play only a structural role (Zamble et al., 2000) - as well as regions containing nearly 
invariant tyrosines and arginine residues thought to be involved in FMN binding in 
dehydrogenases. Adding complexity to this reaction, ATP hydrolysis is required 
(Milne et al., 1998; McIntosh & Schmidt, 2010), yet in some clusters the 
cyclodehydratases contain no bioinformatically identifiable nucleotide binding sites 
(a notable exception which will be discussed later is TruD), and it is only the docking 
protein which strangely contains any resemblance of a nucleotide binding site (Milne 
et al., 1998). However, these residues are not conserved across all docking proteins 
and so ATP is most likely involved in some other way. Although the requirement for 
ATP hydrolysis with respect to azoline formation remains largely undescribed, it has 
been suggested that it may have a role as a dynamic regulator of the trimeric 
synthetase complex or potentially a role in the activation of the peptide backbone 
during cyclisation (Li et al., 1996 & Schmidt, 2010). Recently, Dunbar et al., (2012) 
demonstrated that ATP can be used directly to phosphorylate the peptide backbone 
during heterocycle formation, and that interestingly, the docking protein component 
of the trimeric synthetase complex is also able to perform the ATP-dependent 
cyclodehydration reaction when other related proteins are not present. This could 
give insight into how the furan moiety is introduced into the proximicin biosynthetic 
pathway.  
 
It is logical to assume that a homologous system could be involved in proximicin 
biosynthesis – a precursor molecule is produced via the NRPS system, which is then 
subjected to processing to incorporate the furan groups. For example, the cyclised 
groups resulting in oxadole-groups present in microcin - if the nitrogen was 
replaced by carbon it would result in a furan group with the same 2,4-disubstitution 
pattern exhibited in proximicins. Interestingly, within the ppb cluster, components of 
a trimeric synthetase system are present: a cyclodehydratase - ppb090, and a 
dehydrogenase – ppb055, both of which have moderate, to high similarities to 
systems reported to utilise this trimeric synthetase complex. No homologs to the 
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Figure 17. Cyclodehydratase and dehydrongenase reactions. (a) genetic organisation of 
the Sag and Mcb clusters responsible for streptolysin microcin biosynthesis, respectively. 
Similar genes present in the ppb cluster. (b) the cyclodehydratase and dehydrogenase 
catalysed reactions in the streptolysin and microcin pathways. (c) potential route for furan 
incorporation in proximicin biosynthesis via cyclodehydratases and dehydrogenase enzymes.  

(a) 
(b) 
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precursor peptide or the docking protein are present in the ppb cluster (Fig. 18); 
however, these would not be required as the peptide precursor is produced via the 
NRPS system, and the A-domain would act as an enzymatic scaffold, anchoring the 
substrate in the correct orientation for cyclisation, respectively (Fig. 17c & Fig. 18). 
Importantly, the conserved residues shown to be vital for activity, are present in 
both Ppb090 and Ppb055. Previous studies on cyclodehydratase reactions has 
shown that they are conducted by trimeric synthetase complex, usually annotated 
as a C protein (cyclodehydratase), a D protein (docking) and a B protein 
(dehydrogenase) – in some species the C and D protein are fused (e.g. TruD). As 
above, these annotations were questioned by Dunbar et al., (2012) as they 
demonstrated that it is the D protein that displays ATP-dependent cyclodehydratase 
activity in the absence of the cognate C protein; the presence of the C protein 
increasing the reaction 1,000-fold. The ATP-binding site of the D protein was later 
identified as a conserved and novel motif in D proteins (Dunbar et al., 2012). 
Structural alignment of Ppb090 with TruD (Fig. 19) reveals that it is a C protein 
Ppb090 also lacks the ATP-binding site present in some C proteins such as MccB. 
The lack of ATP binding site is interesting as (i) ATP is known to be essential for 
these cyclization reactions and (ii) to date, no D protein homologue has been 
identified in the ppb gene cluster. The requirement of ATP has been well 
documented; it is needed by TruD to produce a highly reactive intermediate which 
decomposes to thiazoline by rapid elimination of AMP following the attack on ATP 
by the hemiorthamide intermediate displacing pyrophosphate. It is plausible that a 
similar reaction occurs in proximicin biosynthesis, but due to the lack of ATP binding 
domain, the phosphate must be added by another process. This means that the ppb 
cluster theoretically contains the genes responsible for post-transcriptional 
modifications, potentially with the ability to cyclise precursor residues that result in 
the introduction of the furan groups. This theory is based largely on the sequence, 
and by extensive structural homology exhibited by genes in the ppb cluster and 
trimeric synthetase complexes utilised in the production of secondary metabolites in 
bacteria. As discussed, despite sequence similarities in core residues, there are 
several discrepancies, making it extremely important to support this bioinformatic 
work with experimental research. If an equivalent system is present, it would mean 
that the molecule activated by the initial A-domain in the peptide producing chain 
accepts – potentially iteratively – a linear, and not a pre-cyclised compound.  
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Figure. 19. Structural prediction (i-TASSER) of Ppb090 (purple) overlaid and aligned with 
TruD (C domain in blue, D domain in pink). The conserved region of the C proteins is 
circled. 

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The proposed activity of the McbB and SagC enzymes makes it possible to predict 
the likely chemistry of this linear precursor (Fig.17) It may also be possible that the 
cyclodehydratases and dehydrogenase are involved in precursor synthesis, which is 
then accepted into the NRPS system in the heterocycle form. This is unlikely, 
however, it has been shown that these enzymes require the substrate to be in a 
specific orientation for cyclisation to proceed, and – as there is no docking protein 
homolog, the only reasonable explanation is that this job must be done by the NRPS 
proteins.  
 
To determine which of the two proposed routes to proximicin biosynthesis is the 
one utilised by the Verrucosispora species, experimental analysis of the A-domain 
proteins must be done. By confirming the chemical nature– whether a linear 
molecule or a heterocycle containing molecule – of the initially accepted precursor 
by the A-domains present in ppb will allow the outlining of the route to proximicin 
biosynthesis.  
 
2.4.6 Future applications of NGS  
The research described here reports the sequencing, assembly, annotation and the 
outlining of a biosynthetic route responsible for novel chemistry incorporation. From 
this relatively straight forward pipeline, an entire microbial genome was assembled; 
as the ability and large scale implementation of sequencers continues to increase 
exponentially, as with the bioinformatical ability to handle the data produced, the 
potential applications of this technology will be unmatched. As previously 
discussed, antimicrobial resistance is an ever-looming threat to the sustainability of 
the human race, and so it is of paramount importance that antimicrobial compounds 
with novel cellular targets are discovered. NGS platforms offer an unparalleled 
glimpse into all potential clusters present in an organism, revealing novel chemistry 
millions of years in the making. Here, a biosynthetic cluster with potentially high 
pharmaceutical value, was identified and characterized using free to use programs, 
in a facile manner; resulting in a high-quality output. This technology is no longer 
reserved for the excessively funded and those groups with large computing 
capabilities. The latest advancements leading to wide scale applicability of NGS has 
allowed advancements in novel antimicrobial drug discovery. A large amount of the 
research is currently focused on mining genomes for compound biosynthetic 
 90 
clusters which are silent; to identifying the molecular and enzymatic mechanisms 
which underlie the biosynthesis of a compound lead, first the genes responsible 
must be identified.  
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Chapter 2. Genome sequencing, assembly, annotation of 
Verrucosispora sp. str. MG37, and identification of putative 
proximicin cluster 
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Chapter 3.  NRPS Adenylation Characterisation 
 
3.1 Introduction  
 
3.1.1 Importance and structure of NRPS systems  
The study of the of adenylating enzymes dates back to the 1940’s, with Lipman et 
al’s., (1944) discovery of the activation of biological carboxylates as thioesters with 
Coenzyme A (CoA). McElroy et al., (1967) was first to note this group contained 
proteins far beyond the Acyl/Aryl-CoA Synthetases to include proteins which 
catalyse the production of an Acyl-adenylate intermediate, which is then followed by 
further modification in a second partial reaction. The term ‘ANL superfamily’ was 
later coined, and is comprised of the Acyl/Aryl-CoA Synthetases, firefly luciferases 
and the A-domains of NRPS’s. An overview of the reactions catalysed by this 
superfamily is given in Fig. 20. This group comprises a mechanistically diverse 
superfamily with low sequence homology (~ 20% identity), but share a homologous 
structure and a conserved mechanistic step – the adenylation partial reaction. This 
family is distinct from other adenylate forming enzymes – such as the acyl-tRNA 
synthases – and is typically split into three sub-families, however, areas of structural 
and activity overlap exists. This enzymatic similarity is important to note when 
determining A-domain specificity as it can give insight into the structure and 
mechanism potentially responsible. 
 
3.1.2 A-domains as ‘gate-keepers’ 
NRPS systems and their possibly limitless potential for novel antimicrobial and 
antifungal compound isolation has been the focus of much research, specifically 
into the mechanics and protein structures which govern substrate specificity. NRPS 
adenylating domains catalyse the conserved primary partial reaction – activation of 
the amino acid substrate with ATP; this is then transferred to the pantetheine 
cofactor of the neighbouring thiolation domain followed by peptide bond formation. 
To understand and harness this potential avenue for novel compound discovery, the 
enzymatic mechanics must first be elucidated. The adenylation domains are 
considered to be the ‘gate-keepers’ of the reaction, and dictate the chemical nature 
of building blocks incorporated into the elongating peptide chain. As interest peaked 
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Figure 20. The three reactions catalysed by members of the ANL 
superfamily of enzymes. All reactions include an initial partial reaction – the 
adenylate forming reaction (a) with ATP to form an acyl-, amino acyl- or aryl-
adenylate, with the release of inorganic pyrophosphate (PPi). The adenylate 
intermediate then reacts in a second partial reaction, resulting in the release of 
AMP. For NRPS-adenylation enzymes (yellow), a pantetheine thiol group from 
the Thiolation (T) domain attacks the carboxylate carbon displacing the AMP 
leaving group (b) This is similar to that of the Acyl-CoA synthetases (blue), in 
which Coenzyme A (CoA) results in the displacement of AMP (c) Finally, the 
luciferases (pink) result in the production of the intermediate luciferyl-adenylate 
undergoes oxidative decarboxylation resulting in the formation of an 
intermediate compound that decomposes to yield a photon of light (d).  
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in NRPS-system and further members were identified, several research groups 
proposed conserved sequences motifs which exert control over substrate selection. 
This is based on the logical assumption that A-domains with identical or similar 
activity would likely have a similar mechanism, and hence, protein structure and 
active site. This idea was first investigated by de Crecy-Lagard etal., (1995) who 
began isolating potential substrates based on sequence homology of NRPS-
adenylation domains across a 200 aa region comprising the A3 to A6 motifs (de 
Crecy-Lagard et al., 1995), which was later refined to a substrate binding pocket - 
~100 aa stretch between core motifs, A4 and A5 with 10 well defined principal 
residues (Stachelhaus et al., 1999). These residues represent 10 amino acids 
responsible for binding the substrate to be activated. Work by Stachelhaus et al., 
(1999) extensively studies these residues, summarized in Table 9, to determine their 
requirement, variability and function. Of these, some are described as ‘wobble’ 
positions –of high flexibility with respect to amino acid usage – for example 
positions 239 and 278 which are known to have a major role in distinguishing 
between sidechains of possible substrates, and some are described as invariant. 
One of the latter motifs - Asp235 - is involved in the stabilization of the α-amino group 
on the substrate, and is very highly conserved within the ANL superfamily. This 
position has been shown to have a variability of ~3% (Stachelhaus et al., 1999) and 
where variability is observed, it is typically in luciferases and Acyl-CoA synthases 
enzymes and not NRPS-adenylation domains. This is because most adenylation 
domains have an α-amino acid substrate, and so this residue is required to direct 
the amino acid side chain into the binding pocket; hence, mutations lead to 
complete enzyme inactivity. These ‘guidelines’ for correlation between substrate 
conferring residues and activity are not upheld by all NRPS systems, especially 
those involved in non α-amino acid incorporation; hence, the choreography that 
delivers the substrate bound to the T-domain is evidently more complex and not 
highly conserved across all the NRPS systems.  
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3.1.3 Novel adenylating activity 
Congocidine is a pyrrole-amide compound and one such example of a novel 
adenylation domain structure and mechanism. Pyrrole-amides are a family of natural 
products which contain one or several pyrrole-2- carboxamides which confers novel 
DNA binding and antimicrobial activity, and are typically synthesised by 
Streptomyces and related Actinobacteria. Congocidine, first discovered by Finlay et 
al., (1951), is produced by S. netropsis, and the biosynthetic cluster responsible for 
production has been well defined and the enzymatic route established. The gene 
cluster – denoted as cgc - contains 3 NRPS-like enzymes, in addition to other 
proteins responsible for precursor synthesis and regulation.  Of the present 
adenylation domains one is atypical –Cgc18; this NRPS-adenylating domain 
contains a mutation at the 235 position, from an aspartate to serine (Juguet et al., 
2009); this residue is known to be involved in activity and substrate selection, and it 
was initially proposed that due to a specific unique substitution in a substrate-
specifying residue, Cgc18 was responsible for the novel pyrrole incorporation. This 
was shown to be incorrect however, and the enzymatic integration of the novel 
structure was in-fact due to non-NRPS adenylating enzyme Cgc3* (Al-Mestarihi et 
al., 2015). The elucidation of the congocidine biosynthetic route is pertinent to 
proximicin research as they have similar structures and both are formed by the 
iterative introduction of 2,4-disubstituted heterocycles, pyrrole and furans, 
respectively. Hence, it is assumed that their biosynthetic routes would be similar. 
This was supported by the identification of an adenylation domain in the Ppb cluster 
with the same substitution pattern in Cgc18; however, the exchange of adenylation 
domains coming into question. Despite the extensive research into active site 
residues of adenylation domains and the assembly of ‘guidelines’ which control 
substrate selection, the route to proximicin biosynthesis appears to be completely 
novel. Determining how this selection of uncharacterised NRPS-proteins work 
together to result in proximicin production will likely greatly increase the repertoire of 
knowledge into the boundaries known to govern adenylation domain activity. To do 
this, the novel enzymatic machinery to which activity cannot be bioinformatically 
assigned, substrates must be tested in vivo using assays which monitor adenylation 
activity. 
 
 
 104 
3.1.4 Assessing A-domain activity  
Previous work focused on the characterisation of A-domain activity, have largely 
used the radioactive ATP-[32P] pyrophosphate (PPi) exchange assay (Fig. 21b), which 
monitors aminoacyl-AMP formation (Santi et al., 1974, Otten et al., 2007). This 
approach is widely employed as it has been shown to maintain a high level of 
accuracy and be able to detect even low activity; however, many facilities are not 
equipped to handle radioactive materials in a high-throughput manner required for 
these studies. And so increasingly these methods have been replaced by simpler, 
non-radioactive assays; however, investigation into comparing approaches has not 
been widely done. Characterisation of the A-domains responsible for proximicin 
synthesis presented a good opportunity to test the suitability of these newer 
methods, in comparison to the traditional PPi exchange assay. The malachite green 
assay is a newly outlined approach by McQuade et al., (2009) which monitors A-
domain activity, it is reported to give results comparable to 32PPi, circumventing the 
requirement for radioactive materials. The malachite green assay utilises the PPi 
produced during aminoacyl-AMP formation to produce orthophosphate (Pi) via an 
inexpensive pyro-phosphotase which is then quantified using a malachite green 
reagent (Fig. 21c). Although done in differing ways, both the traditional exchange 
and malachite green assay measure adenylation domain activity, by the reversible 
phosphodiester bond cleavage and the rate of PPi release, respectively. Despite 
differences, comparison of the enzyme kinetics for both methods (Km and Kcat) 
appear to be very similar to previous reports (McQuade et al., 2009); however, these 
are few and relatively limited studies, and so further investigation is required. This 
research here gives a good opportunity to conduct an unbiased report on the 
applicability of the malachite green assay to this research field. The discovery of an 
accurate and time-efficient activity assay would facilitate the discovery of new A-
domains and further the determination of the enzyme mechanics responsible for A-
domain activity and specificity, both of which would propel combinatorial formation 
of novel NRPs.  
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3.1.5 Dependence on MbtH proteins  
Work conducted on the intricate enzyme mechanics responsible for A-domain 
activity began decades ago, with the recognition of conserved sequences shown to 
be have a role in specificity; and with the discovery that many important compounds 
are NRPS in origin, the focus on these enzyme systems has increased dramatically. 
One critical recent finding is the dependence of many A-domains on MbtH-like co-
proteins (Drake et al.,2007, Lautru et al., 2007); these are small (~70 amino acid) 
proteins which contain a conserved three tryptophan residue and are named after 
the primarily discovered MbtH protein from the mycobactin biosynthesis gene 
cluster (Drake et al., 2007). Recent research has demonstrated the ability of these 
proteins to influence protein production levels, A-domain activity (Drake et al., 2007) 
and solubility (Heemstra et al., 2009). With the advent of cheap and rapid 
sequencing methods, the extent of the presence of these small proteins in 
association with many secondary metabolite clusters, specifically NRPS genes, has 
been revealed. For example, the Streptomyces producers of the antibiotics 
daptomycin and A54145 have single MbtH-like proteins, DptG and LptG 
respectively, located downstream of the NRPS genes (Miao et al., 2005; Miao et al., 
2006). This pattern is mirrored in many economically important compounds, such as 
antibiotics vancomycin and teicoplanin (Stegmann et al., 2006). However, despite 
their apparent importance, their function has remained largely obscure. Early work 
questioned a direct role in catalysis (Gehring et al., 1998), but more recent studies 
have shown they lack motifs indicative of catalysis (Drake et al., 2007), hence 
suggesting a role as facilitators or chaperones. The solution of the MbtH structure 
gave further insight into their function (Buchko et al., 2010): they have an intrinsically 
disorganised C-terminus which is known to be generally associated with binding of 
multiple partners and functional diversity. Furthermore, the overall conserved shape 
of MbtH-like proteins is described as ‘flat with a two-sided arrowhead’ (Drake et al., 
2007). The MbtH-like protein from the pyoverdine pathway shows the localisation of 
the invariant tryptophan residue on one face of the arrowhead, inferring that the 
other face must be variable (Drake et al., 2007). This implies the possibility of the 
MbtH interacting with two proteins – one interaction on each face of the arrowhead 
– one of which is more variable in structure than the other. Where the MbtH-specific 
conserved tryptophan residue sits suggest that it is this side which interacts with the 
NRPS-proteins, exerting its function. Several studies have suggested possible 
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chaperone roles, including the facilitation of modification of A/T-domain bound 
amino acids, as well as direct roles in amino acid activation which is abolished when 
the MbtH-like protein is absent (Felnagle et al., 2010). Interestingly, it has also been 
shown that some heterologous MbtH-like proteins can partially complement missing 
pathway-specific MbtH-like proteins, but the extent and mechanism responsible for 
this is largely still unknown. This extensive research importantly demonstrates that 
not all MbtH-like proteins have equivalent activities, and hence, a number of 
mechanistic questions still remains.  Further NRPS exploitation requires that these 
are resolved and so additional work into characterising the function and enzymatic 
role in NRPS-systems is required. During elucidation of the putative proximicin 
biosynthetic cluster in Chapter 2 (Table 4), a singular MbtH-like protein was 
identified to likely be involved in proximicin biosynthesis- ppb125. Due to the 
established requirement in many NRPS systems, the necessity of MbtH-like protein 
in proximicin biosynthesis was investigated; specifically, if production was reliant on 
the proximicin-specific MbtH and which, if any, of the A-domains had a dependence 
on MbtH-like proteins for activity and solubility.  
 
3.1.6 Aim of Research  
The aim of this research is to determine the route by which proximicin is 
biosynthesised in its producers V. maris AB18-032 and V. sp. str. MG37– and hence, 
conclude the origin of the furan moiety. Furans are economically important 
compounds, and a simple and inexpensive approach to large scale production 
would be advantageous for many reasons. As previously discussed, many genes 
within the ppb cluster resemble that determined to be involved in the biosynthesis of 
congocidine. This allows the putative function for ppb genes to be partially implied, 
however, experimental evidence is required to explicitly conclude the route to 
proximicin. As discussed in Chapter 2, ambiguity exists concerning the route to 
furan incorporation, leading to the subsequent production of four potential routes:  
I) Ppb120 works in a similar way to Cgc18, activating a linear molecule, and 
once tethered is then cyclised via cyclohydratase-mediated formation of 
heterocycles (outlined in chapter 2: 2.3.5);  
II) Ppb120 is responsible for furan activation, and similarities in core residues 
exhibited in Ppb120 and Cgc18 does not have such an effect on 
specificity as previously reported (outlined in chapter 2: 2.3.5); 
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III) Ppb120 works in a similar way to Cgc18, activating a linear molecule and 
a separate A-domain is responsible for furan activation; or  
IV) Ppb120 is not responsible, and another ppb A-domain activates the furan-
containing precursor in proximicin biosynthesis.  
 
The research here outlines the production of recombinant E. coli strains for Ppb A-
domain protein expression and purification. The successfully purified Ppb120 
protein was used to conclude that the furan moiety in proximicin is incorporated 
pre-amide bond formation, and that Ppb120 is a highly promiscuous enzyme which 
can activate a range of 2,4-disubstituted pyrroles. Pyrrole-containing molecules 
were substituted for furan compounds due to issues involved with the synthesis of 
2,4-disubstituted furans; the similar chemistry between the two families of 
compounds was concluded to be enough to infer activity of furans. It was also 
shown that the proximicin MbtH-like protein –Ppb125 – was required for Ppb120 
activity, as well as solubility of other NRPS proteins. Furthermore, it was determined 
that it could not be partially complemented by a non-native MbtH protein – TioT. 
Ppb220 was shown to be completely inactive, and may mark the end of the 
proximicin cluster, as well as the remnants of a larger, ancient cluster. A-domains – 
Ppb195 and Ppb210 – were not successfully purified in an active form, and hence, 
the system which governs the differentiation between different proximicins – A, B 
and C - was not established. However, vital information on A-domain studies, in 
regard to the requirement of MbtH-like proteins, linker regions and chemical 
additives were reported, which will inform future similar work.  
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Chapter 3.  NRPS Adenylation Characterisation 
  
3.2Materials and Methods  
 
3.2.1 Media and Reagents   
LB media and agar was routinely used for growing up E. coli strains: 10 g Tryptone, 
5 g Yeast extract, 10g NaCl and 7.5 g agar (optional) and 950 mL of water added 
and the pH adjusted to 7.0 using NaOH and the volume brought up to 1 L, with 
ddH2O followed by autoclaving. For growing V. maris AB18-032 and V. sp. str. 
MG37 strains, SSG media, first described by Fiedler et al., (2008): 10 g soluble 
starch, 10 g glucose, 10 g glycerol, 2.5 g corn-steep powder, 5 g Bacto peptone, 2 
g yeast extract, 1 g NaCl and 3 g CaCo3, dissolved in 1 L of tap water and adjusted 
to pH. 7.3 with NaOH before sterilization.  
 
Through the course of this research, issues encountered required many constructs 
involving many vector types and DNA fragment lengths of the same gene, created 
via different primer sets. Where possible I have included tables outlining exactly 
what genotype shorthand is referring to aid in understanding. For sake of clarity, 
when referring to DNA constructs they will contain the vector utilised in the name i.e. 
p28 (pET28) however, the resultant strains produced encompassing this vector will 
not contain this.   
 
3.2.2 Verrucosispora maris AB18-032 and V. sp. str. MG37 gDNA extraction 
Genomic DNA was extracted from V. maris AB18-032 and V. sp. str. MG37 using 
the cetyltrimethyl ammonium bromide (CTAB) method. 30 mL cultures of V. sp. str. 
MG37 were grown up in SSG media at 28°C for 16 hrs and harvested at 16,000X g 
and re-suspended in 5 mL TE25S buffer (25 mM Tris-HCl pH. 8; 25 mM EDTA pH. 8 
and 0.3 M sucrose). Lysozyme was added to final concentration 2 mg/mL and 
incubated for 1 hr at 37°C. Proteinase K and SDS were added to final concentration 
0.18 mg/mL and 0.5% respectively, and incubated for 1 hr with occasional inversion 
at 55°C. NaCl added to final concentration 0.8 M and mixed; CTAB/NaCL added 
and mixed followed by incubation at 55°C for 10 mins followed by cooling to 37°C. 
Chloroform/isoamyl alcohol added and mixed my inversion for 30 min. Centrifuge at 
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13,500 X g at 20°C for 15 mins. Supernatant decanted and 0.6 volumes of 
isopropanol added and mixed; after 3 min DNA spooled and rinsed in ethanol and 
air dried before dissolving in 1 mL TE buffer (1 mM Tris-HCl; 1 mM EDTA pH. 8) at 
55°C. Extracted gDNA was confirmed by running products on 1% agarose gel 
stained with ethidium bromide. Genomic DNA was quantified using Qubit 2.0 
Fluorometer according to ThermoFisher guidelines.  
 
3.2.3 Initial studies I – Vector construction  
pOPINF_ppb vector construction  
Primers were designed to amplify the entire proximicin NRPS A- domain containing 
proteins in V. maris AB18-032: ppb120 (Primer # 11 & 12), ppb195 (Primer # 13 & 
14), ppb210 (Primer # 15 & 16) and ppb220 (Primer # 17 & 18); primers were 
designed with In-FusionTM extensions.  Amplification of proximicin genes ppb120, 
ppb195, ppb210 and ppb220 was done using MyFi taq polymerase. The PCR 
mixture (25 μL) contained 2X MyFiTM High-Fidelity Polymerase Master-Mix (Bioline), 
primers (0.5 μM each), template DNA (25 ng) and DMSO (3%). The PCR was 
performed using MyFiTM Thermal Cycling Procedure. Annealing temperature was 
varied depending on Tm of primers used – varying from 55-67°C. PCR was checked 
by gel electrophoresis, using standard DNA visualisation protocol. PCR products 
were gel purified and eluted into 50 μL water, using the GenEluteTM PCR Clean-Up 
Kit (SIGMA NA1020) according to Sigma guidelines. PCR fragments were then 
quantified using Qubit 2.0 Fluorometer according to ThermoFisher guidelines. 
 
The pOPINF plasmid (Addgene) was transformed into NEB® 5-alpha competent E. 
coli cells, using the five-minute NEB transformation protocol (cat. no C2987H), with 
an additional outgrowth step (referred to hence as the Adapted Five-Minute 
Protocol): NEB® 5-alpha competent E. coli cells were allowed to thaw on ice ~5 
min, and ~25 ng of DNA was added and mixed with the cells and placed on ice for 2 
mins. The mixture was heat shocked at 42°C for exactly 30 seconds and placed on 
ice for 2 mins. 950 mL of LB media was added and incubated at 37°C for 45 mins. 
100% of transformants were plated on LB plates with relevant antibiotic selection – 
here 30 μg/mL ampicillin, overnight at 37°C. 50 mL cultures were used to prepare 
high quantities of pure plasmid using the GenEluteTM Plasmid Miniprep Kit (SIGMA 
PLN10), according to the supplier guidelines. The plasmid was then linearized by 
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restriction digest enzymes NcoI and KpnI according to NEB Double Digest Finder 
protocol and gel purified using GenEluteTM Gel Extraction Kit (SIGMA NA1111), 
according to manufactures protocol, and eluted into 100 μL water. The pOPINF 
backbone and PCR fragments were then annealed using an In-Fusion reaction: ~80 
ng PCR product and ~100 ng pOPINF backbone were mixed with 2 μL 5X In-Fusion 
HD enzyme Premix (TakaraBio), and water added to 10 μL. The reaction mix was 
incubated at 50°C for 15 min. This mix was used directly for transformation into 
NEB® 5-alpha competent E. coli cells using the adapted five-minute adapted 
protocol. The following day, when visible colonies were present, colony PCR was 
performed: ~ 8-10 colonies/ treatment were picked using a sterile wooden pick and 
simultaneously suspended in 10 μL ddH2O and spread on a LB plate with 
appropriate antibiotics. The mixture was boiled in a thermo-cycler for 10 minutes at 
98°C. The resultant solution was used as the source of DNA for a PCR. For colony 
PCR, MyFi Taq Master Mix was used with standard MyFi conditions, along with 
correlating primers used in vector construction. Strains showing the correct plasmid 
determined by correct fragment length were purified using GenEluteTM Plasmid 
Miniprep Kit (SIGMA PLN10), according to the supplier guidelines and transformed 
into E. cloni Express BL21(DE3) E. coli expression strain (Lucigen) using the 
Adapted Five-Minute Protocol.  
 
Control vector  
A control plasmid containing a well characterised A-domain– Ncpb_A4 – on pET28a 
was generously provided by Dr. Garneau-Tsodikova. This adenylation is well 
activated by isoleucine, and its activity is very highly characterized, and so this was 
used as a control for both induction strategies and the malachite green adenylation 
domain activity assay. This plasmid was transformed using the Adapted Five-Minute 
Protocol into E. cloni Express BL21(DE3) E. coli expression strain (Lucigen) and its 
presence confirmed by colony PCR using Ncpb_A4 specific primers – Primer # 19 & 
20.  
 
Protein expression and purification   
A singular proximicin protein– Ppb120 – was chosen to be used for preliminary 
protein expression, purification and assay work, alongside the control – Ncpb_A4. A 
routine protocol was developed for small protein expression and purification studies: 
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Ppb120 and Ncpb_A4 were grown up in LB media, supplemented with ampicillin (50 
μg/mL) and kanamycin (50 μg/mL), respectively. 25 mL cell cultures were grown to 
OD600. 0.4 at 37°C /200 rpm. 1 mL un-induced sample removed, spun at 16,000 X g 
for 15 mins, supernatant removed and the cell pellet frozen at -20°C. Cells were 
induced with IPTG final concentration 1mM and left at 37°C with 200 rpm shaking 
overnight. 1 mL of culture removed and spun at 16,000 X g for 15 mins and the 
supernatant removed. The un-induced pellet was mixed 1:4 and the induced 1:20 
with 2X SDS loading dye and boiled for 5 min. The samples were briefly spun at 
16,000 X g and 5 μL loaded onto a pre-stained SDS-PAGE gel, ran at 200V for 40 
mins. The gel was imaged using the BioRad imager. Proteins were purified using 
His-PurTM Ni-NTA Spin Columns, 0.2 mL (Thermo Scientific, cat. no. 88224) 
according to the manufactures directions.  
 
3.2.4 Initial studies II - Malachite Green assay 
Assay development  
To ensure the malachite green reagent and assay worked accurately, the assay was 
run with varying amounts of phosphate and varying amounts of PPi. These were 
carried out in 398-well plates with each reaction (100 μL) containing: Tris–HCl (pH 
7.5, 50 mM), NaCl (100 mM), MgCl2 (10 mM), inorganic pyrophosphatase (0.2 U/mL) 
and ATP (5 mM). To check the applicability malachite green reagent concentrations 
(0 – 1000 pmol) of phosphate (potassium phosphate monobasic) was added and the 
OD630 measured. To ensure that the enzymatic part of the assay worked, a similar 
test was done but with varying levels of PPi (0 – 100 μM).  
 
Control Adenylation domain: Activity of Ncpb_A4 control  
The well characterized adenylation domain protein - Ncpb_A4 – was used to test the 
efficacy of the Pi detection assay; this was performed in 396-well plates. All 20 
proteogenic amino acids were tested to determine substrate specificity. Reactions 
(40 μL) containing Tris-HCl (50 mM, pH 7.5) MgCl2 (10 mM), NaCl (100 mM), 
inorganic pyrophosphatase (0.2 U/mL)], ATP (5 mM), amino acid in water (6mM) and 
adenylation domain protein (1 μM) were performed at 25°C. The assay was 
performed as follows: in a 384 plate, 10 μL of amino acid (in H2O, 6 mM) was added 
in duplicate, followed by the addition of the adenylation domain protein (Ncpb_A4) 
and inorganic pyrophpsophatase [in 1X reaction buffer: Tris-HCl (50 mM, pH 7.5) 
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MgCl2 (10 mM), NaCl (100 mM)]. The reactions were initiated by addition of ATP (5 
mM), incubated for 2, 4, 6, 8, 12, 16, 24, 32 and 60 min. Reactions were quenched 
with the addition of malachite green reagent (10 μL). After 15 min of colour 
development, the liberated Pi concentration was measured by reading absorbance 
at 600 nm. The experiments were carried out in duplicate for each substrate 
concentration with a negative control (no adenylation domain protein).  
 
Activity of pOPINF_120 using malachite green assay 
The activity of Ppb120 was tested as above using the purified Ppb120 instead of 
Ncpb_A4, all proteogenic amino acids, as well as an array of pyrrole containing 
compounds were tested, as well as demonstrated substrates of similar A-domain 
Cgc18 – guanidinoacetate (GA) (Fig. 22).  
 
 
 
 
 
Figure 22. Pyrrole containing analogues of furan-containing precursors. 
Compounds with the same substituted pattern as the predicted substrate involved in 
proximicin biosynthesis. GA is the substrate of Cgc18A, the adenylation domain 
containing the same amino acid substitution as Ppb120, and hence, potential alternative 
substrate.
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Reactions outlined in Figure 23. 
 
Synthesis of compound C7 
Compound C7 was prepared according to a previously published protocol (Al-
Mestarihi et al., 2016). A solution of A (5 g, 23.53 mmol) in Ac2O (27mL) was cooled 
to -20°C and fuming NHO3 (2.83 mL) was added dropwise over a period of 30 min. 
The mixture was then slowly warmed to room temp for 12 hrs. The mixture was 
poured into ice-H2O and filtrate collected, washed several times with toluene, and 
dried over MgSO4. The residue was re-crystallised using CHCl3:EtOH/95:5 and 
compound C7 was isolated as an off-white solid (31% yield), this matches the 
literature which reported a 41% yield (Al-Mestarihi et al., 2016). 
 
Synthesis of compound C8 
Compound C8 was prepared according to a previously published protocol (Al-
Mestarihi et al., 2016). Compound C7 (0.42g, 1.62 mmol) was dissolved in dry 
MeOH (4 mL) and a catalytic amount of DMAP (10.5 mg, 5%) added. The reaction 
was stirred for 12 hrs at 70°C, until all C7 had disappeared. The reaction mixture 
was evaporated to dryness under reduced pressure to yield C8 (87%) as an off-
white solid, which could be used without any further purification, this matches the 
literature which reported a 93% yield (Al-Mestarihi et al., 2016). 
 
Synthesis of compound C9 
Compound C9 was prepared according to a previously published protocol (Al-
Mestarihi et al., 2016). A mixture of iron (2.66g, 47.65 mmol) and HCl (0.49 mL, 12 
M) in EtOH (16 mL) was stirred at 65°C for 2 hrs. A solution of NH4Cl (8 mL, 24 % in 
H2O) was added to which compound C8 was added over a period of 25 mins. The 
solution was stirred for 12 hrs at 70°C. The mixture was then cooled to room temp 
and filtered through celite. The resultant solution was concentrated to dryness under 
reduced pressure and the residue dissolved in EtOAc. The resulting solution was 
washed twice in NaOH (50 mL, 1 M) and brine (50 mL) and dried over MgSO4 and 
evaporated to dryness to yield C9 (40%) as a yellow solid, this matches the literature 
which reported a 45% yield (Al-Mestarihi et al., 2016). 
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Synthesis of compound 3 
Compound C3 was prepared according to a previously published protocol (Al-
Mestarihi et al., 2016). Compound C9 (0.1 g, 0.71 mmol) was dissolved at 0°C in 
MeOH (4 mL), and NaOH (4 mL, 1 M) was added dropwise. The reaction was then 
stirred at room temp for 12 hrs, then cooled on ice and neutralized with HCl (1M). A 
precipitate formed immediately and the solid collected via filtration and washed with 
H2O and Et2OH to yield compound 3 as a dark brown solid at a 67% yield. this 
matches the literature which reported a 67% yield (Al-Mestarihi et al., 2016). 
 
All compounds were synthesised following the previously published protocol, and 
confirmed using 1H NMR taken (400 MHz, (CDC3)2SO). All other substrates tested 
were kindly supplied by Dr. Garneau-Tsodikova, and the route used also outlined.  
 
3.2.6 Identification of adenylation domains and primer design 
Identification of adenylation domain boundaries  
BLAST search was used to reveal characterised adenylation domain proteins, these 
were aligned with proximicin A-domain protein sequences using BioEdit (Hall, 1999), 
and then the boundaries of the proximicin adenylation domains identified. Sets of 
primers were designed for each to i) include just the A-domain and ii) include linker 
regions with neighbouring domains. Many cloning strategies must be employed to 
create constructs with optimum protein purification and, depending on which 
cloning strategies was used dictates the modifications these primers underwent. For 
ease of understanding, Table 10 summarises all primer sets used for vector 
construction, including the domains present in the resultant protein and strains 
these vectors were used to produce.  
 
Primer design – pET28a   
For pET28a clones, primers were designed to include restriction sites NdeI and 
HindIII in the forward and reverse primers, respectively. Primers were designed by 
hand, checked to prevent any frame shifts and optimised to be appropriate length, 
Tm and GC%. An additional stop codon was added to each reverse primer.   
 
Primer design – pET30a_Xa/LIC 
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For pET30_Xa/LIC cloning, 5’ end adaptor sequences were added to allow Xa/LIC 
cloning:  
Sense primer: 5' GGT ATT GAG GGT CGC – insert-specific sequence 3'  
Antisense primer: 5' AGA GGA GAG TTA GAG CCX–insert-specific sequence 3'  
Where X is any base.  
 
Primer design – pACYC_Duet1  
Primers designed for cloning into pACYC_Duet1 using the restriction sites EcoRI 
and HindIII in the forward and reverse primers, respectively.   
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3.2.7 Amplification of ppb genes  
PCR amplification, gel purification and quantification 
The PCR mixture (50 μL) contained Phusion® High-Fidelity polymerase (0.10 units, 
NEB), dNTPs (200 μM), Phusion® High Fidelity buffer (1X), primers (0.5 μM each), 
Verrucosispora maris DNA (50 ng) and DMSO (3%). The PCR was performed using a 
typical thermal cycling procedure referred to hence as: Phusion Thermo-Cycling 
Conditions - 1 cycle, 98°C for 30 s; 30 cycles, 98°C for 10 s, 71°C for 30 s and 72°C 
for 3:00 min; and 1 cycle 72°C for 10 min. Annealing temperature was varied 
depending on Tm of primers used. PCR was checked using gel electrophoresis using 
the standard technique. PCR fragments of the correct size were gel purified using 
GenEluteTM Gel Extraction Kit, according to Sigma Aldrich guidelines. Fragments 
were eluted into 50 μL of ddH2O and quantified using the Qubit 2.0 Fluorometer 
according to ThermoFisher guidelines.  
 
Thermo-cycling conditions  
Basic PCR condition were kept as Phusion® Thermo-Cycling Conditions but 
adapted to increase yields. The annealing temperature was varied from 54-72°C in 
1°C increments, depending on the Tm of the primers being used. Initial denaturation 
was increased from 98°C to 103°C in 1°C increments; the time was increased from 
3 min to 8 min in 30 sec increments.  
 
PCR additives 
Both enzymes: 2X MyFiTM High-Fidelity Polymerase Master-Mix (Bioline, error rate: 
3.5 X10-6) and HF Phusion® (error rate: 9.5X10-7) were used. Mg2+ concentration was 
increased form 1.4 mM – 4 mM in 0.2 mM increments. DMSO was increased from 
3% to 10% in 1% increments. Betaine was added, in concentration 0.25 M to 1.25 
M in 0.25 M increments.  
 
Slow-Down PCR conditions 
A master mix was created with final concentrations: KCl (50 mM); Tris-HCl (10 mM, 
pH 8.8); Nonidet-P40 (0.08%); MgCl2 (1.5 mM); dATP, dCTP, dTTP (all 200 mM); 7-
deaza-2’deoxyguanosin (150 mM) (NEB); GTP (50 mM); and Taq polymerase (0.01 
U) (Fementas, cat. no. EP0281). To 43 μL of master mix, each Primer (final 
concentration 100 mM) and DNA (final amount: ~80 ng) was added, with ddH2O to 
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make a total volume of 50 μL. The slowdown PCR conditions are as follows: 
amplifications are run for 48 cycles with 30 s denaturation at 95°C, 30 s annealing 
with a progressively lowered temperature from 70°C to 53°C (at a rate of 1°C every 
third cycle) and a primer extension of 40 s, followed by 15 additional cycles with an 
annealing temperature of 58°C. The cycling conditions were altered to have a lower 
ramp rate of 2.5°C/s and a cooling rate of 1.5°C/s for reaching an annealing 
temperature, with 48 cycles. 
 
Hot-start PCR conditions 
Phusion® Hot Start Flex 2X Master Mix (BioLabs, cat. no. M0536L) was used. The 
PCR mixture (50 μL) contained Phusion® HF Polymerase containing an aptamer 
based inhibitor (0.0025 units, NEB), dNTPs (0.5 μM each), 5X HF Phusion® buffer 
(1X), primers (0.5 μM each), V. maris AB18-032 DNA (50ng) and DMSO (3%). The 
PCR was performed using Phusion Thermo-Cycling Conditions. 
 
3.2.8 Design and construction of synthetic ppb195 
Design of SYNppb195  
The A-domain protein ppb195 was codon optimised for E. coli K-12, successful 
optimization was checked by analysing the sequence for: a high codon adaptation 
index (>0.8), codon frequency index of >30%. A synthetic construct was produced 
in three G-block fragments. Primers were designed for both: the amplification of 
each synthetic G-Block and amplification of the joined synthetic fragments with 
pET30a_Xa/LIC adapter arms.  
 
Gibson assembly of SYNppb195 
Gibson assembly was used to combine the fragments of the synthetic ppb195. 
Overlap PCR was preformed using a 25 μL volume reaction: Q5 2X master mix (1X), 
primers (#’s 35-38) (0.5 μM) and G-block fragments 1 and 2 (each 0.4 ng/μL). With 
Q5 specific conditions: 1 cycle, 98°C for 30 s; 15 cycles, 98°C for 10 s, 71°C for 30 
s and 72°C for 1:00 min; and 1 cycle 72°C for 2 min. The fragment and linearized 
pET30a_Xa/LIC vector were assembled: pET30 (100 ng), SYNppb195 amplicon (80 
ng), NEBuilder assembly master mix (10 μL). 5 μL of ligation reaction was used to 
transform E. coli NEBalpha using the Adapted Five-Minute Protocol. Strains were 
checked for the presence of a correct construct using the described colony PCR 
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method using primer #’s 35 & 37; correct strains were grown up in 10 mL LB media 
with 50 μg/mL kanamycin, plasmids were extracted according to Sigma Aldrich 
GenElute Mini-prep kit and checked using sequencing.  
 
3.2.9 Construct preparation 
pET28a vector production: restriction digest; purification; quantification, ligation and 
transformation: 
Restriction digest mixture (50 μL) contained purified PCR DNA (1 μg), RE buffer (1X 
NEB CutSmart buffer, cat. no. B7204S), HindIII-HF and NdeI-HF enzymes (10 units, 
NEB); and incubated at 37°C overnight. Fragments were gel purified using 
GenEluteTM Gel Extraction Kit (SIGMA NA1111) according to Sigma Aldrich 
instructions, and eluted in 50 μL ddH2O. DNA quantity determined by 2.0 
Fluorometer according to ThermoFisher guidelines. Ligation mixture (20 μL) 
contained 10 X T4 ligase buffer (5X, NEB), linearized pET28a (50 ng), insert DNA 
(37.5 ng) and T4 DNA ligase (400 U, NEB). Incubated at 37°C overnight. 3 μL of 
ligation reaction was used to transform E. coli TOP10 (ThermoFisher Scientific) using 
the Adapted Five-Minute Protocol. Strains were checked for the presence of a 
correct construct using colony PCR with corresponding primer sets as previously 
described in insert amplification; strains were grown up in 10 mL LB media at 37°C 
with 50 μg/mL kanamycin, plasmids were extracted using GenEluteTM Plasmid 
Miniprep Kit (SIGMA PLN10), according to the supplier guidelines, and checked 
using sequencing. 
 
pET30_Xa/LIC vector production: Ligation 
For pET30_Xa/LIC cloning, the Novagen vector kit was used (Novagen, cat. no. 
70073-3). T4 DNA polymerase treatment of target insert, annealing into supplied 
pET30_Xa/LIC vector and transformation into NovaBlue GigaSinglesTM Competent 
Cells (cat. no. 71127) was done according to Novagen (User protocol TB184). 
Strains were checked for the presence of a correct construct using the described 
colony PCR method with corresponding primer sets used for fragment generation; 
correct strains were grown up in 10 mL LB at 37°C media with 50 μg/mL 
chloramphenicol, plasmids were extracted according to Sigma Aldrich GenElute 
Mini-prep kit and checked using sequencing. 
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pACYC_Duet vector production: restriction digest; purification; quantification and, 
ligation: 
Restriction digest mixture (50 μL) contained ppb125 purified PCR DNA (1 μg), RE 
buffer (NEB CutSmart buffer 1X), HindIII-HF and EcoR1-HF enzymes (10 units); and 
incubated at 37°C overnight. Fragments were gel purified using GenEluteTM Gel 
Extraction Kit, according to Sigma Aldrich guidelines. DNA quantity determined 
using Qubit 2.0 Fluorometer according to ThermoFisher guidelines. Ligation mixture 
(20 μL) contained ligase buffer (5X NEB T4 ligase buffer), linearized pACYC (50 ng), 
digested ppb125 insert DNA (37.5 ng) and T4 DNA ligase (400 U, NEB). Incubated at 
37°C overnight. 3 μL of ligation reaction was used to transform E. coli TOP10 
(ThermoFisher Scientific) using the Adapted Five-Minute Protocol. Strains were 
checked for the presence of a correct construct using the described colony PCR 
method; correct strains were grown up in 10 mL LB media with 50 μg/mL 
chloramphenicol, plasmids were extracted according to Sigma Aldrich GenElute 
Mini-prep kit and checked using sequencing. 
 
3.2.10Production of competent E. coli expression strain with mbtH inactivation 
Production of expression strains  
Three expression strains were produced, all starting from E. coli BL21(DE3)ybdZ. 
This strain was generously provided by Dr. Garneau-Tsodikova; this strain has the 
chromosomal copy of ybdZ (E. coli MbtH-like protein) inactivated and replaced by a 
chloramphenicol resistance marker and hence, the native E. coli MbtH-like protein 
will not interfere with future applications. 
 
A vector containing TioT - an active MbtH protein involved in the biosynthesis of 
Thiocoraline - was also kindly supplied by Dr. Garneau-Tsodikova to allow testing of 
non-native MbtH-like proteins effect on proximicin A-domain activity. pET28a_TioT, 
in addition to ppb-specific MbtH-like protein – pACYC_Duet_ppb125 were 
transformed into BL21(DE3)ybdZ to create strains for the A-domain vectors to be 
transformed into.  
 
 
Production of competent expression cells and testing transformation efficiency of 
BL21(DE3)ybdZ_pACYC_ppb125 
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A typical procedure to produce cell competency was used for all expressions trains, 
but efficiency only tested for BL21(DE3)ybdZ_pACYC_ppb125 : a starter culture of 
the strain was grown in LB supplemented with relevant antibiotics, was grown 
overnight at 37°C; this was diluted 1:100 into 1 L fresh LB with antibiotics and 
grown to OD600. 0.4, cells were harvested at 3000 X g for 15 min at 4°C in ice cold 
centrifuge bottles. The pellet was re-suspended in 100 mL ice cold 100 mM MgCl2. 
Cells were harvested again at 2000 X g for 15 min at 4°C. The pellet was re-
suspended in ice cold 100 mM CaCl2. The suspension was incubated on ice for ~1 
hour. Cells were then harvested at 2000 X g for 15 min at 4°C. The pellet was re-
suspended in ice cold 85 mM CaCl2, 15% glycerol. The cells were harvested at 1000 
X g for 15 mins at 4°C. The pellet was re-suspended in 2 mL ice cold 85 mM CaCl2, 
15% glycerol. 50 μL aliquots were snap frozen in liquid nitrogen and stored at -
80°C.   
To test the efficacy of the transformation strain: 100 pg of control pUC19 DNA was 
transformed into 50 μL of each of the expression strain cells using the Adapted Five-
Minute Protocol. The transformation efficiency was calculated by the equation:  
 
TE = Colonies/μg/Dilution  
Colonies = the number of colonies counted on the plate  
μg = the amount of DNA transformed expressed in μg  
Dilution = the total dilution of the DNA before plating 
 
Transformation 
All vector constructs were transformed into expression strains:  
i. E. coli BL21(DE3)ybdZ (with no MbtH-like protein);  
ii. E. coli BL21(DE3)ybdZ_pACYC_ppb125 (with proximicin-specific MbtH-like 
protein),  and  
iii. E. coli BL21(DE3)ybdZ_pET28a_TioT (non-specific MbtH-like protein). 
 
This was done using the Adapted Five-Minute Protocol. Strains were checked for 
the presence of the correct constructs using the described colony PCR method. 
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3.2.11Protein purification 
Proximicin biosynthetic gene constructs: p28_120_LATL, p28_220_LAT and 
p30_210_LATL were tested for their expression and protein solubility in three 
conditions:  no MbtH protein, TioT and with proximicin specific MbtH – gene 
ppb125, co-expressed. The same purification method was used: cells were grown 
up in 10 mL LB media starter cultures, supplemented with MgCl2 (10 mM), 
kanamycin for pET30a_Xa/LIC (50 μg/mL) and chloramphenicol for pET28a (50 
μg/mL) constructs. 25 mL cell cultures were grown to OD600. 0.4 at 37°C /200 rpm, 
and then cooled at 16°C for 1 hr. 1 mL un-induced sample removed, spun at 16,000 
X g for 15 mins, supernatant removed and the cell pellet frozen at -20°C. Cells were 
induced with IPTG final concentration 1 mM and left at 16°C with 200 rpm shaking 
overnight. 1 mL of culture removed and spun at 16,000 X g for 15 mins and the 
supernatant removed. The un-induced pellet was mixed 1:4 and the induced 1:20 
with 2X SDS loading dye and boiled for 5 min. The samples were briefly spun at 
16,000 X g and 5 μL loaded onto an SDS-PAGE gel, ran at 200 V for 40 mins. The 
gel was stained with cromassie blue and de-stained overnight. 
   
Large scale protein purification: 125_120_LATL and 125_220_LAT 
To get large quantities of purified protein, 60 mL starter cultures of 125_120_LATL 
and 125_220_LAT with kanamycin (50 μg/mL) and chloramphenicol (50 μg/mL) were 
grown overnight at 37°C; these were diluted 1:100 into fresh LB with antibiotics and 
supplemented with MgCl2 (10 mM) and grown at 37°C /200 rpm to OD600. 0.4 then 
cooled at 16°C for 1 hr. IPTG was added to final concentration 1 mM and grown 
overnight at 16°C /200 rpm. The cell culture was spun 5000 rpm/ 4°C / 10 mins and 
the pellet washed in water and then lysis buffer (40 mM imidazole, 20mM tris-HCl 
pH. 8.0, 400 mM NaCl, 10% glycerol) and then re-suspended in ~ 40 mL lysis 
buffer. DDT and DMSF (both final concentration 1 mM) were added. Cell suspension 
was sonicated for 6 cycles of pulses for 5 seconds and 20 % amplitude with 5 
second gap, and then centrifuged 16,000 rpm/ 4°C / 30 min. The supernatant 
removed and moved to a new tube and centrifuged again. 250 μL/L of culture of Ni-
NTA beads (HisPur Ni-NTA resin, ThermoFisher) were prepared by washing twice 
with diH2O. The supernatant was mixed with the prepared beads and batch bound 
on a shaking platform 2 hrs / 4°C. The bead solution was added to a column and the 
liquid drained; the beads were then washed with 10 X 10mL fractions of wash buffer 
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(40 mM imidazole, 20 mM tris-HCl pH. 8.0, 400 mM NaCl, 10% glycerol) and the 
flow through collected. The protein was eluted using 3 X 5 mL elution buffer; wash 
and elution fractions run on an SDS-PAGE gel and fractions containing purified 
protein of the correct MW were dialysed using 3.5 K MWCO tubing (SnakeSkin 
Dialysis tubing, ThermoFisher). The protein was dialysed in three steps, in 2 L 
dialysis solution firstly for 3 hrs / 4°C, then the dialysis solution refreshed and left 
overnight at 4°C and then for a further 3 hrs in fresh dialysis solution, supplemented 
with glycerol (10%).  Proteins were concentrated using a regenerated cellulose 
membrane column (Amicon Ultra-15) to a concentration 50-100 μM, flash frozen in 
liquid nitrogen and stored at -80°C.  
 
Troubleshooting protein purification of insoluble 125_210  
Different length fragments of ppb210 were used to try and resolve solubility issues: 
ppb210 strains: 125_210_LATL, 125_210_AT and 125_210_ATL were grown up in 
various conditions changing temperature, OD600 of induction, IPTG concentration 
and presence of non-ionic detergents (Triton-X100, NP-40 and IGEPACa-40) to 
determine if solubility could be achieved. Cells were grown to OD600 of various 
points between 0.2 and 0.6 at 16°C and 25°C, cooled to 16°C if required and 
induced with 1 mM IPTG and grown overnight at 16°C. Cells were harvested at 5000 
rpm/ 4°C / 10 mins and the pellet re-suspended in either lysis buffer or non-ionic 
detergents and left for 60 min at 4°C on a shaking platform. The non-ionic 
detergents used were Triton-X100, NP-40 and IGEPACa-40 along with 6 M urea 
being used as a control. All tested conditioned summarised in Table 11. Cell 
suspension was sonicated for 6 cycles of pulses for 5 seconds and 20% amplitude 
with 5 second gap, and then centrifuged 16,000 rpm/ 4°C / 30 min. The supernatant 
removed and moved to a new tube and centrifuged again. The supernatant was 
removed, and labelled as Sol. 1. The pellet was re-suspended in detergent and left 
again for 60 min at 4°C with shaking. The suspended insoluble pellet was then 
centrifuged 16,000 rpm/ 4°C / 30min, the supernatant removed again and labelled 
Sol. 2. The pellet was kept for further analysis, along with both Sol. 1 and Sol. 2 for 
viewing on SDS-page.  
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Strain 
Grown 
Temp 
(°C) 
Induction
Temp (°C) 
Induced 
OD600 
Cell pellet 
re-
suspended 
Insoluble 
pellet re-
suspended 
125_210_LATL 37 16 0.6 Lysis buffer NP-40 
125_210_LATL 37 16 0.6 Lysis buffer Triton-X100 
125_210_LATL 37 16 0.6 Lysis buffer IGEPACa-40 
125_210_LATL 37 16 0.6 Lysis buffer 6M Urea 
125_210_LATL 25 16 0.2 Lysis buffer NP-40 
125_210_LATL 25 16 0.6 Lysis buffer Triton-X100 
125_210_LATL 25 16 0.2 Lysis buffer IGEPACa-40 
125_210_LATL 25 16 0.2 NP-40 NP-40 
125_210_LATL 25 16 0.6 NP-40 NP-40 
125_210_LATL 25 16 0.2 Triton-X100 Triton-X100 
125_210_LATL 25 16 0.6 Triton-X100 Triton-X100 
125_210_LATL 25 16 0.2 IGEPACa-40 IGEPACa-40 
125_210_LATL 25 16 0.6 IGEPACa-40 IGEPACa-40 
125_210_LATL 37 16 0.6 Lysis buffer NP-40 
125_210_LATL 37 16 0.6 Lysis buffer Triton-X100 
125_210_AT 37 16 0.6 Lysis buffer IGEPACa-40 
125_210_AT 37 16 0.6 Lysis buffer 6M Urea
125_210_AT 25 16 0.2 Lysis buffer NP-40 
125_210_AT 25 16 0.6 Lysis buffer Triton-X100 
125_210_AT 25 16 0.2 Lysis buffer IGEPACa-40 
125_210_AT 25 16 0.2 NP-40 NP-40 
125_210_AT 25 16 0.6 NP-40 NP-40 
125_210_AT 25 16 0.2 Triton-X100 Triton-X100 
125_210_AT 25 16 0.6 Triton-X100 Triton-X100 
125_210_AT 25 16 0.2 IGEPACa-40 IGEPACa-40 
125_210_AT 25 16 0.6 IGEPACa-40 IGEPACa-40 
125_210_ATL 37 16 0.6 Lysis buffer NP-40 
125_210_ATL 37 16 0.6 Lysis buffer Triton-X100 
125_210_ATL 37 16 0.6 Lysis buffer IGEPACa-40 
125_210_ATL 37 16 0.6 Lysis buffer 6M Urea 
125_210_ATL 25 16 0.2 Lysis buffer NP-40 
125_210_ATL 25 16 0.6 Lysis buffer Triton-X100 
125_210_ATL 25 16 0.2 Lysis buffer IGEPACa-40 
125_210_ATL 25 16 0.2 NP-40 NP-40 
125_210_ATL 25 16 0.6 NP-40 NP-40 
125_210_ATL 25 16 0.2 Triton-X100 Triton-X100 
125_210_ATL 25 16 0.6 Triton-X100 Triton-X100 
125_210_ATL 25 16 0.2 IGEPACa-40 IGEPACa-40 
125_210_ATL 25 16 0.6 IGEPACa-40 IGEPACa-40 
Table 11. Conditions for optimizing protein solubility. Induction conditions and 
detergent treatment combinations for increasing the solubility of the ppb210 adenylation 
domain.  
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3.2.12Radioactive adenylation domain activity assay 
Determination of substrate specificity and kinetic parameters by ATP-[32P]PPi 
exchange assay 
To determine substrate specificity, ATP-[32P]PPi reactions (100 μL) containing Tris–
HCl (pH 7.5, 75 mM), MgCl2 (10 mM), tris-(2-carboxyethylphosphine) (TCEP, pH 7.0, 
5 mM), ATP (5 mM), amino acid/pyrrole (5 mM), and [32P]PPi (1 mM, 84.12 Ci/mM) 
were performed at 25 °C. The reactions were started by the addition of the 
ppb_22120 (1 μM) and incubated for up to 3 h before quenching with charcoal 
suspensions (500 μL, 1.6% [w/v] activated charcoal, 4.5% [w/v] Na4P2O7, and 3.5% 
[v/v] perchloric acid in H2O). The charcoal was pelleted by centrifugation prior to 
being washed twice with the wash solution (500 μL, 4.5% [w/v] Na4P2O7 and 3.5% 
[v/v] perchloric acid in H2O), resuspended in H2O (500 μL), and counted by liquid 
scintillation (Beckman LS6500, Beckman Coulter, Fullerton, CA, USA). 
 
Time course determination  
Time course of the active substrates was determined using the same reaction 
parameters, but a single substrate in duplicate, quenching each reaction at a time 
point: 10, 20, 40, 60, 120 and 240 min.  
For the determination of Km,ex and kcat,ex for formation of pyrrole-AMP, reactions 
(100 μl) containing Tris–HCl (pH 7.5, 75 mM), MgCl2 (10 mM), TCEP (pH 7.0, 5 mM), 
ATP (5 mM), [32P]PPi (1 mM, 84.12 Ci/mM), and varying concentrations of pyrrole 
(0.00, 0.025, 0.05, 0.10, 0.175, 0.25, 0.50, 1.00, 1.75, 2.50 and 5.0 mM) were done 
at 25°C. The reactions were initiated by the addition of ppb_22120 (5 μM) and were 
stopped after 5 min. The experiments were carried out in duplicate for each 
substrate concentration with a negative control (no enzyme). This was repeated with 
higher substrate concentrations: 0, 0.25, 0.5, 1.0, 1.75, 2.5, 5, 10, 17.5, 25 and 
50mM. 
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3.2.13Comparing radioactive phosphate vs. malachite green assay 
Activity of Ppb120 when co-purified with Ppb125 
Using the same protocol as previously outlined for the malachite green assay, 
purified 120_LATL protein - which had been co-expressed and purified with 
Ppb125, was tested for activity. The assay was performed as previously outlined.  
 
3.2.14Re-testing pOPINF construct activity with MbtH 
Production of pOPINF_120_125 strain, and purifying protein  
pOPINF_120 was transformed into BL21(DE3)ybdZ_pACYC_ppb125 using the 
Adapted Five-Minute Protocol, and small scale protein expression and purification 
was done, according to the previously outlined method.   
 
Activity of pOPINF_ppb120 
The activity of purified Ppb120 when co-expressed with Ppb125 using the pOPINF 
vector was tested as with previous A-domains, all proteogenic amino acids as well 
as an array of pyrrole containing compounds.  
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Chapter 3.  NRPS Adenylation Characterisation 
  
3.3 Results 
 
3.3.1 V. maris AB18-032 and V. sp. str. MG37 gDNA extraction 
High quality DNA from V. maris AB18-032 and V. sp. str. MG37 was successfully 
extracted (Fig. 24) – and PCR showed correct bands for proximicin gene cluster 
genes confirming the correct organism.  
 
 
 
 
 
 
 
 
 
  
 
Figure 24. Verrucosispora spp. genomic DNA extraction. 1% agarose gel showing CTAB 
extracted genomic DNA. 1. GeneRuler 1Kb ladder 2. V. maris AB18-032, 3. Verrucosispora sp. str. 
MG37 
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3.3.2 Initial studies I - Vector construction 
pOPINF_ppb vector construction
DNA fragments of complete ppb120, 210 and 220 genes were successfully 
amplified using PCR; optimization was required to get a high enough quantity of 
product for restriction digest. ppb195 was not able to be amplified using MyFi 
polymerase. PCR fragments were successfully gel purified (Fig. 25); concentration of 
resultant fragments was >100 ng/μL. The empty pOPINF vector was effectively 
transformed into BL21 E. coli cells, purified, restriction digested and gel purified with 
a final concentration of >108 ng/μL (Fig. 25). Ligation of ppb fragments into pOPINF 
and subsequent transformation into NEBalpha E. coli cells was confirmed using 
colony PCR. This showed successful incorporation of ppb genes into pOPINF. 
Correct frame and complete fragments were confirmed using sequencing.  
 
 
 
 
 
 
 
 
 
 
Figure 25. ppb gene amplicons for ligation into pOPINF. 1 % agarose gel showing 
the successful gel purification of DNA fragments containing entire ppb genes generated 
with primers containing In-Fusion modifications to allow efficient ligation into pOPINF. 
1. 1Kb ladder 2. ppb120 3. ppb210 4. ppb220 5. 1Kb ladder. 
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Control Vector  
Ncpb_A4 was successfully transformed into BL21 E. coli cells. This was confirmed 
using colony PCR, with Ncpb_A4 specific primers giving the correct 1500 bp 
product.  
 
Protein expression and purification of Ppb_120 and Ncpb_A4 
Initial protein induction studies demonstrated a low induction rate - specifically for 
Ppb_120 - but a high purification factor (Fig. 26). A large amount of both proteins 
was required – Ncpb_A4 for assay development and Ppb120 for activity studies - 
with ~1 μM for each assay run/substrate, and so optimisation of protein induction 
was done.  
 
Induction of Ncpb_A4 was successfully increased, leading to higher purified protein 
yields (Fig. 27); this was done by using fresh transformants each purification and 
using a slow IPTG induction technique – inducing and growing overnight at 18°C. 
Induction rates for pOPINF_ppb120 failed to increase despite changes in IPTG 
concentration, growth and induction temp and using fresh transformants; it was 
always present in the soluble fraction and so solubility was not investigated. To by-
Figure 26. Successful purification of Ncpb_A4 and Ppb120. SDS-PAGE protein gel 
showing purification of Ncpb_A4 (Lane 2-7) and pOPINF_ppb_120 (Lane 8-13) before 
optimization. Lane 1. BR ladder 2. FT 3. Wash_1 4. Wash_2 5. Wash_3 6. Wash_4 7.
Elution_1 Ncpb_A4. 8. FT 9. Wash_1 10. Wash_2 11. Wash_3 12. Wash_4 13. Elution_1 
Ppb120
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pass this issue, large quantities of culture were used (~16 L) and purified to get a 
large enough amount of protein for succeeding assays (Fig. 28). 
Figure 27. Purification of Ncpb_A4The SDS-PAGE of Ncpb_A4 optimised purification, 
showing very high proportion of all desired protein in the purified fraction 1. BR ladder 2. 
Elution 3. Wash_2 4. Wash_1 
Figure 28. Successful purification of Ppb120. The SDS-PAGE of pOPINF_ppb120 
optimised purification, showing very high proportion of all desired protein in the purified 
fraction, and little remaining in the insoluble fraction. 1. BR ladder 2. Wash_1 3. Wash_2 4. 
Wash_3 5. Concentrated fraction 1 6. Concentration fraction 2 7. Concentrated fraction 3. 
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To produce a large array of chemically relevant potential precursor molecules to be 
tested, the 2,4 di-substitution pattern on the heterocycle was essential. An initial 
literature review and a preliminary study into producing 2,4 substituted furans was 
done (data not shown), and were unsuccessful. Major issues encountered were 
primarily associated with high cost associated with potential starting compounds 
and subsequent over substitution of the heterocycle ring. This was supported by 
research conducted by Garneau-Tsodikova et al., (2017) [personal correspondence]. 
This high cost/low yields associated made it not feasible for the large assay 
application for which they are required. To circumvent this issue, it was decided that 
the pyrrole analogue would be used in its place. The high-yielding synthesis routes 
to 2,4-disubstituted pyrroles are well characterized (Wolter et al., 2009), and the 
scheme utilized by Al-Mestarihi et al. (2015) was used as the basis of the research 
here.  
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3.3.4 Initial studies II - Malachite Green assay development  
To ensure the assay was reproduced correctly, and was able to monitor the level of 
liberated phosphate at a useful level, different concentrations of phosphate was 
used and the change in absorbance recorded (Fig. 30). The assay gave a linear 
output to increasing phosphate concentrations, successfully confirming its 
application as a phosphate detection assay. To test the enzyme component of the 
assay (conversion of PPi to Pi via inorganic pyrophosphotase) (Fig. 31), PPi was 
added at known concentration. It was shown that the increasing level PPi gave a 
linear correlation with absorbance, showing the assay worked and was suitable to 
monitor A-domain activity.  
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Figure 30. Assessing malachite green assay applicability to monitor A-domain 
activity. The linear relationship between phosphate concentration and absorbance (630 
nm), demonstrating the phosphate assay correctly works. R² = 0.999. Error bars show SE. 
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Figure 31. Assessing malachite green assay applicability to monitor A-domain 
activity.  The positive linear relationship between PPi concentration and absorbance (630 
nm), showing the enzyme component of the assay works correctly. R² = 0.9954. Error bars 
show SE. 
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Activity of Ncpb_A4 control  
The purified Ncpb_A4 protein was used in the malachite green assay and tested 
again with all 20 proteogenic amino acids. As shown in Fig. 32 19 amino acids: 
isoleucine, leucine and valine were shown to have a significant A-domain activity 
shown by an increase in absorbance, in comparison to other amino acids. The 
amino acids included in the graph are those with R-groups with similar chemical 
structure or properties of the known substrates to show the level of specificity of the 
A-domain. The difference in absorbance between 1 hr and 16 hrs is due to residual 
Pi reacting with the malachite reagent, not more PPi being produced as the addition 
of the reagent stops the enzymatic conversion of PPi to Pi. 
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Figure 32. Ncpb_A4 activity with a selection of amino acids assessed by the malachite 
green assay. A significant increase in absorbance can be seen with amino acids 
isoleucine, leucine and valine. Error bars represent standard error. 
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Activity of pOPINF_ppb120 
Ppb120 showed no significantly increased activity with any amino acid or acetylated 
pyrrole (Fig. 33). This inactivity with all substrates was determined to be most likely 
due to the protein being inactive, this was supported by previously low yields of 
protein induction and purification. To circumvent this issue, all the adenylation 
domains were re-analysed and new constructs designed.  
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
Ab
so
rb
an
ce
 (6
30
nm
)
Substrate
Figure 33. Ppb120 adenylation domain activity assessed by malachite green assay. 
pOPINF_ppb120 activity with all proteogenic amino acids and a selection of pyrrole 
containing compounds. Error bars represent standard error 
 140 
3.3.5 Identification of adenylation domains and primer design 
Changing approach to NRPS protein cloning 
After issues were encountered with the activity of Ppb proteins when using the 
pOPINF vector system, it was decided that – taking heed from other adenylation 
domain work – the A-domains specifically would be targeted and not the entire 
protein as done in initial studies. Starting over gave us the option to change vector 
system to one more robust, commonly used in successful adenylation domain 
studies and so the pET vector system was chosen. This change was also due to the 
increasing realisation that a MbtH-co protein would likely be important in the ppb A-
domain activity as ppb120 was shown to be inactive in the initial studies. And so, it 
was important to chose a vector system which could be used in tandem with 
another vector system. pACYC_Duet gave an interest opportunity to incorporate the 
ppb genes and MbtH-like protein onto the same vector. This was initially attempted, 
but induction of ppb genes was greatly reduced (results not shown). When 
discussing this issue with other research groups, a similar problem was encountered 
and so a combination of pET and pACYC_duet was used. To identify just the 
adenylation domains, the exact boundaries were determined.  
 
Identification of adenylation domain boundaries  
Adenylation domain boundaries were successfully confirmed using known, well 
characterised domain features. Adenylation, thiolation, condensation and linker 
region-specific motifs were highlighted and their similarity to well characterised 
NRPS systems to identify any sequence level reasons for inactivity or unique 
specificity.  
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Primer design – pET28a   
Figure 34.  Multiple sequence alignment of ppb NRPS-genes, showing core domains and 
primer sets for amplification of A-domains. Amino acid alignment of all NRPS-related genes 
in the proximicin gene cluster. Blue boxes show core adenylation domain motifs; black boxes 
show other NRPS motifs, and pink arrows show placement of PCR primers. 
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For ease of understanding, gene fragments and the resultant constructs and 
expressed proteins are named according to the domains present, for example, 
adenylation, thiolation and linker region. Table 12 below shows the primer sets 
designed, named by the amino acid residue number they begin at, which were used 
to generate the fragments. When referring to a DNA fragment the ppb prefix will be 
used, and when referring to cognate protein, it will be absent. For example, 
ppb120_AT is the DNA fragment produced and inserted into a vector, to yield 
120_AT protein. Further, the vector system utilised will proceed the gene name. 
Figure 35 gives an overview of results from PCR to A-domain activity assays. 
 
 
 
For pET28a, primers were successfully designed for all ppb adenylation domains, 
with the NedI restriction site in the forward primer, and the HindIII and a stop codon 
in the reverse primer. For ppb210, pET30_Xa/LIC primers were successfully 
designed, in the same location as for the pET28a primers, but instead of the 
restriction sites, Xa/LIC arms were added. Primers were designed for the entire 
ppb125 gene, restriction sites: EcoRI and HindIII added to the forward and reverse 
primers respectively.  
 
 Fwd 
Primer 
F 
Primer 
# 
Rev 
Primer 
R 
Primer 
# 
Product 
size (bp) 
Domains 
present 
ppb120 
120_F 21 120_R 24 2322 L-A-T-L 
120_F 21 120_672R 23 2064 L-A 
120_185F 22 120_R 24 1758 A-T-L 
120_185F 22 120_672R 23 1500 A-T 
ppb195 
195_F 29 195_R 31 2119 L-A-T-Te-L 
195_F 29 195_591R 30 1819 L-A-T 
ppb210 
210_271F 26 210_R 28 1751 A-T-L 
210_271F 26 210_750R 27 1419 A-T 
210_F 25 210_R 28 2111 L-A-T-L 
ppb220 220_F 32 220_R 33 1444 L-A-L 
Table 12. Overview of ppb adenylation domain constructs produced. List of 
identified proximicin adenylation domain PCR primers, and base pair product size. L – 
Linker A – Adenylation T – Thiolation  
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3.3.6 Amplification of ppb genes  
PCR amplification, gel purification and quantification
Initial attempts were made to clone all ppb genes into pET28a; products were 
successfully generated for fragments as shown in Table 13 and Figure 36. 
Proximicin gene ppb120 generated products for all primer sets, however 
combination 120_A-T-L gave a lower yield and so was not taken forward to ligation. 
ppb195 was not successfully amplified using PCR. All successful amplifications 
were successfully purified (Fig. 37). 
 
 
 Fwd 
Primer 
Rev 
Primer 
Product 
size 
(bp) 
Domains 
in 
product 
Lane 
in 
Fig. 
36 
Alterations 
to PCR 
method 
μg/mL 
of 
purified 
product 
Fig. 36 
ppb120 
F R 2322 L-A-T-L 2 
Ex. Time 
ext. to 2:30 
min 
101 
F 672R 2064 L-A 3 
Ex. Time 
ext. to 2:30 
min 
125 
185F R 1758 A-T-L 4 None 67 
185F 672R 1500 A-T 5 None 139 
ppb195 
F R 2119 L-A-T-Te-L 8 Unsuccessful PCR 
F 591R 1819 L-A-T 9 
ppb210 
271F R 1751 A-T-L 6 None 59 
271F 750R 1419 A-T 7 None 81 
F R 2111 L-A-T-L / None 132 
ppb220 F R 1444 L-A-L 10 None 99 
Table 13. Overview of ppb gene fragments produced for construction of adenylation 
domain vectors. Summary of PCR method alterations to generate high enough product 
yields for restriction digests. 
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Figure 36.  PCR of ppb genes. 1. 1Kb DNA ladder 2. 120_LATL 3. 120_LA 4. 120_ATL 
5. 120_AT 6. 210_ATL 7. 210_AT 8. 195_LATTeL 9. 195_LAT and 10. 220_LAL 
Figure 37. Gel purified ppb gene fragments. 1. 1Kb DNA ladder; 2. 120_LATL 3. 
120_LA 4. 120_ATL 5. 210_ATL; 6. 210_AT and 7. 220_LAL.  
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Troubleshooting ppb195 amplification    
The proximicin gene pbb195 was extremely difficult to amplify using PCR – primers 
were designed for both pET28a and pET30_Xa/LIC primer sets. Products of the 
correct size were generated, but at very low yields with many non-target products 
(Fig. 38). To increase this, many PCR cycling conditions and additives, as well as 
enzyme and pET vector systems were tested, the results are summarised in Table 
14. Overall, the best results were achieved by a combination of: PCR cycle 
optimization, higher DMSO concentration (>7%) and using MyFiTM polymerase. This 
resulted in a lower amount of off-target amplicons, as shown in the difference 
between Fig. 38 and 39. However, any fragment cloned into a vector had mutations 
present in the DNA sequence. It was thus decided to avoid issues that a synthetic 
version of ppb195 would be designed and synthetically produced.  
 
 
 
 
 
 
 
 
Figure 39. Trouble-shooting of PCR of 
ppb195 I. The highest amount of product 
achieved MyFi Taq polymerase and 7% 
DMSO. 1. 1 Kb DNA ladder 2. 
P30_195_LAT 3. P30_195_AT 4. 
P30_195_LATTe. The yellow asterisk 
denotes the correct product size. 
Figure 38. Trouble-shooting of PCR 
of ppb195. The highest amount of 
product achieved Phusion polymerase - 
using 10% DMSO. 1. 1 Kb DNA ladder 
2. P30_195_LAT 3. P30_195_AT 4. 
P30_195_LATTe. The yellow asterisk 
denotes the correct product size.  
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3.3.7 Design and construction of synthetic ppb195 
Design of SYNppb195
When re-designing ppb195 primers, it became evident that it has an extremely high 
GC content surrounding the adenylation domain, particularly at the beginning of 
ppb195 where the A-domain is located (Fig. 40), has a GC content of ~80%. Due to 
the inability to produce a correct ppb195 DNA fragment, a synthetic E. coli 
optimised ppb195 was successfully designed into three fragments. The codon 
adaptation index (>0.8), codon frequency index of >30%, GC% and number of 
negative CIS and repeat elements were all improved with optimization – to allow for 
efficient expression of protein (Table 15).  
 
 
 
Codon 
adaptation 
index 
Codon 
frequency 
index 
GC 
content 
(%) 
Negative 
CIS 
Negative 
repeat 
elements 
WTppb195 0.68 12 73.9 1 2 
SYNppb195 0.98 29 56.6 0 0 
Figure 40. GC% across the entire native V. maris AB18-032 ppb195 gene. 
Exceptionally high GC content across large spans of the gene explains previously 
encountered issues with PCR. 
Table 15. Assessing the success of E. coli optimization of ppb195. A lower average 
GC% content was observed – the main aim of synthesizing ppb195, but also the 
occurrence of rare codons was lowered, which should aid in E. coli expression. 
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Fragments were designed to incorporate overlapping regions to allow Gibson 
assembly. Primers were designed for amplification with Xa/LIC over hang arms for 
ligation into pET30. The synthetic design of ppb195 was done in a such a way to 
include the A domain in fragment A, the T domain in fragment B and linker regions in 
fragment C. 
 
Gibson assembly of SYNppb195 
Issues with Gibson assembly of all three fragments were encountered; however, 
fragments A and B were successfully joined, confirmed by sequencing. As it is 
fragments A and B which hold the functional regions of the protein (Fig. 41), this was 
initially deemed enough for activity of Ppb195.  
 
 
 
 
Figure 41. Assembly of synthetic ppb195 G-Blocks 1 & 2 containing the A-domain. 
Successful assembly of ppb195 synthetic (SYNppb195) fragments A and B giving a resultant 
product of ~1900bp. 
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3.3.8 Construct preparation  
pET_ppb construct production 
pET28a was supplied by Novagen, and digested successfully using NdeI and 
HindIII. The vector backbone was gel purified to give a high purity and quality DNA 
fragment. The gene fragment ligation into pET28a had the highest efficiency when 
left at 37°C overnight, and so, this was used as standard procedure. ppb gene 
purified fragments were successfully cloned into pET28a to produce constructs: 
p28_120_AT, p28_120_A, p28_210_A, p28_210_AT and p28_220_LAL. 
 
In addition, p30_SYNppb195, p30_210_A and p30_210_AT were all successfully 
produced. ppb125 was also successfully ligated into pACYC_Duet1. All were initially 
confirmed via colony PCR and then sequencing.  
 
3.3.9 Expression strain production 
Production of competent expression strain  
pACYC_Duet_ppb125 was successfully transformed into BL21(DE3) )ybdZ 
confirmed by colony PCR. Competent cells were successfully produced and 50 μL 
aliquots frozen in liquid nitrogen and stored at -80C. The transformation efficiency 
using the control plasmid pUC19 was calculated to average at 3.9 x1010 cfu/ μg 
DNA, which is reasonable for a plasmid of that small size.  
 
Transformation into expression strains 
All generated ppb-containing expression vectors were successfully transformed 
into:  
i. E. coli BL21(DE3)ybdZ (with no MbtH-like protein);  
ii. E. coli BL21(DE3)ybdZ_pACYC_ppb125 (with proximicin-specific MbtH-like 
protein),  and  
iii. E. coli BL21(DE3)ybdZ_pET28a_TioT (non-specific MbtH-like protein). 
 
The transformation efficiency was generally lower, ranging from an average of 0.9 – 
3.1 x1010 cfu/ μg plasmid DNA, likely due to the increased plasmid sizes.  
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3.3.10Protein purification 
Co-expression with no MbtH protein or with non-native MbtH-like protein: TioT
Initial induction studies were done to test protein expression and solubility with 
either a) no MbtH protein and b) with a non-native TioT MbtH protein (Fig. 42 & 43). 
Protein construct combinations: TioT_210_ATL; TioT_220_A and TioT_SYN195_LA 
displayed no increased expression when TioT was present in comparison to when 
no MbtH was present, or a change in solubility. Conversely, TioT_120_AT, 
TioT_210_LATL and TioT_210_AT had a lower level of expression when TioT was 
present, showing the presence inhibited expression. Of those which did express, 
none were purified successfully. All ppb constructs had large quantities of insoluble 
desired protein – were seen in the insoluble pellet. Due to these results, it was 
deemed that there was some level of MbtH specific to the proximicin biosynthetic 
route, and so a non-native MbtH protein was not able to do this.  
 
 
 
 
Figure 42. SDS-PAGE of Ppb A-domain proteins initial induction studies with either 
no MbtH-like protein co-expressed, or co-expressed with TioT. 1. Sigma BR ladder 
2.120_LATL – 3. 120_LATL + 4. TioT _120_LATL – 5. TioT_120_LATL + 6. 120 AT – 7. 
120_AT + 8. TioT_120 AT - 9. TioT_120_AT + 10. 210_ATL – 11. 210_ATL + 12. 
TioT_210_ATL – 13. TioT_210_ATL +. A blue asterisk denotes the increased presence of 
protein in the induced culture in the left hand lane, of the correct size. +/- = induced/non-
induced, respectively.  
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Co-expression with native Ppb125 MbtH-like protein 
All strains tested – 125_120_AT, 125_220_LAL, 125_210_AT, 125_210_ATL, 
125_210_LATL and 125_SYN195 – showed a markedly improved, high levels of 
induction when co-expressed with proximicin-specific MbtH protein Ppb125. Large 
quantities of purified soluble protein were achieved with proteins 120AT and 220A. 
However, protein constructs: 210_AT, 210_LATL and SYN195_LA remained 
insoluble, and 210_ATL was only partly soluble - most of the expressed protein 
remained in the insoluble pellet. For ppb210 A-domain constructs, this was partly 
resolved in two ways: a) designing a vector with the more of the linker regions on - 
210_ATL, and b) the addition of detergents in the purification process (see later 
results).  
 
 
 
 
 
 
Figure 43.  SDS-PAGE of Ppb A-domain proteins initial induction trial. 1. Cont. Sigma 
BR ladder 2. 210_AT– 3. 210_AT + 4. TioT_210_AT – 5. TioT_210_AT + 6. 220_LATL – 7. 
220_LATL+ 8. TioT_220_LATL – 9. TioT_220_LATL + 10. BR ladder. A blue asterisk 
denotes the increased presence of protein in the induced culture in the left hand lane,  of 
the correct size. +/- = induced/non-induced, respectively. 
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Large scale protein purification  
Large scale purification and concentration of – 125_120_AT and 125_220_A was 
successful, giving high yields of purified proteins shown in Figure 44 and 45, 
respectively. 
 
Figure 44. Induction and purification of 125_120_AT. The SDS-PAGE shows: 1. BR 
ladder 2. Insoluble pellet 3. Flow-through 4. Wash 1 5. Wash 3 6. Wash 5 7. Wash 7 8. 
Wash 9 9. Elution 1 10. Elution 2 11. BR ladder 
Figure 45. Induction and purification of 125_220_A. The SDS-PAGE shows: 1. BR ladder 
2. Insoluble pellet 3. Flow-through 4. Wash 1 5. Wash 3 6. Wash 5 7. Wash 7 8. Wash 9 9. 
Elution 1 10. Elution 2 11. BR ladder 
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Troubleshooting protein purification of insoluble 125_210_ATL, 125_LATL and 
125_SYN195_LA 
After extensive protein solubility testing, 125_210_LATL was shown to produce a 
small amount of soluble protein which could be purified. The exact conditions to 
achieve this were a combination of the presence of non-ionic detergents, the best 
being 25 mM triton X-100 incubated with the insoluble pellet, and a lower growth 
and induction temperature of 16°C (Figure 46 – 48). This meant the strain was 
extremely slow growing, and with the low yield, large amounts of culture had to be 
harvested to get the desired amount of protein required for substrate testing. 
 
 
 
Figure 46. Solubility studies of 125_210_LATL. Temperature prior to induction varied and 
OD600 of induction. 1. BR ladder 2. Insoluble pellet control 37/16 OD600 0.4 3. 25/16 OD600 
0.4 Elution 1 4. 25/16 OD600 0.4 Elution 2 5. 25/16 OD600 0.4 Elution 3 Urea 6. 16/16 OD600 
0.4 Elution 1 7. 16/16 OD600 0.4 Elution 2 8. 25/16 OD600 0.4 Elution 3 Urea 9. 25/16 OD600 
0.1 Elution 1 10. 25/16 OD600 0.1 Elution 2 11. 25/16 OD600 0.1 Elution 3 Urea 
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Figure 47. Solubility studies of 125_210_LATL I. Temperature prior to induction varied 
and OD600 of induction. 1. 37/16 OD600 0.4, 25mM Triton X-100 Elution 1 2. 25/16 OD600 0.4, 
25mM Triton X-100 Elution 1 3. 16/16 OD600 0.4, 25mM Triton X-100 Elution 1 4. 37/16
OD600 0.4, 5mM Triton X-100 Elution 1 5. 25/16 OD600 0.4, 5mM Triton X-100 Elution 1 6. 
16/16 OD600 0.4, 5mM Triton X-100 Elution 1 7. 37/16 OD600 0.4, 15mM Triton X-100 Elution 
1 8. 25/16 OD600 0.4, 15mM Triton X-100 Elution 1 9. 16/16 OD600 0.4, 15mM Triton X-100 
Elution 1. A yellow asterisk marks the correct MW band.  
Figure 48. Solubility studies of 125_SYN195_LA. Temperature prior to induction varied 
and detergent varied. 1 37/16 OD600 0.4 Elution 1 2. 25/16 OD600 0.4 Elution 1 3. 16/16 
OD600 0.4 Elution 1 4. 16/16 OD600 0.4, Elution 1 Urea 5. 16/16 OD600 0.4, Elution 1 NP-40 6. 
16/16 OD600 0.4 Elution 1 Urea on pellet 7. 16/16 OD600 0.4 Elution 1 NP-40 on pellet 8. 
16/16 OD600 0.4 Elution 1 Urea 9. 16/16 OD600 0.4 Elution 1 Triton X-100 10. 16/16 OD600 0.4, 
Elution 1 Urea on pellet 11. 16/16 OD600 0.4, Elution 1 Triton X-100 on pellet 12. 16/16 
OD600 0.4, Elution 1 IGEPACa-40 13. 16/16 OD600 0.4, Elution 1 IGEPACa-40 on pellet. A 
yellow asterisk marks the correct MW band. 
* 
* 
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125_SYN195_LA solubility was not increased with the addition of any detergent or 
growth/induction conditions. Of the protein which was soluble, when tested using 
the malachite green adenylation domain assay showed no activity – likely denatured 
protein (results not shown). 
 
3.3.11Radioactive adenylation domain activity assay 
Determination of substrate specificity  
For all purified proteins, all proteogenic amino acids, along with a variety of 2,4-
substituted acetylated pyrrole and furans were tested for activity.  
 
For 125_120_AT, of the amino acids, asparagine, glutamine, threonine and valine 
gave results over the standard threshold for activity (>3000cpm) (Fig. 49). However, 
the acetylated pyrrole gave a much larger activity response. To further see the 
activity – a range of substituted pyrroles were tested – with compounds 4 and 6 
giving a large amount of activity. This demonstrates both the level of promiscuity 
125_120_AT possess, but also how the structure of the compound is detrimental to 
whether it is activated or not.  
Figure 49. Activity of 125_120_AT purified A-domain determined via radioactive 
phosphate exchange assay. All proteogenic amino acids were tested in triplicate, with error 
bars denoting standard error. Initial assays also tested the acetylated pyrrole molecule 1.  
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Other available acetylated pyrrole containing compounds were tested for activity 
(Fig. 50), including substrate ‘A’ which is an additional pyrrole derivative tested in 
later assays (Fig. 51). Compounds 4 and 6 showed high activity, over the 3000cpm 
threshold for successful activity. 
 
 
 
 
Figure 50. Activity of 125_120_AT purified A-domain determined via radioactive 
phosphate exchange assay I. 2,4-disubstituted pyrroles were tested, along with GA – the 
substrate of a similar A-domain. Error bars denoting standard error.   
Figure 51. Pyrrole containing analogues of precursors predicted to potentially be 
involved in proximicin biosynthesis. GA is the substrate of Cgc18A, the adenylation 
domain containing the same amino acid substitution as Ppb120, and hence, potential 
alternative substrate
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Kinetic parameters by ATP-[32P]PPi exchange assay were determined for 
125_120_AT, using the compounds which displayed the most activity – compounds 
4 and 6. The time course data demonstrated that, although the overall activity of 
125_120_AT adenylation domain is high, it is a very slow working enzyme – in 
comparison to other characterized domains.  
Figure 52. Time course determination of 125_120_AT adenylation domain. Determined 
using the radioactive phosphate exchange assay, using substrate 4. Kcat min-1=0.0204 +/- 
0.016, Km[μM] = 6.2923 +/- 0.9491 
Figure 53. Time course determination of 125_120_AT adenylation domain I. 
Determined using the radioactive phosphate exchange assay, using substrate 6. Kcat min-
1=0.0294 +/- 0.014, Km[μM] = 3.843 +/- 0.821
 157 
The enzyme kinetics of 125_120_AT with pyrrole containing compounds 4 and 6, 
gave the steady state kinetic parameters in Table 16, with Michaelis-Menten kinetic 
parameters in graphical form in Appendix F.  
 
Enzyme Substrate Km [μM] kcat [min-1] 
125_120_AT 4 
6.2923 +/- 
0.9491 
0.0204 +/- 
0.016 
125_120_AT 6 
3.843 +/- 
0.821 
0.0294 +/- 
0.014 
 
 
Purified adenylation domain protein 125_220_LATL displayed no activity (Fig. 54) 
with any proteogenic amino acid, pyrrole-containing compounds or furan-containing 
compound.  
 
 
Figure 54. Activity of 125_220_A adenylation domain when tested against all 
proteogenic amino acids. Done in triplicate using the radioactive phosphate exchange 
assay.  
Table 16. Summary of enzyme kinetics of 125_120_AT 
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Purified adenylation domain protein 125_210_LATL displayed no activity towards 
any proteogenic amino acid (Fig. 55), pyrrole-containing compounds or furan-
containing compound – it specifically did not activate the substrate proposed in my 
proximicin synthetic route.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55. Activity of 125_210_LATL adenylation domain when tested against all 
proteogenic amino acids. None exhibited any activity with Ppb210 (only predicted compounds 
shown). Done in triplicate using the radioactive phosphate exchange assay.  
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3.3.12Radioactive phosphate vs. malachite green assays 
To assess the validity of the malachite green assay, 125_120_AT was tested against 
all the substrates tested using the malachite green assay. The results show that 
although some significant activation can be seen, the background noise is so high 
that it is hard to be sure of the results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56. Activity of 125_120_AT determined using the malachite green adenylation 
domain assay. Error bars represent standard error.   
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3.3.13Re-testing pOPINF construct activity with MbtH 
Re-testing pOPINF_120 vector with ppb125 MbtH-like protein 
The addition of Ppb125 had no effect on the induction level of pOPINF_ppb120, 
induction can still be seen but it is still at a relatively low rate.  
 
Activity of pOPINF_ppb120 with Ppb125 
pOPINF_ppb120_ppb125 showed no significantly increased activity with any amino 
acid or acetylated pyrrole. This inactivity with all substrates was determined to be 
most likely due to the protein being inactive, this was supported by previously low 
yields of protein induction and purification.  
 
 
 
 
 
 
 
 
Figure 57. Activity of pOPINF_ppb120 + ppb125. Tested towards all proteogenic amino 
acids and a selection of pyrrole containing compounds. Determined using the malachite 
green adenylation domain activity assay. Error bars represent standard error.
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Chapter 3.  NRPS Adenylation Characterisation 
  
3.4 Discussion  
 
3.4.1 Overview of findings 
In order to elucidate the proximicin biosynthesis pathway, all identified adenylating 
enzymes in the putative cluster were investigated - these enzymes dictate the amino 
acids incorporated into the natural product, providing evidence of the biosynthetic 
route utilized by Verrucosispora spp. The Ppb120 adenylating enzyme was revealed 
to be inefficient and promiscuous, able to activate a large range of heterocycle-
containing substrates, giving support to a previously outlined route for proximicin 
biosynthesis. This was proven using two competing assay approaches to determine 
their applicability and accuracy to this type of research. Ppb220 was shown to be 
completely inactive, which was expected due to previously described bioinformatic 
analysis of the protein. This gave insights into possible origins of the proximicin 
cluster and avenues for potential combinatorial chemistry approaches to novel 
natural product production. Issues were encountered in the recombinant expression 
of two of the adenylation domains – Ppb195 and Ppb210 – due to their high GC% 
and solubility, respectively. This research will inform future work into novel furan-
containing compound discovery and synthesis, as well as future experimental 
approaches used in adenylation domain activity elucidation, for example the 
importance of linker regions between neighboring domains and compound-specific 
MbtH-like proteins.  
 
3.4.2 Novel activity and unique structure of Pbb120  
The unique predicted structure of Ppb120 and the presence of 2,4-disubstituted 
furan groups is what initially attracted interest in proximicin biosynthesis; it poses an 
attractive target for novel antimicrobial compound production and combinatorial 
chemistry. This research has confirmed the novel activity of Ppb120, and discovered 
a high level of promiscuity in the compounds it can activate. Adenylating activity 
towards 2,4-disubstituted 5-membered heterocyclic compounds has only been seen 
previously once before – in congocidine biosynthesis with the AMP-binding super-
family protein - Cgc3* which activates 4-aminopyrrole-2-carboxylate (Al-Mestarihi et 
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al., 2015). Cgc3* is not an NRPS adenylation domain, but a member of the ANL 
family, and shares high-to-moderate sequence identity with the acyl-CoA 
synthetases (Al-Mestarihi et al., 2015). To be able to harness the biosynthetic 
potential of Ppb120 it is important to determine the source of the novel activity; do 
both adenylating proteins work in the same way to activate this family of molecules, 
demonstrating common functions of two diverged proteins? Or is it a case of 
convergent evolution?  
 
3.4.3 Enzyme kinetics of Ppb120 
This work describes the adenylating activity of Ppb120 when tested against a range 
of potential substrates from the 2,4-pyrrole-containing family of compounds. In the 
outlined biosynthetic route of proximicin, a 2,4-furan precursor is iteratively 
incorporated into an elongating peptide chain. The complex chemistry which makes 
furans such an alluring target for investigation, makes them extremely difficult to 
synthesize; and, despite extensive attempts, the 2,4-furan containing precursor 
compounds were never successfully synthesized with a high enough purity and 
hence, could not be tested for activity. However, this gave an exciting opportunity to 
assess the promiscuity of the Ppb120 enzyme towards other heterocycle substrates 
containing a similar substitution pattern. Ppb120 was shown to be able to activate a 
large selection of 2,4-pyrrole molecules; the specific substitution pattern was 
extremely important for activity, and when absent activity was abolished. The two 
compounds with the greatest activity – compound 4 and 6 - appear contradictory: 
the length of carbon chain attached to the 2-carbonyl group increased activity when 
odd numbered, but even numbered carbon chains tended to decrease activity by a 
factor of >3. Potential explanations for this unusual result is discussed later, but it 
highlights the complexity of the enzyme/substrate interactions occurring. The 
enzyme kinetics, when compared to previous similar work (Sun et al., 2015), 
demonstrates that overall Ppb120 is active, but slow working protein which 
supports the theory that pyrroles are not the native substrates, but can be accepted 
and activated with reduced efficiency. Activity for a compound which exceeds 
>5000 pcm in the radioactive 32PPi exchange assay is typically categorized as a 
substrate of the enzyme; interestingly Ppb120 showed activity just over this 
threshold towards polar hydrophilic α–proteogenic amino acids, these included: 
asparginine, glutamine, threonine and valine. This result is extremely unusual when 
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considering Ppb120 has such stringent requirements for the compounds it will 
activate – seen particularly by inactivity towards compounds with even carbon 
lengths. As the research effort was focused on identifying the A-domain responsible 
for furan-precursor activation, this result was not regarded as being significant in the 
scope of this investigation, and hence will not be further discussed here. It should 
be noted, however, that it was concluded that this apparent activity was most likely 
an artifact of the assay methodology, and any genuine activation was at a very low 
and inefficient level, but should be considered in further research into the 
promiscuous activity of Ppb120 as an exciting prospect for unnatural natural 
product combinatorial biosynthesis.   
 
3.4.4 Asp235 substitution   
To exploit the novel activity exhibited by Ppb120, it is important to identify the 
enzymatic architecture responsible. Ppb120 forms part of the ANL family of 
adenylating enzymes, which is composed of the acyl- and aryl-CoA synthases, 
firefly luciferases, and the adenylation domains of NRPS’s; it is a mechanistically 
diverse enzyme superfamily. Members catalyze two partial reactions: i) the initial 
adenylation of a carboxylate substrate with ATP to form an acyl-AMP intermediate 
and, ii) most commonly, the formation of a thioester. All ANL enzymes share a 
conserved mechanistic step – the adenylation partial reaction- and are structurally 
homologous, but share only ~20% sequence identity. Due to the breadth and 
importance of the reactions they catalyze, the ANL family have been subject to 
extensive study, with much work centered on the understanding of their enzymatic 
architecture. Early studies described Asp235 as strictly invariant (Stachelhaus et al., 
1999); however, examples of non-conforming NRPS-adenylation domains have 
been discovered. One of interest and previously discussed is Cgc18 that is involved 
in the biosynthesis of the antibiotic congocidine, and has the same substitution 
pattern as Ppb120: Asp235 → Ser235. This radical substitution from a very acidic to 
polar-hydrophilic amino acid in an apparent ‘invariant’ residue seemed an extremely 
good reason to explain the proposed adenylation domain activity of Cgc18 and 
Ppb120 i.e. the selection and activation of pyrroles and furans, respectively (Table 
17). This hypothesis was shared by Juguet et al., (2009) when the initial congocidine 
pathway was outlined. It was thought that the Cgc18 adenylation domain was 
responsible for the activation of a pyrrole-containing molecule, 4-aminopyrrole-2-
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carboxylate – a molecule not previously seen to be activated by an adenylation 
domain; a novel enzyme activating a novel compound. This would support a 
homologous route to furan activation in Ppb120 – a molecule very similar to that 
activated by Cgc18. However, the congocidine pathway was later revised (Al-
Mestarihi et al., 2015) and it was shown to activate guanidinoacetic acid (GA), and it 
is a different adenylating protein – Cgc3* – which activates the pyrrole-containing 
molecule. Cgc3* was shown to begin the Congocidine biosynthetic pathway by the 
ATP-dependent activation of 4-acetamidopyrrole-2-carboxylic acid. Cgc3* also has 
a residue substitution: Asp235 → Tyr235. Using the chemical complementarity between 
the binding pocket and the substrate as the basis for clustering (Rausch et al., 2003; 
Challis et al., 2007; Reger et al., 2007) and predication (Lautru et al., 2007) of NRPS 
adenylation domain activity is not a new concept. It is well documented that 
adenylation domains which activate similar compounds, will likely have a similar 
binding pocket arrangement; this is indeed the premise used by many NRPS-
predicting programs. To this end, it would be sensible to suggest that Cgc3* and 
Ppb120, as activating similar molecules, would have a similar binding pocket 
architecture. However, by doing simple phylogenetic studies considering only the 
specific conferring code, it can be seen that despite similarities in activities, they 
belong to distinct clades in the ANL family of proteins (Fig. 58). The whole binding 
pocket consensus residues of Cgc3*, as determined by Stachelhaus et al., (1999) 
are atypical, with most being completely absent. This is expected as Cgc3* is not a 
NRPS-adenylating protein, and hence, will not conform to the parameters dictated 
for that specific group of proteins. However, it is logical to assume that being able to 
activate the same compounds would be the result of similar enzymatic machinery, 
but no homology can be found. Because of this, it is hard to propose how the Cgc3* 
binding pocket is able to accommodate and activate its substrate, and hence, how 
this relates to Ppb120 activity. Employing this substrate prediction method for novel, 
non-conforming adenylation domain activity is bottle-necked by the lack of 
characterization of such enzymes. As the capability of NGS continues to flourish, 
currently unidentified or silent biosynthetic gene clusters will inevitably add to this 
sub-family of novel enzymes and increase bioinformatical substrate identification 
capabilities, as well as how different members of the ANL with distinct structures are 
able to support the same activity. 
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3.4.5 Similarity with other ANL superfamily enzymes 
When looking at the clustering pattern of the specificity conferring code Ppb120 
(Fig. 58), it is not closely related to other NRPS-adenylating enzymes: neither Cgc18 
which has an identical substitution pattern in a fundamental residue, nor Cgc3* 
which is shown to activate the same family of compounds. It branches from the 
other NRPS-adenylation domains at a very early node; it does, however, cluster with 
the firefly - Photinus pyralis – and another luciferase adenylating enzyme. Both 
enzymes catalyze the activation of a carboxylate substrate by reacting with ATP to 
form an acyladenylate and PPi (Fig. 59). Distinct from NRPS systems, luciferase 
adenylating enzymes activate luciferase to produce a luciferacyl-adenylate 
compound which undergoes oxidative decarboxylation resulting in the production of 
a photon of light (Fig. 59a). It is expected to see a certain level of homology as they 
share a similar initial partial reaction and it can be assumed that they do not share a 
similar secondary reaction – Ppb120 is not a luciferase. However, they do share 
similarity when looking directly at the active site residues responsible for substrate 
binding. The two substrates known to be activated by Ppb120 (Fig. 59b) and the P. 
pyralis luciferase appear to occupy a similar chemical space -  they have a notable 
Maximum Common Substructure (MCS) value of 9 (Fig. 59c). MSC gives a numerical 
value to common elements shared by two structures; a value of 9 means a path of 9 
identical bonds can traced through each molecule, specifically 9/12 (75%) bonds 
present in the furan-containing compound can be mapped directly onto luciferin – 
this represents a large amount of structural similarity. The common substructure is 
interesting as it has a similar structure to GA (Fig 59d) – the substrate of Cgc18, 
which is the other adenylation domain with the Asp235 substitution. Without knowing 
how the pocket binding interacts with the substrate, it is difficult to make 
conclusions regarding the similarity between Ppb120, Cgc18 and the luciferases. 
However, it is possible to theorize that Ppb120 and indeed Cgc18, may represent an 
early diverging ancestor of the NRPS adenylating enzymes and luciferases, which 
have evolved different secondary enzymatic reactions but maintained similar 
substrate activity. Or simply, the Asp235 mutation has allowed the NRPS-adenylating 
enzymes to activate molecules which coincidentally share a high MCS with the 
luciferase substrate - luciferin. This is not the first time overlap between these two 
apparently distinct ANL sub-families has been described: GrsA – the phenylalanine 
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Figure 58. Phylogenetic analysis of the conserved specificity conferring code of 
NRPS-adenylation domains. Demonstrating how substrate structure can be predicted 
from the comparison of characterised A-domains and their substrates. Grey shading 
shows clades of very conserved activity for specific amino acids. Blue shading shows 
that the luciferases diverge very early from the other family of NRPS adenylation 
domains, as expected. Pink shading shows the lack of clustering the specificity 
conferring code of Ppb120, indicating its unique adenylating activity.  
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Figure 59. Formation of an acyl-AMP intermediate from a carboxylate and ATP via 
enzymes representative of two ANL sub-families. (a) The adenylation reaction of 
luciferin, catalysed by Firefly luciferase. (b) The adenylation reaction shown to be 
catalysed by NRPS-protein Ppb120 of a heterocycle-containing compound. Despite 
being shown to activate similar initial substrates, both differ in the second partial 
reaction they go on to catalyse. (c) The conserved chemical structure of both luciferin 
and 2,4-disubstituted furan highlighted in purple, which shares a similar structure to the 
demonstrated substrate of Cgc18 – GA (d). This shows potential crossover between 
families of adenylating enzymes, not previously highlighted.  
(a) 
(b) 
(c) (d) 
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activating adenylation domain involved in gramicidin production – has a similar 
three-dimensional structure to that of firefly luciferase (Conti et el., 1997). They do 
not cluster according to these substrate conferring residues – as they activate 
different substrates – but they have a conserved tertiary arrangement. This is 
unusual as structural studies of luciferases has shown that despite a similar overall 
2-domain architecture, the C-domain is rotated by ~ 90° in luciferases compared to 
the orientation seen in NRPS enzymes. To further determine whether Ppb120 has a 
luciferase-like C-domain orientation, the crystal structure of Ppb120 would have to 
be solved, and hence, issues surrounding getting a large enough quantity of soluble 
protein would have to be resolved. Other overlaps between ANL enzymes has been 
exhibited previously, Al-Mestarihi et al., (2015) stated that Cgc3* has ‘high to 
moderate’ sequence similarity with Acyl-CoA synthetases, and has been shown to 
be able to act as a acyl-CoA synthetase – once the substrate has been activated by 
ATP in the first partial reaction, Cgc3* could then produce substrate-CoA. As the 
ANL super family have been shown to accept both CoA an T-domains as acyl 
accepters and the amino acid sequence similarities between Ppb120 and Cgc3*, it 
would be interesting to determine whether Ppb120 has this promiscuity in the 
second partial reaction. The ANL superfamily is a relatively new concept, and the 
work described here reiterates the need for further investigation into this complex 
enzyme group and enzymes which potentially occupy activities and structures 
between sub-families.  
 
3.4.6 A5-core motif altered  
The novel adenylation activity of Ppb120 and Cgc3* may be the consequence of 
other, less investigated residues. As well as the specificity-conferring code 
previously discussed, Marahiel et al. (1997) outlined ten NRPS adenylating enzyme-
specific core motif residues– A1-A10. One of particular interest here is core motif 
A5, which is responsible for both structure of the enzyme and substrate binding; 
specifically, the aromatic residue of the conserved tyrosine is stacked against the 
adenine base of the ATP molecule during binding. Crystal structures have also 
shown it to form the walls of the active site, and is required for the binding of Mg2+ 
ion for activity (Gullick, 2009). In both Cgc3* and Ppb120, this region is atypical (Fig. 
60a); Ppb120 has substitutions in core residues, and in Cgc3* the domain is missing 
entirely. When analyzing the predicted protein structure produced by iTASSER, 
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Figure 60. Importance of A5 domain in NRPS-adenylation domains. (a) The aligned 
sequences of domain A5 known to be important in ATP, Mg2+ and substrate binding, of 
many characterised A-domains, with Ppb120 and Cgc3 highlighted to show the lack of 
conserved residues in either adenylating enzyme in this region – in stark comparison to 
the highly conserved motif seen in all other A-domains. (b) The predicted secondary 
structure of Ppb120 using iTASSER and rendering done in Chimera with all core 
domains highlighted, showing the central role A5 (Blue) has and how mutations in this 
region will likely cause ambiguity in substrate preference and promiscuity.  
(a) 
(b) 
 171 
(Fig. 60b) the area which spans the A5 domain is completely novel in structure – it 
has very low identity with any solved NRPS-domains. It is known that this stretch of 
amino acids – between A4 and A5 motifs - form a pocket that is responsible for 
accommodating the sidechain of the substrate. It is also important for maneuvering 
the substrate and AMP into the correct conformation for the adenylation reaction to 
take place. The adenylate is bound in the cleft on the surface of the A domain by 
means of van der Waals and hydrophobic interactions, in addition to hydrogen 
bonding (Weber et al., 2002). Any change to the amino acids present or charges 
which line the binding pocket would detrimentally affect both adenylation activity 
and substrate specificity. This region is of such importance, that a single amino acid 
substitution resulting in the introduction of a negative charge can result in a 
complete enzyme inactivation (Saito et al., 1995). The overall similarity of Ppb120 
and Cgc3* is very low, and so it is unlikely – despite their activity towards the same 
substrates – that they act in a similar mechanism. Rather, it is possible that the lack 
of this region simply allows the activation of unusual substrates as the confines 
these residues typically present are absent. Further work into both Cgc3 and 
Ppb120 to discover the rules which govern their substrate selection and activity is 
required to be able to appreciate and utilize their naturally exquisite molecular 
design. 
 
3.4.7 Novel binding pocket structure 
The adenylation protein GrsA which activated PheA can be considered a precedent 
for the entire family of adenylating enzymes and allows the binding pockets of other 
adenylation domains to be determined and assumptions of structure made. 
Conclusions can be drawn about the mechanisms responsible for the unusual 
substrate activation patterns demonstrated by Ppb120 by using comparisons to the 
solved structure of GrsA. An example being the previously discussed conserved 
Asp235 in GrsA is modified to Ser235 in Ppb120 (Table 17) a variation from an acidic to 
polar and highly hydrophilic group. This residue is responsible for the stabilization of 
the α-amino group of the substrate, but as, unlike GrsA, Ppb120 does not display 
significant activity towards α-amino acids, this is not required. Other adaptations of 
the binding pocket can be observed and used to explain the novel activity, such as 
the high incidence of small side-chain amino acids (Fig. 61). It has been shown that  
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Figure 61. The binding pocket of the adenylation domain in Ppb120. Potential 
interactions with the substrate, dictated by the binding pocket residues are shown. The 
red asterisk marks an area of potential conflict, leading to the paradoxical substrate 
activity exhibited by Ppb120 A-domain towards substrates with even numbered carbon 
chains. Adenylation domain in the style of Challis et al., (2000).  
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substrate specificity can be relaxed by a factor >5 if large residues are replaced by 
smaller ones (Stachelhaus et al., 1999); such amino acids - glycine and alanine - 
represent a large proportion of the top of the active site. The reduction of space 
occupied by binding pocket residues allows more space to be utilized by the 
substrate. This supports the experimental findings that Ppb120 is a very 
promiscuous enzyme, with a large potential substrate pool. In GrsA, the large 
sidechain of Trp239 residue at the bottom of the pocket allows the active side to be 
successfully separated; this is not the case in Ppb120 which has the relatively small 
Glu239 (Fig. 61). However, neighboring this at the bottom of the of the active site is 
Tyr278 which has a large sidechain, and so we can assume these residues together 
have a similar structural role. Also, we know that these two residues either 
separately or in combination, must be responsible for securing the furan-containing 
compound into the active site. They both represent well described ‘wobble-like’ 
positions in the binding pocket, and hence, are most likely responsible for binding 
unique side chains. One potential way this could be achieved is by hydrogen 
bonding between the amide group on substrate and the hydroxyl group on Tyr278 or 
more likely due to increased polarity – Glu239; this would ensure that the substrate 
was in a very specific orientation for activation.  The unusual finding that only odd 
chain lengths are tolerated for high enzyme activity suggests that this dynamic is 
very fragile, and any slight change to structural shape leads to ineffective activity; 
the acidic residue Thr229 may interfere with the hydroxyl-amide hydrogen bonding if 
the substrate is not in a very specific orientation i.e. has odd branched R-group 
chains; the location of this potential conflict is marked with a red asterisk. Until the 
structure of Ppb120 is solved, this is simply interesting conjecture; the affect that 
these unusual binding pocket residues exert can, at this point, only be theorized.  
 
3.4.8 Inactivity of Ppb220  
Possible end of cluster 
As seen from the results, Ppb220 is completely inactive against all proteogenic 
amino acids and any furan/pyrrole containing molecule tested. Despite containing all 
the essential residues, ppb220 lacks many of the highly conserved domains – 
specifically at the N-terminus of the protein: motifs A1-A7. It was suspected that due 
to the lack of large spans of required residues, Ppb220 is likely to be completely 
inactive; this is supported by the experimental results. The missing or obscured core 
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regions are known to be vital in the adenylating activity and structure of the protein, 
and so inactivity was expected. Although differences between outputs given by 
secondary metabolite finding programs, all included ppb220 as part of the ppb 
cluster. As ppb220 lies at the far boundary of the ppb cluster, and no genes beyond 
it have a function in the proposed proximicin biosynthetic route. I suggest ppb220 is 
not part of the proximicin biosynthetic gene cluster, and the boundaries of the 
cluster have been over-estimated. To confirm this, gene deletion studies must be 
undertaken, inactivating or deleting genes sequentially until proximicin production is 
stopped.  
 
Potential ancient products 
The ppb220 gene was regarded as part of the ppb cluster as it has characteristics of 
an active adenylating enzyme: it contains at least some core motifs and structural 
anchors that secondary metabolite programs search for to identify biosynthetic 
enzymes. The non-functioning ppb220 gene may represent the remnants of a once 
active A-domain, this suggests that the ppb genes were once responsible for the 
production of a larger product which would of likely contained a furan moiety. This is 
further supported by the presence of a partial neighboring biosynthetic cluster – 
denoted as PNB (Fig. 62)- upstream of ppb220, which some programs such 
AntiSMASH predict as being part of a singular NRPS cluster responsible for a much
Gene Domains present Consensus sequence Proposed substrate 
22280 T / / 
22285 C-T / / 
22290 T / / 
22305  C-A1-T-C-A2-T-Te 
A1   DVPHFSLV Serine 
A2  DLGGLGGI Ornithine 
Table 18. Analysis of the NRPS-domains present in the PNB cluster. The 
specificity conferring code of A-domains present and proposed substrate 
determined by NRPS2Predictor. Genes names based on the published V. maris 
AB18-032 genome.  
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 larger compound. The structure of likely compounds produced from this larger 
cluster are predicted to contain heterocycles, with residues similar to tryptophan 
  and tyrosine present – reminiscent of proximicin, as well as a chain three amino 
acid chain. Mutations leading to the inactivity of Ppb220 could represent a 
disjointing event of this cluster, stopping production of the larger peptide, resulting 
in proximicin production. We dismissed this in the search for the proximicin 
biosynthesis genes, as this only requires the incorporation of a maximum of three 
precursors and hence many of these NRPS-enzymes would be redundant. 
Evaluation of this secondary cluster reveals 4 NRPS-related proteins, shown in 
table, and a small selection of peptide tailoring enzymes. Only a singular NRPS-like 
gene of PNB– 22305 - contains any adenylating domains, of which it contains two. 
As shown in Table 18, using a NRPS-predictor program they were identified as 
potentially activating serine and ornithine. We cannot confirm whether these 
enzymes have intact machinery capable of producing a compound which has yet to 
be identified, if the cluster is simply silent or if these genes represent the remnants 
of a large pathway once in association with the ppb cluster. To determine which it is, 
potential PNB-alone products can be hypothesized and production searched for 
(Fig.62). Trying to identify any compounds produced by the native Verrucosispora 
spp. in vivo will be potentially very challenging: the abundance of standalone T/C-
domains within the cluster, suggests that the compounds produced may contain 
subunits iteratively added to the extending peptide chain. Also, the vast array of 
tailoring enzymes such as aminotransferases and dehydrogenases present suggest 
a potentially large chemical space to explore. It would be interesting to determine 
whether it was once part of a larger single biosynthetic cluster, as this would 
indicate a whole array of enzymes capable of modifying precursors/peptide chains 
containing the furan moiety. Regardless of the origins and historical functions of 
these enzymes, they offer a potentially large array of biosynthetic machinery for 
exploitation. The pharmaceutical potential of furan – containing molecules has been 
extensively discussed, and any other 2,4-furan containing molecules could be of 
significance. Expanding the chemical space of this compound family, and in turn, 
the potential antimicrobial, antifungal or/and DNA binding activity would be 
extremely valuable. It is by their very modular architecture that NRPS systems lend 
themselves to modification; this has been demonstrated extensively with domains 
being inactivated and interrupted to result in the production of novel non-natural 
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natural products. This approach could be used to: I) replace ppb220 with an active 
adenylation domain, or repair ppb220 by CRISPR e.g. change the residues that 
cause inactivity II) delete the Te domain to see whether the elongating peptide chain 
would be moved to 22305 and III) co-purify with a range of tailoring enzymes to 
determine their affect.  
 
3.4.9 Insolubility of Ppb210 and Ppb195  
Despite efforts, both adenylation domain proteins Ppb210 and Ppb195 could not be 
effectively purified in an active form; this is an issue commonly encountered during 
adenylation domain activity studies. Adenylation domains have complex structures 
and the requirement of many co-compounds for solubility and activity; with 
advances in scientific capabilities and the full realization of the potential these 
bacterial systems offer, NRPS clusters will become more widely studied and hence, 
understood. From the work outlined here, much can be gathered which could inform 
future research attempts. Of important note is: the presence of magnesium ions 
(Mg2+); compound specific MbtH-like proteins and, linker regions; these factors 
played an apparent key role in proximicin adenylate enzyme solubility and activity.  
 
Mg2+ Concentration 
Magnesium has been shown to be essential for activity in all adenylating enzymes, 
although some have been shown to be able to utilize Mn2+. Proximicin adenylating 
enzymes were a not an exception to this rule, in the absence of Mg2+ in both 
culturing media and activity assays, the enzymes were inactive (results no shown). 
The presence of this divalent metal ion has been shown to neutralize the charge of 
the ATP, stabilize the transition state and neutralize the leaving pyrophosphate 
group. How it accomplishes this, the concentration required and its coordination 
geometry, varies across the ANL super family and even within sub-families. Crystal 
structures of NRPS enzymes have revealed the binding of Mg2+ via a β - γ 
coordination; in this way, Mg2+ also has an important role in ensuring that the correct 
protein structure is present for adenylation to take place. This has been seen in 
NRPS A-domain DltA - Mg2+ cannot bind in the active site and hence allow 
adenylation, unless a conformational change has occurred and the protein is in the 
correct orientation for activity (Yonus et al., 2008). This blocking of activity is the 
result of a salt bridge displacing the Mg2+ preventing activity due to bonding 
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interactions between the anionic carboxylate of an aspartic or glutamic acid with the 
cationic ammonium from a lysine or arginine residue. From previously solved 
structures it can be seen that this bonding occurs at the Glu297 and Arg407 residues in 
the adenylating DltA protein (Yonis et al., 2008); all the proximicin adenylation 
enzymes, however, contain Pro407. The absence of the cognate base prevents any 
salt bridges forming, and so it is more likely that the relationship between metal ions 
and Ppb enzymes is more akin to that seen in Acyl-CoA synthases. This subfamily of 
enzymes has been shown to have an equivalent 407 residue replacement from a 
basic to a non-polar hydrophobic amino acid which results in an open active site 
structure where Mg2+ can freely enter (Hisanaga et al., 2004). The stringent 
requirement of Mg2+ shown here supports the idea a homologous system being 
utilized -  the presence of a divalent metal ion is required for activity and not a 
conformational role. However, crystal structures with bound Mg2+ would be required 
to conclude this is the case for Ppb120 and other Ppb enzymes.  
 
Compound-specific MbtH 
Many bacterial gene clusters encoding NRPS systems involved in natural production 
also code for a small protein which contains three specific conserved tryptophan 
residues (Felnagle et al., 2010). It has been shown that they can be essential 
chaperones for NRPS-dependent natural product synthesis (Drake et al., 2007; 
Lautru et al., 2007), and also have roles in protein production and solubility 
(Heemstra et al., 2009), and play a vital part as activators of acyl-adenylate 
formation (Felnagle et al., 2010 and Zhang et al., 2010). Further work has also shown 
that MbtH-like proteins can operate in different biosynthetic clusters of the same 
species and across species (Boll et al., 2011). A MbtH-like protein was identified as 
being part of the proximicin cluster – Ppb125, and its requirement in proximicin 
biosynthesis was explored. The results show that Ppb125 was required for activity 
and solubility of all Ppb adenylating enzymes, including the novel-substrate 
activating enzyme Ppb120. When replaced with a non-native MbtH protein – the 
MbtH-like protein TioT – solubility was greatly reduced, and any protein purified was 
inactive. This shows a level of specificity of the proximicin biosynthetic pathways 
towards Ppb125. It is possible that Ppb125 could promote adenylate-forming 
activity by either altering the structure of the adenylation domain resulting in the 
adoption of a catalytically competent formation or by the prevention of the alternate 
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catalytic orientation. An important caveat is that we cannot conclude the level 
dependency ppb-NRPS enzymes have on Ppb125; Ppb195 and Ppb210 were never 
purified in an active state, and so it cannot be determined whether Ppb125 alters 
their activity, although it can be concluded that it enhances their protein production 
and solubility. It would be very useful to determine an amino acid sequence 
component of this relationship. It has been established that only specific residues 
can accommodate the distinctive stacked tryptophan residues of a MbtH-like 
protein: both alanine and proline at the 817 position are compatible. This region 
forms part of the A6 motif, and all ppb A-domains have this present, supporting a 
MbtH-like protein dependence. However, some A-domains have this ability to 
potentially accommodate an MbtH-protein, yet show no MbtH binding or 
enhancement (Felnagle et al., 2010). A preliminary bioinformatic search was 
conducted to identify other regions of similarity between A-domains identified to 
have a MbtH-like protein dependence, that was distinct from those which do not 
require MbtH (Fig. 63). It was shown that the region surrounding the A6 domain 
could be used to predict whether an A-domains activity was enhanced via the 
requirement of MbtH for acyl-adenylate formation, solubility or for an unknown 
purpose. Overall, all A-domains which require MbtH interaction have a highly 
conserved region consisting of Pro817, Thr820, Ala821 and Arg823 which is not present in 
MbtH-independent A-domains (Fig. 63). A-domains which require MbtH-proteins for 
solubility had a non-polar hydrophobic residue at the 819 position, - typically Leu819, 
and when required for acyl-adenylate formation activity this was more likely to be 
polar. If this is correct, as Ppb210 has the non-polar Leu819 residue, issues 
encountered regarding its solubility may have been MbtH-related but issues 
concerning activity, theoretically, were not. Similarly, Ppb120 and Ppb195 have 
polar residues at this position and so it can be concluded that they require Ppb125 
for activity as well as solubility. Miller et al., (2016) demonstrated that Pro817 was 
essential in determining the dependency on an MbtH-protein. Here, we extend that 
to include a selection of residues which span the region between A6 and A7 core 
motifs. It is apparent that this area is vital in the binding of MbtH proteins, and 
further work is required to determine what mechanism is responsible for this.  
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Importance of linker regions 
Many issues were encountered regarding protein solubility and activity which were 
resolved by the incorporation of the entire NRPS protein, the A-domain complete 
with sub-domains and linker regions. Previous similar work (Juguet et al., 2009; Al-
Mestarihi et al., 2014; Al-Mestarihi et al., 2015) looking into A-domain substrate 
activity and biosynthetic route elucidation, did not highlight any issues surrounding 
solubility with respect to linker regions - all were described as being cloned 
individually as stand-alone A-domains. It is difficult to determine whether issues 
were not encountered, or just simply not reported; either, the importance of linker 
regions is becoming increasingly apparent. It has been shown that while some 
mutations between neighboring units are well tolerated (Doekel et al., 2008), there is 
a progressively large amount of work suggesting they contain areas vital for activity 
(Yu et al., 2013; Beer et al., 2014). It was shown that Ppb210 was completely 
insoluble and inactive when not cloned as the whole native protein; potential 
explanation for this result comes from previous work on Acyl-CoA synthases which 
demonstrates the restriction of subdomain rotation when mutations were introduced 
into an A-T linker region (Reger et al., 2007; Wu et al., 2009). A-domain activity was 
abolished due to this point mutation in the hinge region leading to the enzyme being 
frozen in a singular configuration. Other work found that there is a proline-rich region 
following the A10 motif found only in A-T domains which, if altered, leads to 
diminished compound production (Miller et al., 2014). It can be hence concluded 
that these linker regions are required to form a specific conformation for activity 
which is partially controlled by these proline residues. This explains issues 
encountered in Ppb210 purification: if the protein is not in its natural configuration, it 
is less likely to be soluble. And also why issues weren’t encountered for other A-
domain - Ppb220 for example, which is a stand-alone A-domain. This work into the 
importance of linker regions is significant for future similar A-domain activity studies, 
but equally for potential combinatorial biosynthesis endeavors.  
 
3.4.10Malachite vs. Phosphate assays 
The modular nature of NRPS systems offers an attractive opportunity for a 
combinatorial chemistry approach to novel compound production; to utilize this, the 
substrate pool of adenylation domains must be established in a high throughput and 
accurate way. As interest in the pharmaceutical potential of NRPS systems, ways to 
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identify A-domain substrate profiles has increased. The traditional cumbersome 
radioactive assays have been replaced by cheaper, quicker and simpler alternatives. 
It is unclear whether these replacement assays have a similar sensitivity and 
accuracy. This study describes the comparison between two of these such assays: 
the radioactive phosphate assay and the new malachite green assay; these assess 
A-domain activity by measuring phosphodiester bond cleavage and rate of release 
of PPi, respectively. The creators of the latter (McQuade et al., 2008) show that the 
enzyme kinetics of both are comparable, and similar to that found in the literature; 
however, this was not supported by work done here. Not only were the two 
substrate profiles of Ppb120 very different, the kinetics – e.g.  Km values -  for both 
assays were very dissimilar. Both assay types had strengths and weaknesses. The 
radioactive phosphate assay represents the classical method for detecting A-
domain activity, although higher in complexity of set up, is very sensitive and has a 
low level of background noise. It is restricted to measuring the formation of 
isotopically labelled ATP from aminoacyl-AMP reacted with an excess of [32P] PPi 
which means it is extremely substrate specific. It is because of this that it has been 
effectively used for many A-domain activity investigations (Garneau et al., 2005; 
Pfleger et al.,2007; Singh et al., 2007). One issue encountered, apart from the 
obvious restrictions dictated by the use of a radioactive substance, was the 
occurrence of false-positive results. This issue has been previously highlighted by 
McQuade et al., (2008), and arises due to inefficient washing steps involved in 
experimental procedure. However, undertaking experiments in triplicate – as done 
here - which is extremely time consuming and expensive, can rectify this issue. The 
malachite green test alleviates many of the hurdles presented by the [32P] PPi assay; 
it is cheaper and less complex, but a sacrifice is made regarding sensitivity. As seen 
in the results, the background level of activation is very high – despite rigorous 
attempts to lower outside phosphate contamination; this results in any, even high 
activity being diminished and low activity being completely eliminated. Despite both 
pyrrole compounds being correctly identified as substrates, their level of activity in 
comparison to other tested compounds is much reduced, in comparison to that 
seen in the [32P] PPi assay. From the results shown here, a combination to exploit 
each assays strengths would be suggested – using the simple malachite green 
assay to determine broad ranges of potential substrates followed by the [32P] PPi to 
determine specific enzyme kinetics. This would be of particular use when testing the 
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promiscuity of synthetically altered or relaxed A-domain enzymes when employing a 
combinatorial chemistry approach to novel compound discovery.   
 
A combination approach, using both assay types would be the ideal solution to the 
issues discussed regarding each individual assay type; however, some research 
groups simply do not have the facilities or funding to incorporate radioactive work 
and hence, a radiation laboratory into their work-flow, irrespective of any methods to 
lower its use. Ideally, a method would be devised which has the efficacy of the 
radioactive phosphate exchange assay, with the cost, ease and safety of the 
malachite green assay. This issue has obviously been encountered by previous 
groups working on adenylation domain activity elucidation as other techniques, for 
example the large molecule mass spectrometry method (LM-MS), have been 
implemented (Dorrestein et al., 2006). This approach uses the mass change 
exhibited when the covalent bond is formed between the A-domain and the 
substrate. Major advantages of this include the ability to screen multiple potential 
substrates in parallel, as the activated substrate can be determined by the specific 
mass change displayed; and, its utilization in determining the order and timings of 
tailoring reactions that may also take place. It has been shown to have a similar level 
of accuracy as the radioactive 32P assay (Dorrestein et al., 2006); however, similarly, 
it requires some extremely costly equipment, making it a not acceptable approach 
for researchers without easy access to a high resolution Mass Spectrometer.  
 
As it stands currently, A-domain activity studies and hence, NRPS cluster 
elucidation and novel compound production is bottle-necked by the lack of easily 
accessible activity assays resulting in their utilization solely in large, well-funded and 
well-equipped labs. To try to ease this bias I have designed an enzyme assay, 
similar to that of the malachite green assay, but precluding any issues surrounding 
phosphate contamination. This approach – termed the Luciferase Assay, and 
outlined in Figure 64 – exploits the luciferase enzymes ability to utilize ATP to yield 
light; this will not be the first time this enzyme has been used as a molecular biology 
tool due its bioluminescent properties, but the first in this A-domain activity 
application. The assay will work in theory, in a similar way to the phosphate 
exchange as it monitors the use of ATP during activation of the substrate. However, 
for the luciferase assay, it will be the chemical conversion and hence the depletion, 
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of ATP during adenylation activity that will be measured. A correlation will be first 
established between bioluminescence and ATP concentration, and then when the 
light produced of the final reaction is measured, we could determine whether ATP 
concentration has been decreased, in comparison to the known concentration in 
the initial reaction. Any lowering of bioluminescence in comparison to the start – 
and hence lowering of ATP concentration – will confirm adenylation domain activity. 
The luciferase enzyme assay, in stark contrast to malachite green, will not have an 
issue with contamination and background noise: there is virtually no non-specific 
light production induced in the cellular environment and so we can be certain any 
exhibited will be a result of luciferase activity on ATP. One potential encounterable 
issues would be that luciferase enzymes themselves are a member of the ANL 
superfamily – and hence, have the ability to adenylate luciferin in the presence of 
ATP. This may present an issue if any compounds being tested have a similar 
structure as luciferin, and hence, have the ability to be substrates to both the A-
domain being tested and luciferase. This can be overcome either by (a) avoiding the 
use of this method when any molecules of similar chemistry to luciferin is being 
tested, (b) ensuring the activity of the substrate against luciferase is nil before 
starting, or preferably (c) design a luciferase enzyme with the adenylation activity 
promiscuity restricted resulting in a very high specificity. The former two schemes 
are less desirable as they require excluding molecules and additional assay runs, 
respectively, both of which would detrimentally reduce the applicability of this 
method to A-domain-substrate assays; hence, the concept of producing a 
luciferase with only activity for luciferin is superior. Branchini et al., (2015) has 
demonstrated the ease and tolerance of Photinus pyralis luciferase to genetic 
manipulation, and so this approach is likely to be the best potential route to assay 
application. I propose that P. pyralis luciferase is the initial enzyme tested for this 
application, in addition to its bioluminescent-conferring regions being well 
described and so giving already set boundaries for future manipulations to reduce 
promiscuity, it has been shown to maintain a very highly specific dependence on 
the luciferase catalyzed light emission process on ATP. Furthermore, engineered 
protein lines of this luciferase with two-fold enhance specific activity and 1.4-fold 
greater bioluminescence have already been reported (Branchini et al., 2014). The 
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luciferase assay described here, presents an exciting opportunity for determining, 
and further exploring the governing mechanics of A-domain substrate specificity. 
We currently sit on the edge of an era in which the identification of compounds with 
novel antimicrobial and antifungal targets is going to be of overwhelming 
importance; this cheap and easily implementable assay format is hence especially 
timely, when considering the accelerated rate at which assembly lines that defy 
previous classification – such as Ppb described here – are being discovered.  
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Chapter 3.  NRPS Adenylation Characterisation 
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Chapter 4. CRISPR/Cas gene editing in Verrucosispora spp. 
 
4.1 Introduction  
 
Proximicins represent a family of both medically and industrially relevant secondary 
metabolites (Fiedler et al., 2008). The intriguing structure, action and biological 
activity of these compounds make this small class of natural products an exciting 
starting point for a combinatorial biosynthesis strategy to novel molecule 
development. So far, the putative biosynthetic gene cluster responsible for 
proximicin production has been identified and putatively characterised in the two 
producers: V. maris AB18-032 and V. sp. str. MG37; the cluster harbours a NRPS 
system with a number of additional genes related to post-tailoring, regulation and 
resistance. Extensive analysis of the adenylation domains present led to the 
formation of two competing routes for the production of the novel chemistry 
characteristic of the proximicin family. With the aims of fully understanding the 
proximicin pathway, providing insights into the formation of the 2,4-disubstituted 
furan group, and allowing the generation of novel proximicin derivatives, the ppb 
cluster needs to be investigated further.  
 
4.1.1 Secondary Metabolite Cluster analysis in Actinomycetes 
Actinomycetes represent a well-studied order of bacteria, known to harbour the 
capacity to produce many biologically significant compounds, including many well-
known herbicides, chemotherapeutics and immunosuppressants such as bialaphos, 
doxorubicin and rapamycin, respectively (Berdy, 2005; Berdy, 2012; Hwang et al., 
2014). It is also estimated that they are responsible for nearly two-thirds of the 
natural antimicrobial drug compounds currently in application (Bentley et al., 2002). 
The recent advent of NGS technologies leading to modern genome mining studies 
(Blin et al., 2014) indicate that they harbour a huge as yet unexploited potential to 
produce secondary metabolites with novel structures (Weber et al., 2015); this 
yielded the recent renaissance in the investigation of Actinomycetes. The ultimate 
aim of these research efforts is typically two-fold: (i) to metabolically engineer 
strains to express novel biosynthetic pathways in high enough concentrations for 
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identification, and (ii) to delete genes to confirm the clusters responsible for 
biosynthesis, to aid in the large-scale production of medically important compounds 
(Lee et al., 2009). Both of these approaches share a common challenge: the 
necessity to genetically manipulate strains; this is much more difficult in 
Actinomycetes in comparison to model organisms such as E. coli or 
Saccharomyces cerevisiae. It is typically associated with the characteristically high 
GC content, in addition to diverse genomic contents present in Actinomycete 
genomes, but also inpart to their complex growth requirements. Traditional genetic 
manipulation attempts in these organisms typically used RecA mediated double 
crossover events (Kieser et al., 2000); this approach exploits the complex enzymatic 
machinery responsible for DNA repair in bacteria, at the core of which is the DNA 
recombinase protein RecA. The complementary DNA to the gene to be disrupted is 
provided by a non-replicative or temperature sensitive plasmid, and the 
homologous recombination event results in specific gene interference (Fig. 65a). 
The efficacy of this approach has increased rapidly in the past decade, by using 
templates with long homology regions, such as the ReDirect protocol developed by 
Gust et al., (2004) which modified the highly efficient Red-mediated genetic 
manipulation approach popular in E. coli studies to be utilised in Streptomyces 
spp., using 39 bp homology arms to result in high precision gene disruptions (Fig. 
65b). Further, the meganuclease – I-SceI - from S. cerevisiae mitochondria has been 
codon optimised for use in Actinomycetes by two groups, leading to unmarked 
targeted deletions in Streptomyces spp. Tu6071 (Siegl et al., 2010) and S. coelicolor 
(Fernandez-Martinez et al., 2014) by RecA-mediated homologous recombination to 
repair the double-strand breaks catalysed by I-SceI (Fig. 65c). Other approaches, 
such as the exploitation of large serine recombinases involved in site-specific 
integration of actinophages into Actinomycete chromosomes, have been intensively 
investigated (Zhang et al., 2010; Zhang et al., 2013; Myronovsky et al., 2014; Du et 
al., 2015); however, they all share a collective obstacle: the protocols are time 
consuming and labour intensive (Cobb et al., 2014). For instance, it took six years to 
construct an S. coelicolor strain deficient in subteleomeric DNA and PKS/NRPS 
gene clusters (Zhou et al., 2012). To fully exploit the potential harboured within the 
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genomes of Actinomycetes for the discovery of biologically active compounds, 
efficient genome manipulation techniques must be developed.  
 
 
Figure 65. Previous approaches to bacterial gene editing, and specifically 
Actinomycete gene editing. (a) RecA mediated double cross over event. (b) Red-
mediated genetic manipulation approach. (c, outlined in yellow) Utilisation of 
meganuclease SceI to produce double-strand breaks leading to RecA-mediated repair. 
(a) (b) 
(c) 
 195 
4.1.2  Introduction to CRISPR/Cas systems  
Recent advances in the understanding of clustered regularly interspaced short 
palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) systems have 
revolutionised biological and biotechnological research. These prokaryote-derived 
systems – specifically CRISPR/Cas9 – have been rapidly adopted for genome 
editing in eukaryotes (Cho et al., 2013; Hruscha et al., 2013; Ren et al., 2013, and 
Shan et al., 2013), facilitating some of the most important advances in science of 
the past decade (Fig. 66). The latest applications of CRISPR/Cas9 are ranging from 
treating genetic diseases (Bassuk et al., 2016; Nelson et al., 2016), to the 
introduction of beneficial traits into crops, while circumventing strict GMO 
regulations (Waltz, 2016). In addition to these, and arguably the most remarkable, is 
the approval of the first in-human CRISPR trial to modulate patient immune cells for 
cancer research treatment (Cyranoski, 2016; Kaiser et al., 2016). Just as Sanger et 
al., (1977) bore the genomic revolution with the advent of DNA sequencing, the 
realisation of the potential held within the CRISPR/Cas9 system (Ran et al.,2013), 
has unlocked the genome editing era.  
Figure 66. History of CRISPR/Cas achievements and landmark studies. 
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While the potential of CRISPR/Cas as a genome editing tool was not realised until 
recently, the knowledge of CRISPR systems has been building for decades. The 
initial discovery of a genetic element constituting a CRISPR locus by Ishino et al., 
(1987) began the 30-year progression of understanding, culminating in its 
applications today. Initial bioinformatical studies of CRISPR/Cas9 systems unveiled 
their function in the prokaryotic adaptive immune system (Mojica et al., 2000; 
Jansen et al., 2002; Pourcel et al., 2005). This led to a huge paradigm shift as it was 
previously agreed that prokaryotes had the ability for only innate immune systems, 
comprised of restriction modification systems and exonucleases. In contrast to the 
adaptive immunity exhibited in jawed vertebrates, as unicellular organisms, 
prokaryotes must store the whole immunological information in a single cell. This 
complex ability was resolved with the discovery of CRISPR loci, in which the 
immunological memories are engraved by the CRISPR/cas9 system; these loci 
consist of short (typically 21-40 bp) palindromic repeats, separated by non-
repetitive sequences (spacers) (Barrangou et al., 2007; Yosef et al., 2012). Each 
spacer represents a ‘scar’ created by, and completely matching to, a heterologous 
DNA sequence that once invaded the host (Barrangou et al., 2007); this array of 
‘scars’ is bordered by cas genes which use the information stored in the spacer 
regions to conduct adaptive immunity (Jansen et al., 2002). This is done in three 
phases outlined in Figure 67: adaption, expression and interference.  
 
I. Adaption is characterised by the sampling a stretch of exogenous DNA 
bases (protospacer), encountered through various events such as viral 
infection; this is done by a set of Cas proteins, potentially in assistance 
with other systems. In many systems, a specific protospacer adjacent 
motif (PAM) is required for protospacer selection; this is an adjacent, 
stereotyped sequence motif, a few bases in length. This protospacer is 
then inserted into the host DNA at the CRISPR array loci, which is done is 
a sequential, methodical order. 
II. Expression follows by the expression of the CRISPR array as a single 
transcript resulting in precursor CRISPR RNA (pre-crRNA) which is then 
cleaved by Cas and ribonuclease proteins to produce a functional 
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III. CRISPR RNA (crRNA) which consists of a sequence corresponding to the 
single spacer and an adjacent single repeat. The crRNA then binds to 
other components present in the CRISPR/cas9 system leading to the 
formation of the effector CRISPR ribonucleoprotein (crRNP) complex. 
IV. Interference denotes the guiding of the crRNP complex by the bound 
crRNA to the target protospacers, and hence the degradation of the  
exogenous DNA targets. The CRISPR arrays in the host genome remain a 
scar of a previous attack from exogenous DNA, and hence, allow a faster 
response to subsequent assaults.  
 
Large sequencing projects have resulted in many bacterial genomes being 
sequenced (Choi & Lee, 2016); using this information, it has become apparent that 
CRISPR/cas systems are diverse across the domain. Attempts at classification of 
these systems has largely been focused on bioinformatical categories (Makarova et 
al., 2015), which are accumulating and adapting, as the full extent of variance 
present in CRISPR/cas systems is realised. However, they typically fall into three 
classes: type I, type II and type II depending on the presence of Cas3, Cas9 and 
Cas10 respectively (Makarova et al., 2011). Despite CRISPR/cas systems being of 
prokaryote origin, the bacterial focus of these systems has primarily been in their 
characterisation and classification, with the aim of their utilisation in eukaryotes. The 
‘CRISPR big bang’ in eukaryotes currently overshadows its bacterial counterparts, 
however, the potential to advance bacterial-based research and industry, is steadily 
advancing.  
 
Genome editing studies is the primary focus of CRISPR/cas9 application; the first 
bacterial genome editing in this way was reported in 2013 (Jiang et al., 2013), 
leading onto many similar reports in following years. Much of this work focuses on 
the exploitation of type II systems, which are distinct from the other classes in the 
requirement of a dual RNA complex consisting of crRNA and transactivating RNA 
(trRNA) (Deltcheva et al., 2011; Jinek et al., 2012). During the final stage of 
CRISPR/cas9 a cas9:dual RNA complex searches for and binds to a PAM sequence 
located on the target DNA, while simultaneously inspecting the 5’ region for 
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complementarity to the protospacer of its crRNA, leading to the initiation of a 
double stranded break in the DNA (Sternburg et al., 2014). This guided the creation 
of many CRISPR/cas9 engineering plasmids containing all the enzymatic machinery 
required for CRISPR/cas9 genome editing, and an insert site for incorporation of 
sequences matching the genomic locus of interest. Further adaptation of the type II 
system for genome engineering, led to the fusion of the crRNA and trRNA into a 
single synthetic guide RNA (sgRNA) transcript, removing the necessity of pre-crRNA 
processing (Cobb et al., 2015). The application of these technologies toward 
seamless bacterial genome engineering is advancing rapidly, however, some 
economically important orders and families remain largely un-investigated.  
 
4.1.3 CRISPR/Cas9 engineering of Actinomycete genomes 
As previously discussed, Actinomycetes and Streptomyces spp. in particular, 
represent a group with high industrial and medicinal importance; however, the 
application of CRISPR/Cas9 technologies towards this bacterial class has not yet 
been fully determined. Importantly, Streptomyces spp. harbour the ability to repair 
double stranded breaks in DNA via non-homologous end joining (NHEJ), a trait 
rarely exhibited by bacteria. This means, that unlike other prokaryotic CRISPR/Cas 
facilitated gene editing approaches, Streptomyces spp. can use a system more akin 
to that of eukaryotic systems. Bacteria without this ability utilise a functionally 
different system, in which CRISPR/Cas is used as a selective pressure opposed to 
the primary gene editing apparatus; this maintains much of the difficulties 
associated with previous approaches, and solutions are discussed in depth in future 
prospects. To exploit this exclusive attribute of Streptomyces spp., Cobb et al., 
(2015) designed a Streptomyces specific CRISPR/Cas9 gene deletion vector 
system, consisting of two plasmids pCRISPomyces-1 and 2; among their notable 
features include a codon-optimised cas9 from Streptomyces pyogenes; a BbsI-
flanked lacZ cassette to allow Golden Gate assembly of spacer sequences, a 
temperature sensitive pSG5 origin, and importantly, a XbaI site for incorporation of 
an editing template. The addition of an editing template via recombination-driven 
repair circumvents issues previously encountered concerning the substantial and 
unpredictable excision of DNA during CRISPR/Cas9 activity, to instead result in a 
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pre-determined, precise genome modification. It has been demonstrated by 
implementation of the pCRISPomyces system, along with similar systems (Tong et 
al., 2015), has the ability to create site-specific alterations to Actinomycete 
genomes; however, not all families have been examined. Elucidation of the 
proximicin biosynthetic cluster, specifically (i) confirming the stage of furan 
incorporation and (ii) the boundaries of the ppb cluster, present an exciting 
opportunity to test the applicability of CRISPR/cas9 technology in the 
Micromonosporaceae family, to which Verrucosispora spp., belong.  
 
4.1.4 Proof of Concept study in Verrucosispora spp.  
Here we report the first instance of CRISPR/Cas9 gene editing technology being 
applied to Verrucosispora sp. str. MG37 the first member of the 
Micromonosporaceae family to have its genome modified utilising this approach. 
The gene responsible for the characteristic orange pigmentation exhibited by 
Verrucosispora spp., was initially targeted resulting in an off-white strain, capable of 
sporulation. The action of the CRISPR/Cas9 system resulted in a sickly V. sp. str. 
MG37strain, incapable of liquid fermentation; this made the extraction of high 
quality gDNA for sequencing difficult, and so, successful gene deletion was 
Figure 68. pCRRISPomyces-2 vector. Streptomyces specific pCRISPR-2 vector 
designed by Cobb et al., (2015) for effective and efficient gene editing via CRISPR/Cas9 
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confirmed using PCR. Once the applicability of CRISPR/Cas9 technology was 
established in V. sp. str. MG37, preliminary attempts into ppb cluster gene deletion 
were completed; this resulted in an V. sp. str. MG37 strain with a large deleted 
region encompassing ppb120. 

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Chapter 4. CRISPR/Cas gene editing in Verrucosispora spp. 
 
4.2 Material and Methods 
 
4.2.1  Media and Reagents 
2 X YT broth: 16 g Tryptone, 10 g Bacto Yeast Extract, 5 g NaCl, add ~900 mL of 
diH2O and adjust to pH. 7.0 with NaOH. Top up to 1 L and autoclave. MS (mannitol 
Soya Flour agar): 20 g Mannitol; 20g Soya Flour; 100 mM CaCl2 and 13 g Agar, add 
1 L of diH2O and autoclave.  
 
4.2.2 sgRNA design  
Targets for CRISPR gene editing were chosen: for the initial studies a phenotypic 
target was chosen. To determine the genes responsible for the orange pigment 
exhibited by both Verrucosispora spp., BLAST homology search was done using 
genes well characterised to be responsible for orange pigment in related species.  
After the proof of concept study, genes identified as being involved in proximicin 
biosynthesis were to be sequentially deleted. For the scope of this research, only a 
single ppb gene was targeted – ppb120.  
 
For both target genes, a 20 nt protospacer was chosen, with priority given to those 
which fulfil specific guidelines:  
- The 3’ protospacer adjacent sequence (PAM) must be NGG, where N is any 
nucleotide.  
- Sequences with purines occupying the last four (3’) bases of the protospacer.  
- Sequences on the non-coding strand.  
- Sequences in which the last 12 nt of protospacer + 3 nt PAM are unique in the 
genome 
For each protospacer, two 24 nt oligonucleotides were designed consisting of a 5’ 4nt 
sticky end and 20 nt spacer sequence. The sticky ends being ACGC on the forward 
and AAAC on the reverse primer.  
4.2.3 Oligonucleotides Annealing and Spacer insert into pCRISPomyces-2 
Both oligonucleotides (oligos) were re-suspended to 100 μM in water. Oligos were 
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annealed using the following ligation reaction: forward and reverse oligos (final 
concentration 5 μM) with HEPES (27 mM, pH7.8) to a final volume of 100 μL. The 
annealed spacer was the ligated into the pCRISPomyces-2 backbone using Golden 
Gate assembly as follows: pCRISPomyces-2 (100 ng); annealed spacer (0.5 μM or 
10-fold dilution of annealed oligo stock); T4 ligase buffer (NEB, 5X); T4 ligase (NEB, 
400U), BbsI (NEB, 10 U) and water added to 20 μL. Mixed and assembled in a 
thermocycler with the cycle conditions: 9 cycles of 37°C for 10 mins then 16°C for 10 
mins; 50°C for 5 mins; 65°C for 20 mins and 4°C forever.  
 
4.2.4 Transformation of pCRISPR-sgRNA into E. coli 
3 μL of each annealing reaction was used to transform NEB® 5-alpha competent E. 
coli cells, using the adapted five-minute NEB transformation protocol (cat. no 
C2987H), with an additional outgrowth step (referred to hence as the Adapted Five-
Minute Protocol): NEB® 5-alpha competent E. coli cells were allowed to thaw on ice 
~5 min, and ~25 ng of DNA was added and mixed with the cells and placed on ice for 
2 mins. The mixture was heat shocked at 42°C for exactly 30 seconds and placed on 
ice for 2 mins. 950 mL of LB media was added and incubated at 37°C for 45 mins. 
100% of transformants were plated on LB plates with relevant antibiotic selection – 
here 30 μg/mL apramycin, overnight at 37°C. Blue/White screening was used to aid 
in successful transformant identification – 0.05 M IPTG and 0.005 mg of X-Gal in 
DMSO was spread on the LB/ 50 μg/mL apramycin plates and allowed to dry prior to 
plating. White colonies were selected and PCR checked for correct insert. 20 mL of 
sgRNA containing plasmid strains were grown up O/N at 37°C with 200 rpm, cultures 
were used to prepare high quantities of pure plasmid using the GenEluteTM Plasmid 
Miniprep Kit (SIGMA PLN10), according to the supplier guidelines. The plasmid was 
then linearized by restriction digest enzymes XbaI according to the NEB protocol: 
Restriction digest mixture (50 μL) contained DNA (1μg), RE buffer (1X NEB 
CutSmart buffer, cat. no. B7204S), restriction enzyme (10 units, NEB); and incubated 
at 37°C overnight. and gel purified using GenEluteTM Gel Extraction Kit (SIGMA 
NA1111), according to manufactures protocol, and eluted into 50 μL water.  
 
4.2.5 PCR of repair template  
Two 1kb ‘arms’ of genomic region for the repair template were produced by PCR 
using 30 nt overlaps between the two arms and XbaI cut sites at the opposite ends. 
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PCR was done using to amplify the arms separately: the PCR mixture (50 μL) 
contained Phusion® High-Fidelity polymerase (0.10 units, NEB), dNTPs (200 μM), 
Phusion® High Fidelity buffer (1X), primers (0.5 μM each), Verrucosispora sp. str. 
MG37 DNA (50ng) and DMSO (3%). The PCR was performed using a typical thermal 
cycling procedure – Phusion Thermo-Cycling Conditions - 1 cycle, 98°C for 30 s; 30 
cycles, 98°C for 10 s, 71°C for 30 s and 72°C for 3:00 min; and 1 cycle 72°C for 10 
min. Annealing temperature was varied depending on Tm of primers used. PCR was 
checked using gel electrophoresis using the standard technique. PCR fragments of 
the correct size were gel purified using GenEluteTM Gel Extraction Kit, according to 
Sigma Aldrich guidelines. Fragments were eluted into 50 μL of ddH2O and quantified 
using the Qubit 2.0 Fluorometer according to ThermoFisher guidelines. 
The two 1Kb arms were then spliced together using overlap-extension PCR. Each 
PCR was subjected to a temperature regimen similar to the following: initial 
denaturation at 98°C for 2 min, denaturation at 94°C for 30 s, annealing at 60°C for 
30 s, extension at 68°C for 90 s/kb for 30–32 cycles, with a final extension of 68°C for 
10 min. PCR was checked using gel electrophoresis using the standard technique. 
PCR fragments of the correct size – ppb120 the repair template was ~2.5 Kb - were 
gel purified using GenEluteTM Gel Extraction Kit, according to Sigma Aldrich 
guidelines. Fragments were eluted into 50 μL of ddH2O and quantified using the 
Qubit 2.0 Fluorometer according to ThermoFisher guidelines. 
The resultant 2.5 Kb repair template were then digested using XbaI to create 
compatible overlaps with the sgRNA-plasmid for ligation, using the NEB protocol as 
previously described, and gel purified using GenEluteTM Gel Extraction Kit (SIGMA 
NA1111), according to manufactures protocol, and eluted into 100 μL water. 
 
4.2.6 Ligation of repair template in pCRISPR-sgRNA to produce pCRISPR-
sgRNA-RT 
The digested pCRISPR-sgRNA plasmid and the digested repair template were 
ligated using the overhangs created during restriction digest. Ligation mixture (20 μL) 
contained 10 X T4 ligase buffer (5X, NEB), linearized pCRISPR-sgRNA (50ng), 
repair template (37.5 ng) and T4 DNA ligase (400 U, NEB). Incubated at 37°C 
overnight. 3 μL of ligation reaction was used to transform E. coli TOP10 
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(ThermoFisher Scientific) using the Adapted Five-Minute Protocol. Transformants 
were plated on LB with 30 μg/mL apramycin, kanamycin and chloramphenicol, 
overnight at 37°C and then checked for the presence of a correct construct using 
colony PCR using primers located on the pCRISPomyces-2 backbone, as previously 
described. Strains showing the correct PCR amplicon, were grown up in 10 mL LB 
media at 37°C with 50 μg/mL apramycin, plasmids were extracted using GenEluteTM 
Plasmid Miniprep Kit (SIGMA PLN10), according to the supplier guidelines, and 
checked using sequencing. Purified plasmids, as well as plasmids not containing the 
RT – pCRISPR-sgRNA, were transformed into E. coli conjugation strain 
ET12567_pUZ8002 which was chosen for all conjugation reactions; pCRISPR-
sgRNA and pCRISPR-sgRNA-RT was transformed into ET12567_pUZ8002 using 
the Adapted Five-Minute Protocol and checked using colony PCR for correct 
insertion of pCRISPR-sgRNA and pCRISPR-sgRNA-RT to create ET-pCRISPR-
sgRNA and ET- pCRISPR-sgRNA-RT, respectively.  
 
4.2.7 Conjugation into Verrucosispora sp. str. MG37  
10 mL of LB supplemented with kanamycin and chloramphenicol (both 30 μg/mL) 
was inoculated with and ET-pCRISPR-sgRNA and ET- pCRISPR-sgRNA-RT and 
grown overnight at 37°C. Cells were diluted 1:100 into 10 mL fresh LB with the same 
selection, and grown for ~4 hrs at 37°C until the OD600. 0.4. The cells were harvested 
and washed twice in 10 mL LB and re-suspended in 1 mL LB.  ~ 108 of V. sp. str. 
MG37 spores were re-suspended in 500 μL of 2 X YT broth; these were heat 
shocked at 65°C for 10 mins and allowed to cool at RT. 0.5 mL of the E. coli 
suspension and 0.5 mL of the spores were mixed and spun briefly; the supernatant 
decanted and re-suspended in any residual liquid. 10-1 to 10-4 dilutions were made in 
a total of 100 μL of water, and plated on MS agar with 10 mM MgCl2 without any 
antibiotics and incubated at 30°C for 20 hrs. Each plates were overlaid with 1mL of 
water containing 0.5 mg naladixic acid and 1 mg apramycin, using a spreader to 
distribute the antibiotic solution evenly; incubation at 30°C continued for 7 days or 
until colonies appeared. Single colonies were plated on MS agar containing naladixic 
acid and apramycin, 25 μg/mL and 50 μg/mL, respectively for 7 days or until colonies 
appeared, and gDNA extracted.  
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To determine the best time/temperature combination for heat shock in 
Verrucosispora spp., varying combinations were first tested and the resulting spores 
analysed under a light microscope and the extent of sporulation determined. Spores 
were analysed using a haemocytometer using a volume of 25 nL as the counting 
area, which typically had ~200 spores present using the spore stock (200,000 
spores/ uL). Temperatures between 40 – 100°C were tested with time varying 
between 5 – 30 minutes. 
 
4.2.8 Genomic DNA extraction  
Many techniques for gDNA extraction from exconjugants for PCR and sequencing 
were tested. CTAB, Sigma-Aldrich kit (cat. No. NA2110) with bead-beating and the 
potassium hydroxide Ethylene Diamine Tetraacetic Acid (KOH-EDTA) method. 
 
CTAB 
Genomic DNA was extracted from V. sp. str. MG37 exconjugants using the 
cetyltrimethyl ammonium bromide (CTAB) method. 30 mL GYM media was 
inoculated with exconjugants from MS plates with single colonies at 7 days and 
grown at 28°C for 3 days and harvested at 16,000X g and re-suspended in 5 mL 
TE25S buffer (25 mM Tris-HCl pH. 8; 25 mM EDTA pH. 8 and 0.3 M sucrose). 
Lysozyme was added to final concentration 2 mg/mL and incubated for 1hr at 37°C. 
Proteinase K and SDS were added to final concentration 0.18 mg/mL and 0.5% 
respectively, and incubated for 1hr with occasional inversion at 55°C. NaCl added to 
final concentration 0.8 M and mixed; CTAB/ NaCl added and mixed followed by 
incubation at 55°C for 10 mins followed by cooling to 37°C. Chloroform/isoamyl 
alcohol added and mixed my inversion for 30 min. Centrifuge at 13,500X g at 20°C 
for 15 mins. Supernatant decanted and 0.6 volumes of isopropanol added and mixed; 
after 3 min DNA spooled and rinsed in ethanol and air dried before dissolving in 1mL 
TE buffer (1 mM Tris-HCl; 1 mM EDTA pH. 8) at 55°C. Extracted gDNA was 
confirmed by running products on 1% agarose gel stained with ethidium bromide. 
Genomic DNA was quantified using Qubit 2.0 Fluorometer according to 
ThermoFisher guidelines.  
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Sigma-Aldrich kit with bead beating  
Prior to the use of the Sigma-Aldrich gDNA extraction kit (cat. No. NA2110), colonies 
were re-suspended in 200 μL of water, and 0.8 g of 0.1mm glass beads were added. 
Cells were disrupted for 30 seconds at an agitation speed of 4,500 rpm and then 
harvested at 10,000X g for 3 minutes and the supernatant transferred to a new tube. 
This was then used for gDNA extraction by Sigma-Aldrich gDNA extraction kit. 
Extracted gDNA was confirmed by running products on 1% agarose gel stained with 
ethidium bromide. Genomic DNA was quantified using Qubit 2.0 Fluorometer 
according to ThermoFisher guidelines.  
 
Potassium hydroxide-EDTA method (Sun et al., 2014) 
A single exconjugant was transferred to a micro centrifuge tube containing 27 μL 10 
mM Tris-EDTA (1 mM, pH. 7.6) and then 3 μL 0.4 M KOH-10mM EDTA added and 
incubated at 70°C for 5 min. 3 μL Tris-HCl (pH. 4.0) was added and this was used 
directly for PCR amplification. The quality of the gDNA extracted was checked by 
running products on 1% agarose gel stained with ethidium bromide and by using it in 
a MyFi PCR reaction using 16S primers to check the quality of the method. PCR 
mixture (25 μL) contained 2XMyfiTM High-Fidelity polymerase master-mix (Bioline), 
primers (0.5 μM each), template DNA (25 ng) and DMSO (3%). The PCR was 
performed using a specified MyFiTM Thermal Cycling Procedure: 1 cycle, 95°C for 60 
s; 30 cycles, 95°C for 15 s, 71°C for 15 s and 72°C for 3:00 min; and 1 cycle 72°C for 
15 min. 5 μL of each product was run on 2% agarose gel with ethidium bromide.  
 
4.2.9 Checking for gene disruption  
The extracted gDNA was used for PCR to check for successful gene disruption: PCR 
mixture (25 μL) contained the outlined MyfiTM procedure. Primer sets were designed 
for each gene being disrupted at varying intervals from the site of the sgRNA – 0.75 
Kb, 2Kb, 5Kb and 7 Kb. Extension time for each PCR was altered depending on the 
expected size of product.  
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4.3 Results  
 
4.3.1 Identification of target genes  
Genes for phenotypic qualities exhibited by V. sp. str. MG37 were determined using 
BLAST search with characterised genes known to contribute to colour in another 
related spp. This led to the identification of one gene - VAB05470 – which is 
predicted to responsible in the biosynthesis of the orange pigment of Verrucosispora
species. The target gene involved in proximicin biosynthesis chosen was ppb120, as 
it is predicted to being vital in proximicin biosynthesis and hence, its absence, should 
result in a drastic and easily detectable reduction in proximicin production.  
 
4.3.2 Design of sgRNA’s
Summarised in Table 19, a single protospacer was designed for VAB05470, 
designed to delete the amino acid sequence: PAVLAA and cause a frameshift 
resulting in an early stop codon. Three were designed for ppb120 to increase the 
likelihood of producing a high efficiency disruption plasmid. All were designed to 
delete a single amino acid resulting in frameshift (Table 19). Each contained the 
adjacent PAM sequence, occupied the non-coding strand, and were unique in the V.  
 Protospacer PAM 
Non-
coding 
Unique Purines 
VAB05470
_1 
CCGGGTGTACGCCGCG
AGGACGG 
Y Y Y 100% 
Ppb_120_1 
CGGCGATCCGCTGTGC 
CGGATGG 
Y Y Y 75% 
Ppb_120_2 
ACCCGCAGGGCGACCT 
GGCGTGG 
Y Y Y 75% 
Ppb_120_3 
CGTCGTCCGACCGGAC 
GGTACGG 
Y Y Y 75% 
Table 19. Design of synthetic guide RNA’s for gene editing. Pigmentation gene in V. 
MG37 VAB05470, and ppb gene ppb120. Pink denotes the 3’ Purines and in bold is the 
PAM sequence.  
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sp. str. MG37 genome. Attempts were made to have purines occupying the last four 
(3’) bases, but this was not 100 % achieved in all. Primers were successfully 
designed to incorporate these protospacers with stated over hangs.   
 
4.3.3 Production of pCRISPR-sgRNA-RT  
All protospacers were successfully assembled and ligated into pCRISPomyces-2. 
Sequencing determined that for VAB05470 the sgRNA inserted correctly; but for 
ppb120, only 2/3 were correctly inserted. A repair template for VAB05470 could not 
be successfully amplified, however, it was deemed as non-essential at these initial 
stages as any disruption resulting in pigment alteration was confirmation of 
CRISPR/cas9 application in Verrucosispora spp. For ppb120, a ~ 2.5 Kb repair 
template was successfully amplified, annealed (Fig. 69), digested and inserted to 
produce pCRISP-120sgRNA-RT. Production of correct plasmid was tested by (i) 
restriction digest and the correct size insert was seen; and (ii) sequencing which was  
correct.  
 
 
 
 
 
Figure 69. ppb120 2.5 Kb repair template. 1. A fragment 2.5 Kb in size which spans 
the ppb120 gene produced by PCR and gel purified.  
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4.3.4 Genomic DNA extraction 
All three genomic DNA extraction methods – CTAB, Sigma-Aldrich kits with bead 
beating and KOH-EDTA - failed to produce high quality DNA for sequencing. CTAB 
was difficult to implement as the disrupted V. sp. str. MG37 strains – even those with 
inserted repair templates – were difficult to grow in liquid culture, resulting in very low 
yields of DNA – too low for the Qubit to register a quantity. DNA was run on agarose 
gels to assess the quality, and the result was typically a complete lack of gDNA being 
extracted. A combination of Sigma-Aldrich kits with bead beating did successfully 
yield genomic DNA, however, it contained many low MW bands – suggesting 
degradation due to the abrasive bead beating (Fig. 70). This quality was enough to 
allow PCR confirmation of gene disruption and where necessary PCR products were 
sequenced for confirmation. Shown in Fig. 70, the concentration of DNA extracted 
from V. sp. str. MG37ΔVAB0547 in comparison to WT V. sp. str. MG37. Despite 
designed for PCR amplification of DNA, the KOH-EDTA-PCR technique did not yield 
any amplicons, and so it was assumed that little gDNA was extracted, if any at all. 
This was tested against already extracted gDNA, with the same treatment done to 
ensure it wasn’t the chemical e.g. KOH preventing the PCR reaction from working 
(Fig. 71).  
Figure 70. Genomic DNA extraction from V. sp. str. MG37 by a combination of 
bead beating and Sigma Aldrich gDNA kit. 1. 1 Kb GeneRuler ladder 2. V. MG37 
ΔVAB0547 3. WT V. MG37  
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4.3.5 Interruption of phenotypic gene - VAB05470 
Exconjugants isolated in V. sp. str. MG37ΔVAB05470 disruption studies were shown 
to have altered pigmentation, in comparison to WT V. sp. str. MG37. This can be 
seen in Figure 72 after 6 days of incubation; single isolated colonies of V. sp. str. 
MG37ΔVAB0547 strains were very slow growing in comparison to WT V. sp. str. 
MG37and showed sporulation only after ~21 days. They show similar morphology 
characteristic to Verrucosispora spp., with the loss of the vibrant orange pigment 
resulting in a creamy/orange colour. In addition to slow growth, the texture of 
colonies was ‘stickier’ in comparison to WT V. sp. str. MG37, suggesting a potentially 
substantial deletion in the absence of a repair template.   
As mentioned, despite extensive attempts, gDNA was never extracted. PCR 
confirmation was done (Fig. 73), which showed a region encompassing the VAB0547 
gene which was 5 Kb was reduced to ~ 1.2 Kb, and primer sets designed to amplify 
3.5 and 2 Kb around VAB0547 did not give any on target amplification in V. sp. str. 
MG37 ΔVAB0547.  
 
 
Figure 71. PCR products of KOH-EDTA-PCR technique using 16S primers. 1. 1 Kb 
GeneRuler Ladder 2-14. Extracted gDNA using KOH-EDTA, 15. CTAB-extracted WT 
gDNA 16. 1 Kb GeneRuler ladder.  
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Figure 73. Confirming the deletion of VAB05470 gene in V. sp. str.  MG37. 1. V. 
MG37 WT 5 Kb 2. V. MG37 WT 3.5 Kb 3. V. MG37 WT 2 Kb 4. V. MG37 ΔVAB0547 5Kb 
reduced to 1.2. 5. V. MG37 ΔVAB0547 3.5 Kb with no products. 6. V. MG37 ΔVAB0547 
2Kb with no products. 7. 1 Kb GeneRuler Ladder.  
Figure 72. Change in phenotypic traits and growth in VAB05470 deletion strains. 
Top left and right. V. MG37 ΔVAB0547 using 55C and 65C heat-shock respectively. 
Bottom left. V. MG37 ΔVAB0547 retained the ability to sporulation – dark spores being 
produced after 21 days. Bottom right. Colour of WT V. sp. str. MG37 
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4.3.6 Disruption of proximicin biosynthetic gene - ppb120  
Both pCRISP-120sgRNA and pCRISP-120sgRNA-RT were successfully produced 
and conjugated into V. sp. str. MG37. Extraction of genomic DNA was once again an 
issue, and PCR was used to confirm gene deletion – in pCRISP-120sgRNA a ~ 7 Kb 
region was deleted and pCRISP-120sgRNA-RT the correct ~ 2.5 Kb repair template 
was present (Fig. 74). Initial PCR of pCRISP-120sgRNA, using primer sets to amplify 
0.75, 2 and 5 Kb regions surround ppb120 showed no products - demonstrating a 
large region of DNA has been disrupted (Fig. 75). Only primer sets which spanned a 
5 Kb region surrounding ppb120 gave products of ~500 bp. Six pCRISP-120sgRNA-
RT exconjugants were isolated and demonstrated consistent apramycin resistance, 
however, PCR confirmed only 3/6 had the repair template present, and one of those 
had a smaller template present. Sequencing of the PCR products confirmed the all of 
the repair templates were correct with a product of ~2.5 Kb; hence the region missing 
in the smaller template amplicon (~ 2 Kb), must be located in the centre of the 
template – the region not resolved by sequencing. Due to time constraints and a 
collaborating group taking on this work, analysis of proximicin production in these 
strains was not done. 
 
 Figure 74. Successful confirmation of the repair template in 3/6 V. sp. str. MG37 
Δppb120 exconjugants. 1. 1 Kb GeneRuler DNA Ladder 2-4. V. MG37 Δppb120 
exconjugants 1-3 with no RT present  5 and 6. V. MG37 Δppb120 exconjugants 4 and 5 
with correct size RT 7. V. MG37 Δppb120 exconjugant 6 with a smaller RT than 
expected. 
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4.3.7 Heat shock optimisation  
Figure 75. Successful PCR confirmation of gene deletion in V. sp. str. MG37 
Δppb120 exconjugants with no repair template. Primer sets are designed to amplify 
fragments of 0.75 Kb, 2Kb, 5Kb and 7 Kb regions surrounding ppb120. 1. 1 Kb 
GeneRuler DNA ladder. 2. 5 Kb Primers WT 3. 3.5 Kb primers WT 4. 2 Kb primers WT 
5. 0.75 Kb primers WT 6. 7 Kb Primers WT 7. 5 Kb Primers Δppb120 showing ~500 bp 
product 8. 3.5 Kb primers Δppb120 9. 2 Kb primers Δppb120 10. 0.75 Kb primers 
Δppb120 11. 7 Kb primers Δppb120 now a ~1 Kb product. 
Table 20. HS combinations tested in optimisation. Temperature and time analysed 
for ability to initiate germination, using the percentage of spores appearing to germinate, 
counted using a haemocytometer. Colours denote extent of germination – white – no 
effect of HS (below 25 %); blue: low induction of sporulation (25-50%); Yellow: very high 
sporulation initiation (51-75%); Pink: Very high sporulation (>75%) 
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The extent of germination was determined by the number of spores in 0.25 nL which 
appeared to have begun germination, and the range noted. As shown in Table 20 the 
lower and upper limits of sporulation were determined - temperatures of 50°C or 
below did not elicit any sporulation response, regardless of the exposure duration, 
and temperatures over 80°C were shown to be detrimental after exposure of over 30 
seconds. The optimal temp/time combination were shown to be at 60 – 65°C for 
times longer than 5 minutes; 65°C for 10 mins was chosen as the routine heat shock 
protocol. When testing conditions around the optimal, it became clear that only small 
changes the duration and temperature of the HS had a large effect on the number of 
V. sp. str. MG37shown to be not disrupted after conjugation, as shown in Figure 76.  
 
 
Figure 76. Heat shock optimisation. Photograph of two CRISPR-targeted V. MG37 
strains showing the number of exconjugants with successful gene editing – pale colour 
colonies when heat shock was applied for 1 minute (Left) and 10 minutes (Right).  
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4.4 Discussion  
 
4.4.1 Overview of findings  
We report for the first time the application of CRISPR/Cas gene editing technology in 
the Micromonosporaceae family of bacteria. The initial proof-of-concept study 
outlines the deletion of the orange pigment-conferring gene in V. sp. str. MG37, to 
result in a sickly, cream coloured strain with the correct genomic region missing 
confirmed by PCR. Using the CRISPR/Cas9 system, double stranded breaks were 
introduced and repaired via the native and highly error prone non-homologous end 
joining (NHEJ) pathway which resulted in large, random gene inactivation, leading to 
substantial areas of gene interruption. Subsequent goals to interrupt genes predicted 
to be essential in proximicin biosynthesis were attempted, however, issues were 
encountered regarding the rapid large scale screening of V. sp. str. MG37 
exconjugants and Cas9 toxicity. Here, I discuss these problems and potential 
resolutions in depth, in conjunction with future directions of CRISPR/Cas9 in 
Actinomycetes, with the aim of yielding novel biologically active compounds.  
 
4.4.2 Efficient gDNA isolation  
CRISPR/cas signifies a breakthrough in gene editing technology, however, issues of 
its implementation in some bacterial families has been encountered (Lou et al., 
2016). Although overcoming many problems concerning traditional gene deletion 
strategies, one caveat remains: the requirement to screen exconjugants. This is an 
issue encountered in every outlined gene-disruption method, as it relates to complex 
genomic DNA extraction required for screening transformants; this is exacerbated by 
intricate growth requirements of many bacteria, especially marine Actinomycetes 
(summarised in Fig. 77). To allow the utilisation of CRISPR/Cas to its fullest potential 
in these classes, these issues must be resolved; two potential approaches discussed 
are: improving routine culturing techniques for viable growth, and increasing the 
quality and quantity of DNA from extraction methods. 

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Improving culturing techniques 
Actinomycetes represent a large group of scientifically important microbes and they 
have been shown to colonise almost every environment on Earth (Bukhari et al., 
2013). They typically occupy complex niches in their natural habitats with intricate 
biotic and abiotic requirements; hence, it is difficult to recreate this environment in a 
lab setting (Joint et al., 2010). This has led to the long-standing observation that 
standard microbiological techniques only isolate a minuscule proportion of the 
microbial diversity present. Verrucosispora spp. are no exception to this obstacle; V. 
maris AB18-032 and V. sp. str. MG37 were isolated from deep sea sediments in the 
Sea of Japan and in Norway, respectively (Fiedler et al., 2008). The remote nature of 
these habitats make it difficult to recreate and yield viable, long-running growth in a 
laboratory setting. This is not a recently appreciated barrier, with Staley & Konopka 
(1985) dubbing it the ‘great plate count anomaly’ with reference to the several orders 
of magnitude difference between the number of colonies which grew on laboratory 
media, in comparison to the total number which could be exhibited by 
epifluorescence microscopy, specifically in relation to marine isolates. This 
discrepancy is typically attributed to lack of knowledge regarding organic substrates 
or concentrations that would have been present in the natural habitat, owing to the 
so few marine bacteria in culture. However, other factors may affect growth, such as: 
disruption of the sensitive biotic factors; high concentrations of substrates required 
for detectable growth may be toxic or large scale growth may result in compound 
production leading to self-toxicity, or the slow growing nature of the bacteria may 
lead to inevitable contamination before they have had time to thrive (Stewart, 2012). 
Alain & Querellou (2009) reviewed this problem of culturability, and culminated in a 
principal resolution being increased periods of growth to allow the transition from a 
dormancy to growing state, likely due to the requirement of de novo synthesis of 
enzymes which enable growth on synthetic medium. Fiedler et al., (2008) was the 
first to attempt Verrucosispora spp. growth and metabolite studies, resulting in the 
development of SSG media, with the aim of optimum Verrucosispora spp., culture. 
As we do not know the chemical composition of the natural environment occupied by 
Verrucosispora spp., it is impossible to assess the resemblance of SSG. SSG and 
other Streptomyces specific culturing media were analysed here (Kieser, 2000), all 
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resulted in very slow growing bacteria with a lag phase of ~11 days and sporulation 
not occurring until >28 days. It is difficult to determine whether this was due to poor 
substrate combinations, or if Verrucosispora spp., simply represent a very sedentary 
microbe. Irrespective of the cause, this led to issues concerning the ability to test 
large ranges of exconjugants for successful CRISPR/cas mediated gene editing. By 
the time exconjugants had grown up to a level capable of gDNA extraction, the 
cultures had typically been contaminated due to the lack of antibiotics necessitated 
by the conjugation protocols (Fig. 77). This was only exacerbated by off target gene 
deletions resulting in sickly, slower growing strains that were easily out competed. 
For the majority of the research conducted here, these issues were largely negated 
by using a phenotypically active protein as the deletion target, and so strains 
harbouring a successful gene interruption could be rapidly identified. However, for 
future work into the proximicin gene cluster, further work into either (i) improving 
growth conditions to better mimic the Verrucosispora natural environment or (ii) 
better extraction methods resulting in high quality gDNA from smaller, ideally single 
colony, cultures.  
 
To stimulate the natural habitat of Verrucosispora spp. to enable optimal growth, it 
would be to advantageous to study the environment, to uncover which of the 
parameters are important for the growth. This could be achieved by moving a portion 
of the sediment into the laboratory; some groups are even going as far as culturing 
the bacteria back in the natural habitat, and then re-isolating it. This can also be 
done by placing the bacteria into a membrane-lined diffusion chamber which permits 
the movement of nutrients and growth factors, but not bacteria; it was shown that this 
yielded micro-colony production of up to 40%, in comparison to the same inoculum 
on standard laboratory plates, which had a recovery of 0.05% (Kaeberlein et al., 
2002; Bollmann et al., 2007). Although this would not applicable for large-scale 
deletion screening, it does demonstrate the powerful tool the environment itself 
represents, which could be exploited. Other studies have shown how sediment taken 
from the habitat can serve as the basis for incubation conditions within the lab 
(Morris et al., 2002; Rappe et al., 2002; Logares et al., 2009; Song et al., 2009); 
using the same premise as before, with the convenience of in-lab facilities. With the 
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current scientific abilities, it is not feasible to determine the complex relationships 
and needs a bacterium has with its neighbouring microbes and its surroundings, and 
so maintaining its natural environment to such a high degree could greatly increase 
culturability. This is not limited to increasing growth rates for screening following 
CRISRP/Cas exconjugants. It has previously been shown that bacteria undergoing 
environmental stress are less amenable to genetic manipulation and conjugation 
(Kieser, 2000; Joint et al., 2010), meaning efficacy of gene editing may too be 
increased. It could be possible to use an amalgamation of approaches presented 
and to reveal a potentially feasible method: culture Verrucosispora spp., in the 
membrane lined pouches, in aquarium-like conditions containing sediment from their 
natural habitat– and harvest shortly prior to conjugation (Kaeberlein et al., 2002). 
This would use unstressed bacteria for the genomic alteration aspects of the 
research, potentially increasing its efficacy. While also increasing growth rates 
following conjugation to allow increased gDNA extraction. These methods are 
already in practice with the steady deviation from synthetic media in favour of more 
nature-mimicking approaches as discussed here, establishing the significance of the 
standard environment of economically important microbes. This area of research is 
constantly expanding, with most current efforts aimed at culture of non-culturable 
bacteria for novel compound identification. However, if these bacteria are to be 
utilised for such a purpose, issues surrounding in-lab growth for large scale 
screening and gDNA extraction need to be addressed.  
 
Improving gDNA extraction techniques  
As shown here, high quality genomic DNA extraction of small V. sp. str. MG37 
colonies for sequencing was not achieved. The major paradox encountered was: 
with increasingly harsh chemical and mechanical treatment to yield higher 
concentrations, came lower quality gDNA, indicated by the increased occurrence of 
low molecular weight bands showing DNA degradation. As previously discussed, this 
could be resolved by better culturing methods of Verrucosispora strains resulting in 
larger biomass production, or as investigated here – by different extraction methods. 
As researchers have encountered similar issues regarding large-scale transformant 
screening, the advent of new techniques has begun, shifting away from more 
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traditional, time intensive approaches (Kumar et al., 2010). This problem is further 
demonstrated in the research here as Actinomycetes possess the characteristic 
robust cell wall composition which makes it difficult to efficiently lyse the cells, while 
leaving the DNA unaffected. This has led to the design of Actinomycete-specific 
genomic DNA extraction protocols, one such being the potassium hydroxide (KOH) 
approach used here (Sun et al., 2014). This utilises the envelope degrading capacity 
of KOH to allow the leaching of gDNA, which can then be used as a PCR template. 
Sun et al., (2014) first described this alkaline lysis method and demonstrated its 
successful application to produce clean PCR fragments using well characterised 
house-keeping genes in many Actinomycete species; I was not able to recreate this 
here using WT V. sp. str. MG37, or any V. sp. str. MG37 gene deletion strains. This 
is likely owing to the extended duration required for V. sp. str. MG37 growth, as it 
was shown that cultures older than 7 days were difficult to disrupt for DNA 
amplification (Sun et al., 2014). The large-scale success of this method amongst 
other Actinomycete strains, suggests it is a viable option for screening projects, and 
potentially Verrucosispora strains if issues surrounding slow growth patterns are 
resolved. Verrucosispora spp. genomic DNA was extracted using either the CTAB 
method or a lysis following mechanical cell wall disruption; the former method is not 
feasible for screening projects as, although it produces high quality DNA, is time 
intensive and requires substantial biomass due to an inefficient process. Mechanical 
disruption of the cell wall by bead beading followed by chemical lysis, allowed DNA 
for PCR template to be extracted; however, the extracted DNA was not of high 
enough quality for sequencing. Other Actinomycete-specific methodologies, for 
example the utilisation of liquid nitrogen to help break the cell wall to allow better 
lysozyme action (Kumar et al., 2010), or bead beating in combination with detergents 
such as Chelex, to better protect the DNA resulting in the ‘perfect combination lysis’ 
(Jaffe et al., 2002), should be investigated. The ability to rapidly and efficiently 
assess exconjugants for gene editing events is likely to become an increasingly 
prominent issue in upcoming years as the bacterial applications of CRISPR/cas 
technology broadens.  
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4.4.3 Bacterial CRISPR/Cas delivery systems  
The explosion of CRISPR/cas applications in eukaryotic cells has over-shadowed 
that of prokaryotes, resulting in a comparatively low amount of well characterised 
bacterial CRISPR/cas delivery systems. CRISPR/Cas techniques used in eukaryotes 
cannot simply be repurposed for application in bacteria; this is due to the non-
homologous end joining (NHEJ) repair pathway in bacteria not being particularly 
robust (Fig. 78), in addition to homology-directed repair being functionally ineffective 
(Fig. 79). This has led to the production of bacteria-specific CRISPR/cas plasmids 
which incorporate phage genetic systems to allow efficient homologous 
recombination in bacteria. This means that CRISPR/Cas gene editing works in a 
functionally different way in comparison to eukaryotic approaches. Instead of the 
innate CRISPR/cas pathway seen in bacterial acquired immunity, bacterial gene 
editing utilises phage-driven recombination to produce gene modification and then 
Figure 78. Distribution of the NHEJ Ku protein in Bacteria. A phylogenetic tree 
showing the major phyla, classes and families of bacteria. Dark pink boxes show phyla 
that contain homologues of Ku – including Actinobacteria (Verrucosispora spp.); Blue 
boxes denote classes or orders that contain homologues of Ku and yellow boxes 
indicate families that contain homologues of Ku. Important to note, is that there is no 
instance in which Ku homologues are present in all species within a phylum or class. 
Adapted from Bowater & Doherty (2006)  
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CRISPR/Cas is used to exert a selection pressure for modification, by degrading any 
WT gene-containing DNA. This system is distinct from those used in eukaryotes as 
CRISPR is not the primary editing force, but instead, a way of selecting against non-
edited microbes resulting in a powerful negative selection system. A current review 
of marketed CRISPR/Cas delivery techniques designed specifically for gene editing 
in bacteria, shows that there are 4 plasmid-based systems available. These include: 
pCRISPomyces (Cobb et al., 2015); dual-RNA:Cas9 (Jiang et al., 2013); noSCAR 
system (Reische & Prather, 2015) and the two plasmid system designed by Li et al., 
(2015). Each consists of a codon optimised Cas9 gene, an insert site for custom 
spacers and repair templates, typically spread over two plasmids, each with a 
selectable marker and temperature sensitivity site. The latter three methods utilise 
CRISPR as a negative selection force (Fig. 70); interestingly, the system employed 
here, pCRISPomyces designed by Cobb et al., (2015) works in a method more akin 
to eukaryotic approaches. This is because it is designed specifically for 
Streptomyces (Fig. 78), which contain homologous NHEJ machinery, and hence, are 
more recombinogenic that other bacteria. Although the pCRISPomyces system 
Figure 79. Double stranded break repair in prokaryotes promotes gene editing. 
DSBs created by Cas9 complex (yellow) can be done in two ways: the error-prone 
NHEJ pathways or a repair template can be supplied – by plasmid – to leverage the 
homology dependent (HDR) repair pathway. Adapted from Ran et al., (2014). 
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successfully employed here to result in genetically modified organisms, issues were 
encountered regarding the viability of the transformants. It is likely due to two 
potential reasons: (i) although the NHEJ pathway is present in Streptomyces, it is 
error-prone and results in large regions of deletion around the target site, potentially 
leading to off-target gene deletion (ii) random Cas9 endonuclease activity across the 
genome, resulting in ‘Cas9 toxicity’. The former can be improved by introducing a 
repair template to allow homologous directed repair following Cas9 activity (Fig. 79). 
This has previously shown a dramatic increase in the efficiency of deletions, 
resulting in 100% frequency, in some cases (Tong et al., 2015). The introduction of a 
repair template requires the PCR and splicing together of two ~1Kb regions 
surrounding the target DNA region; issues were encountered in the amplification and 
Figure 80. The current typical application of CRISPR/Cas technologies in bacterial 
systems. Here the CRISPR/Cas is not the driving gene editing force, rather, used to exert 
selection on those not successfully edited via red-mediated recombination gene deletion. 
Left: Workflow shows the successful editing via Red, and so the homology site present for 
sgRNA binding is no longer present, and so no Cas9 endonuclease activity can occur, 
exconjugants grow on the plate. Right: Workflow shows unsuccessful gene editing via Red, 
and so the homology site for the sgRNA remains, and so Cas9 destroys the DNA and so no 
exconjugants are produced.  
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splicing of this region owing to the considerably high GC content of the fragments, 
resulting in its optimization requiring further investigation. In its absence, large areas 
of the target regions were deleted in comparison to the designed subtle frameshifts 
to inactivate a singular gene (Fig 79). As shown here, in addition to the desired 
colour change, the gene deletion changed many phenotypic characteristics such as 
making the texture stickier and inhibiting sporulation, suggesting important genes 
were disturbed. Future work into optimising PCR protocols for high (>75%) GC 
regions will help rectify these issues, allowing the full potential of CRISPR/cas 
specificity to be utilised. Future directions of these issues are discussed further in 
section.  
 
The pCRISPomyces system (Cobb et al., 2015) was used here to exploit the 
Streptomyces specificity; however, despite resulting in successful target gene 
editing, issues regarding Cas9 toxicity were encountered. This is displayed in the 
lack of successfully modified viable transformants, in comparison to negative 
controls done. Each of the marketed systems contain Streptomyces pyogenes Cas9 
(SpCas9) codon optimised protein under the control of a promoter system, in each 
case a previously characterised strong promoter is used. The potential of off-target 
Cas9 action to cause toxicity is not a surprise, considering the extensive evidence of 
earlier RNA interference-based screening technologies exhibiting non-specific 
toxicity. It was hence commonly proposed as a potential CRISPR/Cas limitation, 
prior to direct evidence confirming its existence. Attempts to hinder Cas9 activity 
towards non-target PAM sites throughout the genome, have centred on overloading 
the nuclease with non-targeting single guide RNAs (sgRNAs). This approach to 
control the disruptive Cas9 enzyme, however, fails to prevent the arguably most 
dramatic off target effect of double stranded breaks, which are fatal towards many 
cell types. Numerous strategies have been employed to negate this affect, including 
paired Cas9 nickases containing individual sgRNA’s to generate two single stranded 
breaks (Cho et al., 2014); truncated guides (<20 nts) to prevent similarity with off-
target genomic regions without sacrificing on-target efficiency, resulting in a 5,000-
fold decrease in undesired mutagenesis (Fu et al., 2014; Tsai et al., 2015) and 
modified Cas9 enzymes to engineer increased fidelity (Kleinstiver et al., 2016; 
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Slaymaker et al., 2015). Genome-wide assay experiments to monitor double strand 
breaks (Crosetto et al., 2013; Kim et al., 2015; Kim et al., 2016) have indicated these 
strategies successfully limit off target mutagenesis. However, these studies have 
focused extensively on eukaryotic systems, and the incorporation of these advances 
in bacterial systems is limited. For use in Verrucosispora spp. and other 
Streptomyces strains, pCRISPomyces could be modified to contain an inducible 
promoter system to lower the overall concentration, and hence, off-target effects of 
Cas9. This would be straightforward to do by using restriction sites to excise the 
current system, and replace with a system under strict inducible control such as the 
XyIS/Pm or PmML1-17 systems which have been shown to exhibit extremely low 
basal expression (Balzer et al., 2013). However, as well as decreasing off target 
mutations, it will likely lower on-target activity. Although this price is acceptable for 
small scale research attempts as outlined here, for the implementation of large SMC 
characterisation resulting in novel compound discovery, other approaches to 
lowering Cas toxicity, such as intelligent sgRNA design, must be investigated.   
 
4.4.4 Optimal sgRNA design 
CRISPR/Cas9 exploitation has the ability to drastically reduce the time and labour 
associated with gene modification in comparison to traditional techniques; now, 
focus is shifting to increasing its on-target specificity. Research into hindering Cas9 
toxicity has seen in-depth investigation into truncated sgRNA’s, along with a building 
cache of other evidence, it has become increasingly clear that not all apparently 
analogous sgRNAs work with the same efficiency (Doench et al., 2014; Wang et al., 
2014). Just as issues regarding off-target Cas9 activity were encountered in the work 
outlined here, it is important that research is ongoing to determine criteria that can 
predict sites favouring high activity and specificity. Currently these can be largely 
grouped into two considerations: the PAM sequence chosen and the composition of 
the sgRNA homology region.  
 
There are some required features for a sgRNA to function, one of the earliest 
recognised is a PAM sequence adjacent to the sgRNA homology region (Shah et al., 
2013). The Cas9 protein most commonly utilised in CRISPR/cas9 studies is that of 
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Streptomyces pyogenes (SpCas9), which has the optimal PAM site: NGG; high GC 
DNA content, exhibited in many Actinomycetes, mean these PAM sequences are a 
common occurrence (Heler et al., 2015). While initially appearing advantageous - as 
there are many potential PAM sequences for sgRNA design, it increases the 
chances of SpCas9 off target effects. This has led to the engineering of spCas9 
proteins with altered PAM specificities, and some design tools offering user-defined 
PAMs. Kleinstiver et al., (2015) has engineered spCas9 proteins exhibiting better 
discrimination between NAG and NGA PAMS, leading to reduced Cas9 toxicity. For 
use in Verrucosispora spp., and other extremely high GC organisms, a more radical 
approach may be required to achieved high efficiency. One such tactic may involve 
the focus shift, from SpCas9, to engineering Cas9 specificity from other species 
which are known to have longer PAM sequences. For example, Staphylococcus 
aureus Cas9 has been shown to recognise NNGRR PAM sites (Ran et al., 2015); 
the longer sequence confers increased on-target specificity in comparison to 
spCas9, as well as increasing potential scope for modification for use in other 
organisms.  
 
While the NGG PAM region is essential for high efficiency gene editing, it does not 
assure it; the sequence features, independent of PAM, are important for target 
efficiency (Fu et al., 2014; Doench et al., 2015). One logical variable is the targeting 
of a region at the 5’ end of the gene, resulting in an early frame shifts or stop codons; 
however, despite the reduced efficacy seen in some cases, the majority show that 
target sites throughout the gene result in similar disruption rates (Wang et al., 2014; 
Doench et al., 2015). Research then shifted to decrease non-specific mutagenesis 
by engineering truncated sgRNAs, the principle being that a shorter stretch of DNA 
will statistically find partial-homology less often (Doench et al., 2015). Although I am 
not convinced that the effects seen aren’t simply the result of an overall decrease in 
Cas activity – leading to lower off- but also on-target events – it is nevertheless an 
interesting observation and, mentioned here for the sake of inclusivity. Another non-
PAM specific consideration is the overall GC content of the sgRNA; intermediate GC 
percentage, outperformed their high and low GC counterparts (Wang et al., 2014). 
This suggests that either high or low affinities of the sgRNA-target duplexes 
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negatively impact Cas9 activity. This is further increased if a purine occupies the 
most PAM-proximal position (Wang et al., 2014). Extensive screening of sgRNA 
efficacies, as done by Doench et al., (2014) in which the specificity of over 6000 
sgRNAs were tested, are forging the way into bioinformatical design of sgRNAs; as 
this research continues, sequence based activity predication modelling programs are 
likely to closely follow the currently available sgRNA designing tools.  
 
Considered sgRNA and PAM selection, in parallel with many freely available sgRNA 
designing tools were used to produce the ppb120 targeting sgRNAs used in the 
research here, and yet Cas9 toxicity – shown by ‘sickly’ or non-viable exconjugants – 
was still present. This could potentially be resolved by increasing the expressional 
control of the sgCas9 protein, as discussed. However, this will not resolve issues 
encountered regarding high GC organisms possessing many NGG PAM sites 
leading to off target effects. Nor will shortening sgRNA’s increase specificity, owing 
to the same principle. As high GC organisms, such as the Verrucosispora strains 
examined here along with other Actinomycetes, are relied upon for such a large 
proportion of novel compound discovery, it is vital that CRISPR/Cas technology can 
be utilised in these organisms. As the number of bacterial genomes sequenced and 
annotated continues to steadily rise, the real extent of CRISPR/cas9 diversity across 
prokaryotes will become apparent. Investigation into the systems utilised in 
Actinomycetes and other families, will likely expose more-suitable CRISPR systems 
for gene editing applications focused on them. Just as bacteria evolve systems to 
allow self-resistance to antimicrobial compounds they produce, they too must 
possess methods which prevent self-DNA degradation from CRISPR/Cas action. A 
cursory look at the Verrucosispora maris AB18-032 genome presents only a single 
area displaying characteristic features of a CRISPR/Cas loci. This region contains 
multiple Cas-related genes, as well as 41 foreign spacers, representing previous 
scars. Further investigation reveals two interesting observations: (i) the repeating 
regions comprising the V. maris CRISPR are completely unique, and (ii) the Cas 
proteins present show no conserved identity with spCas9 (<8%). These together 
further suggest that V. maris AB18-032 utilises a Cas specificity, and hence sgRNA 
and PAM sequence requirements, very different to that of sgCas9. This is supported 
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by work shown here, as when sgCas9 is employed in V. maris AB18-032 it results in 
Cas9 toxicity. Prior to future work in other high GC strains, I suggest the exploitation 
of CRISPR/cas systems in these organisms to engineer more suitable gene editing 
machineries, with the aim of lowering research barriers associated with off target 
DNA mutagenesis affects. 
 
4.4.5 Current uses of bacterial CRISPR/Cas technologies 
The renaissance created in by CRISPR/cas technologies is not limited to the gene 
editing field of biology and biotechnology, with many other approaches being formed 
from its exploitation. The breadth of uses this technology represents is unparalleled; 
the ability to advance other areas, distinct from gene editing, is only just starting to 
become appreciated with efforts being re-directed to areas of bacterial research such 
as: gene expression modulation; imagine of genomes; phylogenetic studies and 
vaccination of bacterial strains. These will each be briefly discussed here: 
 
Modulation of bacterial gene expression 
Repurposing CRISPR/Cas systems for targetable gene regulation is another 
common version of the application. The concept of programmable bacterial gene 
regulation has already been investigated using other forms of controllable DNA 
binding proteins such as Zinc-finger and transcription activator like effector arrays 
(Carroll 2014). The application of CRISPR/cas was initially realised with two papers 
(Bikard et al., 2013; Qi et al., 2013) which similarly used a guided Cas9 protein to 
enable the blocking of transcription of the target gene, achieved by either blocking 
movement of the RNA polymerase or preventing binding of RNA polymerase to the 
promoter sequence, respectively. The latter of these approaches has been shown to 
be highly effective in yielding gene repression (Bikard et al., 2013; Luo et al., 2015; 
Tong et al., 2015), whereas the former is better utilised as a gene down regulation 
tool (Choudhary et al., 2013; Qi et al., 2013; Tong et al., 2015). As investigations 
have progressed, a whole array of CRISPR/cas expression control capabilities been 
have been reported; integrating the results produces in a set of heuristics: target 
promoters for complete gene repression; to loosen control, produce sgRNA’s 
towards the end of the gene and, to lower the control further, target the template 
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strand at the end of the gene (Cleto et al., 2016; Luo et al., 2015; Qi et al., 1023; 
Tong et al., 2015). Concurrent to this work, Cas9-mediated activation of target genes 
has been reported (Bikard et al., 2013) – this was done by fusing known RNA 
polymerase stabilisers to Cas9 to facilitate complex assembly. This resulted in an up 
to 23-fold increase of expression depending on the native promoter strength; change 
in expression was more dramatic for weaker promoter systems (Bikard et al., 2013). 
Mentioned here is just a summary of some approaches of CRISPR/cas repurposing 
for gene expression control, many more exist, and are likely to be developed.  
 
Imaging of bacterial genomes 
Both bacterial and eukaryotic chromosomes are known to be complex and high 
organised structures; growing evidence suggests cellular localisation and structure of 
microbial chromosomes is tightly associated with gene expression (Ryter and 
Change, 1975; Bryant et al., 2014; Wen and Xiao et al., 2014). This is important 
information when intending to control the physiology of industrial strains. The 
characteristic short cell cycle of bacteria dictates the co-occurrence of transcription 
and replication of chromosome, however, the effect each has on the other is vague; 
questions regarding the effect chromosomal modification has on replication is still 
unclear. Current microbial in vivo genomic loci tagging methodologies are laborious 
and time consuming, and this has hindered work in this area. The target specificity 
and simplicity of Cas9 has lent itself to such an application; the ability to optically tag 
a specific genomic locus can result in increased insight into the implementation of 
recombinant gene technologies. DNA imaging via Cas9 uses the same premise as 
Cas9 gene activation, and is typically done by using a site-specific targeting domain 
consisting of Cas9::sgRNA with a fluorescent domain attached (Anton et al., 2014; 
Deng et al., 2015; Ma et al., 2015). As with much of CRISPR/cas applications, this 
research is largely focused on eukaryotic organisms, but it could be rapidly re-
purposed for work in prokaryotes to allow better understanding of chromosomal 
organisation and dynamics present in bacterial systems.  
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Phylogenetic studies  
Millions of years of evolution and a myriad of niches, has resulted in Bacteria being 
an almost incomprehensively broad and diverse domain. To be able to exploit the 
divergent and distinct metabolism and physiology they possess, it is vital to be able 
to accurately identify strains, a problem intensified by horizontal gene transfer 
increasing diversity within species. This is a problem encountered in any bioprocess 
which relies on the characteristics of a specific bacterial strain, such as bio-
refineries; similarly, in the race for novel compound discovery, the ability to identify 
species accurately is vital as to avoid wasting time in previously characterized 
species. CRISPR/Cas systems have been extensively proven to be a reliable and 
precise method for genotyping bacterial strains (Cui et al., 2008; Lindenstrauss et al., 
2011; Shariat et al., 2015; Sun et al., 2015); this is done by analyzing the unique set 
of ‘scars’ a strain has acquired represented in the chronologically ordered spacers 
incorporated at the CRISPR loci. This allows the diversification of two bacterial 
populations by a discrete event series in each strain; this allows detailed insight into 
the history of strains, showing times they existed as a single population – similar 
spacers at the 3’ end – and diversification events – diverging 5’ spacers. Vitally, this 
information can be used to track pathogenic bacteria through human society 
providing insights into the trajectory of pathogens responsible for outbreaks, giving 
insights into potential prevention routes.  
 
Vaccination of microbial strains  
There are many industrially important bacterial strains, such as diary and 
pharmaceutical production, in which contamination with a pathogenic bacteria or 
bacteriophage, can cause catastrophe. Even small infections can be amplified in 
reactors, resulting in huge economic loss to companies. Methods to prevent this has 
traditionally been focused on improving the bacterial innate immune system, 
preventing phage DNA injection or absorption (Sturino & Klaenhammer, 2006). The 
concept of protecting bacteria from potential enemies was one of the first uses of 
complete CRISPR/Cas systems (Barrangou et al., 2007). For implementation of this 
approach, all foreseeable contaminants are predicted and spacers targeting their 
genome are designed and introduced into the CRISPR array. Issues are 
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encountered due to high mutation rates exhibited in viruses, and so areas of the 
genome which are rarely altered should be carefully identified. This approach allows 
the successful protection of the industrially important strain, and hence, cheaper, 
more efficient fermentation practices.  
 
4.4.6 The future of bacterial CRISPR/Cas technology 
As discussed here, the repurposing of CRISPR/Cas systems to allow specific gene 
editing, as well as a whole host of other applications, is a powerful tool. The 
explosion of CRISPR/Cas systems engineered towards eukaryotes continues to 
rumble on, versatile bacterial tools are evolving at a steady pace. Specialized 
bacterial CRISPR/Cas approaches represent tools of promising ability; however, 
issues regarding NHEJ, delivery systems and utilization of host strategies continue. 
The lack of NHEJ ability characteristic of many bacteria species was not 
encountered or discussed here in depth, as it is present in the target species; 
Figure 81. The current issues encountered when utilising CRISPR/Cas technology 
in bacterial species. CRISPR/Cas systems depend on Non-homologous end joining 
(NHEJ systems), which are not present in most bacterial species, and when it is present 
it is not very robust. Dark blue arrows represent currently utilised CRISPR/Cas gene 
editing applications – either using the inefficient host NHEJ system, or incorporating a 
repair template to allow homology dependent repair (HDR), both of which encounter 
issues. In light blue, are the potential ways to overcome these issues explained here: 
supplementing the proteins required for NHEJ into bacterial strains which do not possess 
them or have inefficient versions. Another approach would be, as many bacterial species 
genomes contain NHEJ systems, they could be altered to be under the control of a 
strong promoter, effectively reconstituting their production.  
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however, for future large scale applications it must along with other issues, be 
addressed. The major advantage CRISPR/Cas conveys in comparison to other gene 
editing techniques, is its ease of use and its adaptability to multiplex approaches. 
These capabilities are in part owed to NHEJ-dependent double stranded break 
(DSB) repair systems, which allow template-independent genome editing (Fig. 81). 
The presence of this system negates the complex requirement of multiple template 
DNAs for a single loci dictated by homology dependent repair; however, these 
systems are rare. Currently, this issue has yet to be overcame. One potential 
approach would be to engineer enzymatic requirements for NHEJ – such as Ku and 
LigD proteins – to create a companion plasmid used in combination with other 
bacterial CRISPR gene editing vectors; this would allow gene editing via NHEJ (Fig. 
81). It has also been seen that many bacteria once had the genetic ability for NHEJ 
but it has since been made redundant (Tong et al., 2015), and so simply 
reconstituting the components on the host genome is another potential research 
avenue. This was not an issue for the research here as Actinomycetes represent 
some of the few prokaryotes which contain NHEJ homologs, however, they are 
extremely error prone, resulting in large unpredictable gene interruptions. The wide 
scale applicability of CRISPR/Cas gene editing technology in prokaryotes must be 
resolved. It is interesting to note that ~40% of bacteria contain CRISPR/Cas 
systems, a percentage which continues to rise as their impact widens; this number 
largely eclipses the number of bacterial species with NHEJ homologs. Why would 
these species contain the apparatus for double stranded DNA breaks, without the 
machinery capable of repairing them? These systems obviously serve some 
function, which requires further investigation. With the plethora of evolutionary 
history and diversification, it is hard to imagine that all these systems work in a 
similar manner. Better understanding of the CRISPR/Cas mechanisms comprising 
the bacteria domain, facilitated by improved culturing and sequencing techniques, 
could potentially result in the utilization of the systems present in the target bacteria. 
As outlined specifically for Verrucosispora spp. previously, the idea of switching 
focus away from spCas9 towards better understanding endogenous systems in 
target organism, could eventually lead to facile gene editing systems. By simply 
introducing compatible pre-crRNAs into the target organism, and ensuring their 
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endogenous systems are actively expressed – potentially by other CRISPR/Cas-
driven approach – you could engineer bacteria to target their own DNA. To although 
routine implementation of these applications much still requires research, primarily, 
issues surrounding crRNA delivery systems, it stands to demonstrate the potential 
the already revolutionary CRISPR/cas discovery, encompasses.  
 
Bacteria and other microorganisms provide the basis to much of what we regard as 
healthcare; their ability to produce such diverse biologically active compounds 
comes as a result of millennia of evolution. The recent discovery and potential of 
CRISPR/Cas systems has been adopted by various disciplines; however, bacterial 
application of these technologies has lagged behind in many respects. Here, we 
outline the use of CRISPR/cas gene editing technology for use in marine 
Actinomycete, Verrucosispora sp. str. MG37, to aid in novel compound identification. 
The phenotypic gene responsible for the characteristic orange pigment was targeted, 
and successfully deleted. Issues surrounding its application are discussed here, in 
addition to other repurposing possibilities and future prospects of CRISPR/Cas 
technologies.  
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Chapter 4. CRISPR/Cas gene editing in Verrucosispora spp. 
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Chapter Five. Discussion of Research  
 
5.1 Overview of Findings   
 
Proximicins represent an as-yet unexploited chemical repertoire for novel compound 
discovery, owing to the distinctive 2,4-disubstituted furan group which simultaneously 
conveys attractive yet synthetically complicated chemistry. Previous work aimed at 
exploiting this potentially interesting and biologically active chemical scaffold have 
been hindered by the complex and financially expensive approach associated with 
heterocycle synthesis. Here, we report the sequencing-based identification of the 
proximicin biosynthetic cluster permitting the discovery and characterisation of the 
enzyme putatively responsible for furan group incorporation into the elongating 
peptide via NRPS biosynthetic enzymes. The adenylation domain responsible for this 
mechanism contains a previously undescribed structure, refuting previously outlined 
boundaries thought to confine A-domain specificity and activity. This will inform future 
bioinformatic studies into NRPS identification and substrate prediction, in addition to 
providing new guidelines for exploitation of bacterial NRPS enzymology with the aim 
of novel compound discovery. In the process of this research, other findings became 
increasingly apparent; primarily, the unambiguous nature of furan incorporation, with 
it being either pre / post amide bond, and the high level of promiscuity exhibited by 
Ppb120 adenylation domain capable of furan incorporation. These issues further 
complicate the ability to validate the route to proximicin biosynthesis; although 
confirming enzymes likely capable of introducing the 2,4-disubstituted furan and 
novelty in line previous predictions, we cannot be sure this is the actual in vivo route. 
Issues concerning complete biosynthetic route resolution, however, do not negate 
future exploitation of the uncovered mechanism; the novel enzymology represents a 
completely unique NRPS A-domain activity and structure, offering a potential 
molecular tool for innovative compound production.  
 
The techniques and approaches employed in this research were chosen to assess 
the applicability of cutting edge technical and scientific innovation in combatting the 
void which currently plagues drug discovery pipelines. The aim was to establish a 
cost effective and efficient pipeline for microbe genome sequencing and cryptic 
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NRPS cluster identification, adenylation domain characterisation for biosynthetic 
route prediction, and gene deletion studies to provide the considered ‘gold standard’ 
of gene cluster elucidation. The primary purpose of this research is to inform 
intelligent novel compound discovery, specifically uncovering biologically active 
compounds for facile exploitation of their biosynthetic machinery responsible, leading 
to the ability to construct large compound libraries production. As specific issues 
encountered in each stage of this research – sequencing, adenylation domain 
characterisation and CRISPR gene editing – were discussed in preceding chapters, 
the aim here will be to add context to these findings, explore future research avenues 
and applications.  
 
5.2 Limitations of Research  
 
At the beginning of this research, a selection of likely potential routes to furan 
incorporation and hence, proximicin biosynthesis, were developed. The aim was to 
inform the refinement process of SBC cluster selection after bioinformatic analysis of 
the two producing Verrucosispora strains. The extensively noted similarity between 
congocidine and proximicin compounds laid the foundations for much of this potential 
route construction. Initial research supported this hypothesis with analogous 
mutations appearing in adenylation domains thought to be responsible for 
heterocycle incorporation in both systems, the theory we had unearthed a structural 
residue which confers the novel specificity began to form (Juguet et al., 2008). This 
was disproved with the revision of the congocidine pathway (Al‐Mestarihi et al., 
2015), shattering previously homology-based biosynthetic routes. It was shown that 
during congocidine synthesis, the previously identified heterocycle activating A-
domain – Cgc18 - was instead responsible for incorporation of a linear molecule, and 
that another non-NRPS protein – Cgc3* - was responsible for the pyrrole 
incorporation (Fig. 82a); the perceived structural homology conferring heterocycle 
activity no longer held any weight. As previously outlined potential biosynthetic routes 
were in doubt, and due to the identification of the ppb cluster in the two producers, 
efforts were widened to focus on both the potential homologues, as well as novel, 
routes to heterocycle incorporation (Fig. 82b). In doing this, two opposing theories 
began to appear regarding the nature of furan group incorporation. The core of these 
discrepancies are based on the timing of furan synthesis: prior to activation by A-
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domain, and hence peptide bond formation or after being activated as a linear 
molecule, then cyclised. As discussed in Chapter 3, the former theory is supported by 
previous work on congocidine, and the latter by the presence of cyclases enzymes in 
the putative cluster. It should be noted that the application of the findings described in 
the subsequent discussions do not rely on the natural action of these A-domain 
enzymes, but rather the exploitation of the apparent promiscuity to substrates 
Ppb120 possesses. Conversely, it should not be ignored that one initial goal of this 
research was to determine the proximicin biosynthetic route present in 
Verrucosispora spp., and this was not accomplished in its entirety. Although 
discussed in depth in prior chapters, two specific issues were encountered: i) 
successful production of A-domain recombinant proteins, consisting of many 
multifaceted issues and ii) inefficient CRISPR/Cas9 activity. As discussed in Chapter 
3, rectification of the former issue would consist initially of addressing issues 
associated with high GC organism cloning and recombinant expression techniques. 
This is likely to be facilitated by increased research in these organisms, in 
combination with improved understanding of solubility issues surrounding adenylation 
domains. I predict innovation directed to solubility issues will centre on the presence 
of MbtH-like proteins, proposing that much is still to be uncovered regarding 
establishing the boundaries to roles these co-proteins play; this notion provides the 
foundation of discussed future research avenues. In respect to issues concerning 
inefficient gene editing of ppb genes, resolution will likely arise as the significance of 
microbial applications continues to be realised. It may be noted that CRISPR/Cas9 
gene deletion and metabolite studies were not an area of intense investigation; this 
was due to another collaborating group having the sole research focus of random 
gene deletions in Verrucosispora spp., with the aim of disrupting any secondary 
metabolite synthesis. They were recently able to delete ppb genes outlined in 
Chapter 2, confirming our predictions by proving it is the gene cluster responsible for 
proximicin biosynthesis. This work will likely continue to shed light on the order of 
furan group incorporation, by deleting genes sequentially and analysing the 
metabolic trace to identify accumulating and absent compounds; unfortunately, this 
was not in the scope of this research.  
 
As with any research, limitations were encountered, and largely these were 
overcome. Following a similar tendency to the accidental growth of Peniciilum spp., 
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on Alexander Fleming’s windowsill inadvertently leading to the revolution of medicinal 
capabilities, the area of this research which holds the most clinical application, was 
unintentional. The unforeseen ability of Ppb120 to adenylate an array of structurally 
diverse substrates, provides a potential path to novel compound synthesis. The 
unconventional domain structure present, also conveys important information 
regarding structure-activity relationships within these complex enzymes. The 
following sections will discuss the potential these discoveries possess, primarily in 
relation to its utilisation in the introduction of novel chemistry into other chemical 
scaffolds with the aim of novel antibiotic compound discovery.  
 
5.3 Application of Findings - Novel heterocycle-containing compounds 
 
Heterocycles are a common feature in naturally occurring biologically active 
compounds, often shown to be essential and responsible for conferring the specific 
action. This ability has made them the target of much interest; however, the 
complexity associated with their synthesis has hindered the common application of 
some heterocycles in combinatorial chemistry approaches to compound production. 
An example of this is the 2,4-disubstituted furan group. The furan group is a common 
heterocycle found in natural products, however, the appearance of this specific 
substitution pattern is sparsely recorded. Molecules where it has been reported have 
diverse biological activities – from antifungal compounds such as flufuran produced 
by Aspergillus flavus to antiviral and anti-inflammatory metabolites from soft coral to 
scent components produced in butterflies; specific to Verrucosispora spp., it conveys 
DNA-binding independent cell death by disrupting the cell cycle. Interest in these 
biologically active molecules diminishing is likely owed to the complex synthesis 
protocols they necessitate; they are considered as poor clinical leads. Here, we 
outline the gene cluster responsible for 2,4-disubstituted furan synthesis in 
Verrucosispora spp., along with the adenylating enzyme – Ppb120 - responsible for 
its incorporation into the backbone of the natural peptide family: proximicins. The 
demonstrated unique activity of Ppb120 presents a facile research avenue for 
exploitation. All routes are based on utilising the novel enzymology identified here, 
departing from previously small scale combinatorial chemical synthesis approaches.  
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Exploiting NRPS systems for novel production is not a particularly recent advance, a 
large amount of research effort been expended on adapting precursor supply to 
result in modified products. However, limitations have been met due to the 
uncompromising substrate flexibility exhibited by native adenylating enzymes. This 
led to work being preoccupied with adding in new domains, rather than attempting 
the potentially laborious task of modifying existing ones. Most of the key work done in 
this area was done by Baltz et al., (2006) during the development of daptomycin, a 
clinically approved NRPS-synthesised cyclic antibiotic. Initial success for daptomycin 
derivative synthesis (Baltz et al., 2006; Coeffet-Le Gal et al., 2006; Miao et al., 2006), 
has led to investigation into other modifications; these are discussed below along 
with potential application to novel heterocycle-containing compound production.  
 
5.3.1 Ppb120 promiscuous activity   
Previous work centred on utilising NRPS systems for novel compound production, 
such as that on daptomycin by Baltz et al. (2006) are typically hindered by the strict 
activity of the A-domains; this high level of specificity towards substrates exhibited by 
NRPS adenylation domains is one of their characteristic features. In this respect, the 
identified Ppb120 adenylation domain capable of activating different heterocycle 
substrates is unusual. We demonstrated here the ability of Ppb120 to activate pyrrole 
containing heterocycles with the same substitution pattern exhibited by the predicted 
native furan containing precursor. This novel promiscuity will likely allow pyrrole/furan 
compounds to be incorporated into the peptide chain, without having to produce a 
recombinant gene cluster; by eliminating precursor-synthesising genes and feeding 
into the reaction the pyrrole containing analogue of the native precursor, it would 
likely result in the production of pyrrole/furan hybrids. This presents a potentially 
straightforward initial research avenue to assess the activity these two opposing 
heterocycles – furan and pyrrole – confer. Previous work by Wolter et al., (2009) 
focused on producing congocidine/proximicin hybrids, was only concerned with 
exchanging the terminal groups, not the nature of the heterocycle core. This 
preliminary approach would likely direct future research attempts by 
 Or have another function which would likely help us elucidate their function in NRPS 
systems uncovering the activity these specific groups confer, informing future 
research directions. This method would overcome issues regarding the production 
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Figure 82. Overview of enzymes involved in proximicin and congocidine
biosynthesis which pose attractive opportunities for exploitation. (a) Genome 
organisation of cgc cluster showing NRPS genes (pink), tailoring genes (blue) and non-
NRPS adenylating enzyme (dark pink) and the proposed route to congocidine 
biosynthesis (Al- Mestarihi et al., 2015) (b) Genome organisation of ppb cluster showing 
NRPS proteins (pink) and associate proteins (grey) and proposed route for proximicin 
biosynthesis (c) a summary of the adenylating enzymes and the reactions they catalysed 
discussed in future applications.  
(a) 
(b) 
(c) 
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of complex furan and pyrrole-containing compounds via organic chemistry synthesis 
routes. However, as pyrrole is not the native precursor involved in proximicin 
synthesis, this would likely interfere with application of this approach on a wide scale 
basis; the enzyme activity would be detrimentally altered resulting in low yields of 
desired compounds, this obstacle was demonstrated here by the slow activity rate of 
Ppb120 towards the pyrrole precursor. Because of this, more reliable and robust 
methods are outlined, including the exploitation of the protein responsible for pyrrole 
incorporation in congocidine production being incorporated into the proximicin 
pipeline, as discussed below. It should be noted that all the routes and compounds 
produced are the result of manipulation of those involved in only two NRPS 
biosynthetic pathways – proximicin and congocidine, a minute fraction of the 
enzymes available for exploitation (Fig. 82). These two SMC were chosen as (i) 
previous work has already been focused on proximicin/congocidine hybrids; (ii) 
heterocycle containing compounds typically have biological activity, and (iii) some 
enzyme in each cluster carry out similar activities but in very different ways, and so 
by comparing them it will inform A-domain structure/activity study. For sake of clarity, 
the adenylating enzymes responsible for core groups in both congocidine and 
proximicin are summarised along with the reactions they catalyse in Figure 82. 
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5.3.2 Exchanging NRPS subunits  
The general workflow of this approach proceeds by deleting genes known for 
incorporation of a precursor and complemented in trans with another entire NRPS 
gene consisting of entire A-, T-, C-domains, under the control of a strong promoter; if 
the new addition requires a rare precursor, this is then fed in. Initial studies 
exchanging whole NRPS proteins entirely focused on the replacement with 
homologous subunits from similar pathways to help minimise any interference with 
subunit/subunit interactions within the multimeric structure. Baltz et al., (2006) carried 
out proof of concept experiments using the structural similarity between lipopeptide 
antibiotics. Concluding genes responsible for the additional of the final two amino 
acid units in daptomycin and A54145, were swapped resulting in the production of 
daptomycin derivatives. One reason denoting such success of this initial research 
was the presence of two similarly active adenylation domains – loading either Glu or 
3mGlu - being chosen, theoretically resulting in minimal disruption to the protein 
subunit structure (Miao et al., 2006). The high level of structural similarity exhibited 
by congocidine and proximicin, in addition to the well characterised cgc gene cluster 
responsible for biosynthesis, provides an attractive starting point for similar 
combinatorial biosynthetic approaches which are outlined in Figures 83a & b., which 
could target the core heterocycle chemistry or tailoring groups. With the aim of further 
reducing the obstruction of cross-subunit connections, the last NRPS subunit 
involved in proximicin biosynthesis should be chosen, negating any downstream 
interactions that could affect activity (Figure 83b). In Chapter 3, the importance of the 
linker regions in the activity and solubility of Ppb A-domains became increasingly 
clear, and was a major hurdle encountered for A-domain activity studies. This 
demonstrated reliance on linker regions suggests this method, in which linker regions 
would be completely exchanged, would not be tolerated by the ppb cluster and 
complete abolishment in any production would ensue. Although presenting an 
exciting research opportunity, subtle revisions would likely avoid these issues, and 
hence be prioritised.  
 
5.3.3 Module and domain exchanges 
After demonstrating the initial lack of resilience of some NRPS proteins to tolerate 
subunit exchanges, more refined approaches began to emerge. Research focused 
on replacing either individual domains (e.g. A) or modules (e.g. C-A-T) from other 
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regions of the same cluster, followed by non-native exchanges in place of entire 
subunits/genes, to result in reduced impact on linker regions and downstream 
interactions. Initial studies conducted by Nguyen et al., (2006), again using 
daptomycin as a trial system, demonstrated the ability to replace C-A-T from one 
module with that of another, leading to easily predictable and detectable changes to 
the produced peptide. These smaller alterations were better tolerated and, although 
resulting a slight decrease in yield, permitted novel compound production (Nguyen et 
al., 2006). Domain exchanges could be used in proximicin studies; Fiedler et al., 
(2008) demonstrated that the anticancer and antimicrobial abilities of the proximicin 
family was not uniform, for example only B exhibits antimicrobial activity. This added 
capability exhibited by proximicin B must be due to the presence of an additional 
terminal tyrosine, hence it is logical to assume that alteration of this would have a 
substantial effect on its resultant biological activity (Fig. 83c). Further, novel 
chemistry incorporation could be assessed, such as groups from the cgc gene cluster 
(Fig. 83c). An interesting application would be the introduction of the apparently 
surplus adenylation domains found in the neighbouring cluster (Fig. 83d). This would 
be an interesting avenue of research; the resultant proximicin derivatives would likely 
resemble previously produced compounds if ppb does represent a relic of a 
previously larger ancient SBC. This partial NRPS system, regardless of origin, was 
naturally selected and hence, it is logical to assume that it did/does aid in a 
competitive advantage to its producer – a completely novel action could be revealed 
upon its reconstitution. This approach could also be utilised to build on previous work 
aimed at proximicin/congocidine derivative synthesis, circumventing the previously 
outlined laborious synthesis task associated with the combinatorial chemistry 
approach (Wolter et al., 2009). Domains responsible for the addition of terminal 
groups could be swapped within and between clusters, resulting in similar derivatives 
by an increasingly facile method (Fig. 83c). More extreme modifications could be 
envisioned, including the domains responsible for the core heterocycle incorporation 
which could be exchanged with that of congocidine, producing furan/pyrrole hybrids 
(Fig. 83c). Similar heterocycle core modification studies have been done 
successfully, resulting in the production of activity-altered analogues (Nguyen et al., 
2006). This approach could be applied in the approach for the systematic altering of 
pyrrole groups in congocidine to furans, by replacing cgc3* with ppb120, and testing 
biological activity. For equivalent studies in proximicins, the unique level of 
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promiscuity exhibited by Ppb120 could be exploited. It was shown here that, despite 
low efficiency, the Ppb120 adenylation domain can activate a 2,4-disubstitued pyrrole 
in place of the native furan. Hence, simply feeding of the pyrrole precursors would 
likely result in the production of furan/pyrrole hybrids, without any cloning steps.  
 
5.3.4 Deleting or repeating modules  
Alterations to yield novel activity are not restricted to inserting chemistry possessed 
by other clusters or organisms; an alternative route to be explored is the alteration of 
the peptide chain length. Deleting core substrate-incorporating module has been 
shown to result in reduction of resultant compound ring size (Mootz et al., 2002), and 
the opposite – addition of modules – has led to the increased size (Butz et al., 2006) 
(Further explored - Appendix X). As we predict Ppb120 acts iteratively to add 
heterocycle groups, deleting this enzyme would likely terminate proximicin production 
entirely, and so this is not an application which could be used. Using the same 
notion, due to the repetitive addition of substrates, it would likely be more successful 
to determine the controlling mechanism for heterocycle addition and then alter this to 
result in additional precursor incorporation. As many biologically active compounds 
rely on the presence of heterocycles for their function, it would be interesting to 
establish whether additional heterocycles increase this activity? It has been 
demonstrated that chain length in congocidine production is controlled by competition 
between acetylation of the N terminal amine (thus preventing further condensation 
and peptide bond formation) and the further condensation reactions. No homologous 
enzyme is present in the ppb cluster - there is no obvious acetylase, so what controls 
chain length? One hypothesis could be that the donor portion of the condensation 
domains has such high specificity, resulting in the termination of furan addition at a 
certain chain length/ As mentioned, altering the chemistry of terminal groups present 
in proximicin could yield novel activity, the degree of this could be further investigated 
by increasing the number of additional terminal groups. The adenylation domain 
protein Ppb210, predicted to be responsible for tyrosine or tryptophan addition in 
proximicin B and C targeted. Incurring issues similar to ppb120, ppb210 if deleted 
would just result in proximicin A, and so not a new compound. However, it could be 
duplicated and the corresponding effect on activity measured (Fig. 83e).  
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Figure 83. Continues on next page. 
(b) 
(a) 
(c)
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Figure 83. Potential routes to novel heterocycle-containing compound production 
based on the exploitation of NRPS enzymes involved in proximicin and 
congocidine biosynthesis. (a) proximicin derivatives containing pyrrole heterocycle 
core in place of the furan, by deleting entire furan incorporating enzyme – Ppb120 – and 
replacing with pyrrole activating Cgc3*. (b) congocidine/ proximicin hybrids by, in 
addition to that described in (a), also the deletion of other genes responsible for the 
addition of other peptides e.g. ppb210 – proposed to activated tyrosine and tryptophan in 
proximicin biosynthesis and replace with Cgc18 known to incorporate GA. (c) A 
increasingly subtle approach to core heterocycle alteration – deleting just the A-domain 
region of ppb120 – not the entire protein as in (a). This would again produce 
furan/pyrrole hybrids; this is illustrated along with incorporation of other cgc genes 
involved tailoring of the congocidine molecule. (d) replacement of ppb120 A-domain with 
the A-domains present in the downstream cluster. (e) repetition of A-domains in different 
areas of the cluster, resulting in multiple precursor incorporation and increased peptide 
chain lengths. All reactions include a control of the deleted gene to ensure normal 
biosynthesis is reinstated. 
(e) 
(d) 
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5.3.5 Altering specific residues for novel activity 
The previously outlined methods to novel compound synthesis, despite steps taken 
in its reduction, are continually blighted by issues surrounding inactivity of pathways 
post modification. That reported here with issues regarding activity and solubility of 
just A-domain region of NRPS proteins, in combination with previous research, 
demonstrates the importance of surrounding regions to successfully create active 
native and hybrid NRPS assembly lines, respectively (Doekel et al., 2008; Yu et al., 
2013; Beer et al., 2014). Module-module linker regions play an important role in 
NRPS systems and overlooking their role typically results in truncated peptides as 
well as products lacking cyclization and other modifications (Butz et al., 2006). 
Continual extensive research into the relationships and conformational roles these 
linker regions play, is slowly building a picture describing the full extent of their 
function, and hence, how they can be manipulated. However, routes to novel 
compound synthesis not dependent on altering these regions would be 
advantageous. One potential tactic would be to utilise the knowledge garnered 
concerning substrate-specificity residues to design A-domains with either relaxed or 
altered activity, exploiting the pathway to implement the carefully chosen changes 
introduced. This would likely overcome previously encountered issues as 
modification all arise internally, with no direct contact with other modules and linker 
regions occurs. Previous work has utilised a similar initiative (Crusemann et al., 
2013; Kries et al., 2015); with Han et al., (2012) showing the directed evolution of a 
promiscuous enzyme towards a specific substrate by identifying likely successful 
mutations by comparing the A-domains active site with that of others which activate 
the desired substrate. Adenylation domain engineering via site directed mutagenesis 
has also been shown to alter the specificity of an A-domain to a completely different 
substrate; Kries et al., (2014) conducted an elegant experiment in which the core 
residues known to be responsible for adenylation domain specificity were mutated 
sequentially in the Phe-activating GrsA adenylation domain, resulting in complete 
alteration of its activity profile.  
 
The novel adenylation domain discovered and characterised here – Ppb120 – 
contains mutations in motifs residues previously considered to be intolerable, which 
undoubtable contributes to its ability to adenylate a unique heterocycle-containing 
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Figure 84. Potential routes for resolving binding residues responsible for novel 
heterocycle incorporation. (a) the active site of ppb120 adenylation domain (b) the active 
site of cgc18 adenylation domain. These two A-domains are very similar in two respects (i) 
the variant amino acid (yellow) residue structure – non-polar barrel (light blue border) ended 
with acidic (pink border) and polar groups (dark blue border) and (ii) the presence of a novel 
mutation in in-variant core residue Ser235. They differ in that Cgc18 contains an addition 
polar and non-polar group at the barrel end, marked with an asterisk. Despite their apparent 
structural similarities, these two A-domains have very different substrate specificities. To 
better understand the residues which dictate this difference, these two residues make 
attractive starting points. The substrate conferring residues, and their amount of variance 
across A-domains, is based on work done by Stachelhaus et al., (1999); A-domain structure 
in the style of work done by Challis et al., (2000). 
(a) 
(b) 
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precursor as exhibited here (Fig. 84a). This newly discovered ability for A-domains to 
maintain activity while possessing these changes in apparently core regions widens 
the potential pool of alterations which can be attempted. Introducing this mutation, 
along with other unique aspects of the Ppb120 binding pocket, into other A-domains 
may alter their activity resulting in novel NRP production. Initial research and 
comparison of the Cgc18 and Ppb120 A-domain specificity conferring code 
highlighted a potential residue which strongly supported activity towards 
heterocycles; this theory was refuted as the congocidine pathway was revised. And 
so it remains, which features in Ppb120 enables this novel activity, if not this Asp235 
mutation? Unfortunately, the similarly active Cgc3* AMP-binding protein does not 
belong to the NRPS sub family, and hence, the substrate specificity conferring core 
structure is not present, and so little can be garnered from the comparison of Cgc3* 
and Ppb120 due to the substantial deviation in homology. The in-depth analysis of 
the Ppb120 enzyme in chapter III highlighted two potential origins: an altered A5 
domains, and the presence of the Asp235 mutation. One possibility is that the ability to 
adenylate heterocycles is dependent on a cumulative mutational effect, facilitated by 
both of these interacting; it follows, that if we successively alter Cgc18 binding pocket 
(Fig. 84b) towards Ppb120 mimicry, both within the active site initially and then in the 
distant A5 region we should see the correlated change in activity towards heterocycle 
containing substrates. When analysing the binding pockets within Cgc18 and 
Ppb120, in addition to the unique Asp235 mutation, they both share a similar overall 
structure: a non-polar barrel ending with polar and acidic groups. The main difference 
being Ppb120 contains more polar groups, in comparison to Cgc18; is this disparity 
enough to dictate such a difference in activities? Or does the distal A5 region 
contribute a larger proportion of specificity conference than previously established? 
Point mutations in Cgc18 in regions both within the binding pocket and A5, in 
combination with activity studies would allow confirmation of this. This would inform 
what we currently know about the adenylation domain specificity conferring residues, 
and structure-activity relationships present within A-domain proteins; progressing the 
fundamental goal of gaining the ability to tailor an A-domain to any substrate 
incorporation: an invaluable instrument in the ‘molecular toolbox’.  
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5.4 Application of findings - Large scale implementation  
 
Substantial prospects of research described here build on work previously done, 
shedding new light on the once set boundaries of chemistry which can be introduced. 
Proximicin, and its furan containing derivatives, represent potentially limitless 
opportunities for novel antimicrobial and anticancer active compounds, not only in the 
ability to introduce heterocycle chemistry, but to inform mutational studies on A-
domain specificity boundaries. However, it is important that we don’t get hooked on 
the same snare as the ‘combinatorial chemistry’ approach of the late twentieth 
century which infamously yielded very little. We can gather from that futile era, that 
simple chemical novelty is not adequate, we need to utilise all the currently available 
scientific advances to produce intelligently designed compounds which we predict will 
have activity against a specific target. Implementing the previously discussed 
avenues for novelty, whilst incorporating information we now know about NRPS 
structure, residues dictating A-domain specificity, and quick activity assessment 
techniques, to create feedback loops to ensure effort is not exerted on research 
routes yielding novel but also biologically active and clinically applicable molecules. 
New scientific advancements need to be united into strategies specifically designed 
and integrated for this task. The novel enzymology uncovered here represents a 
potential source of one aspect of this, the novel chemistry by routes as outlined by 
the proposed route; however, this must be used in combined with other recent 
discoveries and advances to allow advancement to gain clinical applicability and 
relevance. Large scale antimicrobial compound searches are typically hindered in 
two ways: issues encountered in synthesising novel biologically active compounds, 
and the costs associated with screening many compounds. How the work described 
here can be integrated with cell free technology and intelligent design, into a system 
designed to uncover biologically active heterocycle compounds is outlined below 
(Fig. 85). 
 
5.4.1 Cell free synthesis approach 
Identifying compounds from bacteria with novel antimicrobial activity presents a 
paradox: moving biosynthesis into a heterozygous host for investigation into the 
enzymes and system responsible for production, results in host death, halting 
research. One approach to avoiding this issues, while optimally exploiting the 
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modular nature of NRPS systems, would be to purify each – potentially specifically 
modified -individual NRPS, along with associated enzymes and substrates, and mix 
them together in a cell-free system as outlined in Figure 85. Reliance on cell free 
systems is increasing as the technology improves in its ability; it is a widely used 
system which negates issues encountered with the complex interactions found in a 
whole cell. These systems have demonstrated a surprising ability to tolerate toxic 
compounds (Wang et al., 2011) and work under a large range of conditions (Zhu et 
al., 2014). Once synthesised by the manipulated NRPS enzymes in vitro, the 
produced compounds would be quickly assayed for either DNA binding or cell cycle 
arresting activity, coupled with intelligent-design feedback loops ensuring only 
increasingly active chemical scaffolds are built up. Exploiting NRPS synthesis to this 
end would produce a facile and rapid approach to novel compound production; 
bringing the ‘molecular toolbox’ representation into reality, by creating libraries of well 
characterised NRPS as well as tailoring enzymes, checked for activity and ready for 
cell-free novel compound synthesis. The combination of NRPS enzymes and hence 
hybrid compounds would give an almost limitless ability for biologically active 
compound elucidation.  
 
5.5 Learning from past mistakes: embracing novelty  
 
In the process of envisaging applications of the novel enzymology discovered here, a 
bottleneck in innovation was anticipated: novel enzymes being overlooked due to the 
currently strict rules dictating A-domain structure. Here, we have shown that a 
functioning A-domain exists outside of the confines previously established to dictate 
A-domain activity. Assessment of the likelihood of a Ppb120 representing an 
operational A-domain, prior to the work done here, would have most likely suggested 
this enzyme was incapable of activity. No substrates were predicted by any 
bioinformatical program, it contained mutations in core specificity conferring residues 
and an essential motif was missing. These assumptions rely on previous extensive 
work into other A-domains, multi-sequence alignments and the identification of 
regions which are present in all active, and lacking in all inactive enzymes. For the 
most part, this approach works well; that is until enzyme novelty is being sought. The 
paradox of isolating new enzymes based on the structure and homology of other 
identified members of the same class, directly exerts restrictions on the level of 
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enzyme novelty which can be recognised. In attempts to halt the looming resistance 
crisis, all novelty created by nature must be embraced; we must implement 
approaches with this concept at the forefront. Here we identify a completely novel 
enzyme, and its huge range of potential exploitation for new antimicrobial drug 
discovery; however, a singular new group is not sufficient. We need to gather and 
exploit as many of these unusual, non-conforming enzymes to be used in this 
application. And hence, the catch twenty-two: how do we identify novel enzyme 
chemistry in the huge expanse of DNA yielded from sequencing experiments, if by its 
very nature, we don’t know what we are looking for, or have any homologs to utilise?  
 
5.5.1 Informing future NRPS cluster bioinformatic searches  
Here, I propose a novel approach to NRPS identification: utilising the co-proteins – 
MbtH-like – to identify NRPS systems, in strict opposition to previous bioinformatical 
approaches utilising pre-established core domains and motifs. These previous 
methods implemented by modern bioinformatical programs, use homology to 
sequences established to be present in currently characterised NRPS enzymes, 
fundamentally preventing the identification of novel enzymes. MbtH-like proteins are 
proteins found to be present and essential in many NRPS systems, being involved in 
A-domain activity and solubility. Although the exact nature of their role has yet to be 
established, they all exhibit high homology with the first identified – MbtH – hence the 
name MbtH-like. I propose an A-domain identification search based on the presence 
of MbtH proteins within the cluster, rather than homology to pre-determined A-
domain residue confines. This would allow the potential discovery of completely 
novel substrate activating A-domains, conferred by their novel structure, to be added 
to the NRPS molecular toolbox and exploited for novel compound discovery. The 
necessity for this change in focus for A-domain identification can be demonstrated in 
the work here; using typical constraints, Ppb120 would have been considered an 
inactive enzyme and excluded from further development. This is supported by the 
revision of many previously bioinformatically formed biosynthetic routes after 
experimental analysis of the A-domains, demonstrating the extent we still have to 
learn about these complex enzyme schemes. The revision of the predicted 
congocidine, and hence the proximicin, biosynthetic route by Al-Mestarihi et al., 
(2015), was the consequence of an unrelated research attempt, and hence largely 
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accidental. If not established, the previously outlined routes would still have been 
considered accurate, when in reality the apparently similar pathways to congocidine 
and proximicin, occur in very distinctive ways, exploiting completely different 
enzymatic machinery. This is just a single example of how the novelty of an enzyme 
was overlooked, an issue which will only be magnified during large scale 
implementation of traditional bioinformatical approaches to novel NRPS discovery.  
 
Recent research, and that included here, is continually working towards 
understanding the role of these simple MbtH-like co-proteins; the core signatures 
they possess which determine and hence allow the prediction of the nature of their 
governance over NRPS systems are becoming increasingly apparent. The structure 
of an A-domains determines the chemistry of its potential activation pool, this 
uniquely strict reliance on structure-activity relationships makes it possible to assume 
that MbtH-like proteins will not possess the same extent of dependence on core 
domains. Simply put, A-domains must retain the ability to act on every potential 
substrate nature has to offer – a potentially limitless necessity for novelty; MbtH 
proteins have to only exert activity on this family of proteins, and so search homology 
Table 21. MbtH guided NRPS cluster identification. NRPS-gene clusters identified by 
NRPS-related gene motifs, and potential clusters identified by MbtH-guided searching. 
Many MbtH proteins have been putatively identified as phosphoglycerate mutases (blue) 
or unknown.  
* Verrucosispora maris AB18-032 
 261 
within MbtH proteins will likely not be as detrimental to uncovering novelty in 
comparison to the analogous approach in A-domains. To initially test the applicability 
of this approach, the V. maris AB18-032 genome was used as an example. The first 
hurdle to integration is the identification of core MbtH residues to allow for homology 
searches to be employed – a process which will likely take refinement and large 
scale multi-alignment analysis of MbtH proteins; for the preliminary work done here, 
regions of homology between currently identified V. maris AB18-032 MbtH proteins 
were assimilated. Previous annotation by traditional SBC techniques led to the 
identification of five NRPS systems; in comparison, the MbtH-focused approach 
uncovered 12, an additional 7 MbtH-core motif containing proteins (Table 21). These 
identified hypothetical MbtH-like proteins demonstrated a high level of homology with 
the MbtH-like protein shown to be essential in proximicin biosynthesis – Ppb125 – 
and the first identified MbtH protein, specifically in regions previously identified to be 
essential in MbtH function. These proteins must be associated with some 
biosynthetic pathway or have another function which would likely help us elucidate 
their function in NRPS systems, or their presence wouldn’t be maintained. A cursory 
look at these highlighted, identified a region of V. maris AB18-032 genome which 
were surrounded by other genes typically associated with SMB clusters such as – 
transport, tailoring and transcriptional regulator proteins. To further confirm the 
applicability of this approach, these regions require further investigation for even 
minor similarity to NRPS or other biosynthetic enzymology. As no currently available 
integrated bioinformatic tools actively search for novelty in A-domains, oppositely 
searching for homology to allow substrate prediction, this would have to be done by 
hand. Initially, genes should be prioritised on their sequence similarity to the ANL 
super family of enzymes – as for an A-domain to be active, it has to retain its 
adenylating activity justifying this ranking. And then other NRPS components 
searched for i.e. potential T, Te and C domains. Although this may highlight enzymes 
which have MbtH similarity randomly, or are a remnant of an ancient and now 
obsolete pathway, its ability to identify potentially unique A-domains for novel 
compound production, outweighs these issues. Its application is not limited here, as 
further investigation into the MbtH-like proteins may give insights into the presence of 
multiple, or currently unidentified proteins. One example of this is the identification of 
an MbtH protein downstream of the NRPS-M cluster (Table 21)– if this cluster was to 
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Figure 86. Potential homology between MbtH proteins and Phosphoglycerate 
mutases (PGM). (a) Multiple sequence alignment of characterised PGM enzymes and 
MbtH proteins, as well as those identified here: moderate similarity (yellow) and low 
similarity (yellow). (b) reactions catalysed by PGM and adenylation domains know to be 
helped by MbtH-like proteins. (c) potential role of MbtH based on PGM similarities – 
potentially adding an additional phosphate group creating a lower energy intermediate –
pushing the forward adenylation reaction.  
(a) 
(b) 
(c) 
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be investigated, issues would likely ensue regarding A-domain activity and solubility 
due to the corresponding MbtH-like protein not being accounted for.  
 
It is not yet established the exact role which is played by MbtH-like proteins, only 
their requirement for in some NRPS-catalysed synthesis is proven. It is hence 
interesting to note that of those MbtH-similar enzymes which have been previously 
given a putative function, they are typically phosphoglycerate mutases (PGM) (Table 
21). MbtH-like proteins and this family share moderate sequence homology, across 
entire sequences this is typically ~20%, however, these the similarity is seen in 
distinct regions maintain > 60% homology, opposed to being across the entire protein 
– suggesting some homologous structures (Fig. 86a). Phosphoglycerate mutases are 
an extremely highly conserved enzyme family which catalyse the isomerization of 
phosphoglycerate substrates (Fig. 86b), a process essential for glucose metabolism. 
It is interesting to note that this reaction involves the movement of a phosphate group 
within a molecule by first adding a phosphate and then removing another, which 
occurs in the same way as adenylating activity – the addition of a phosphate group in 
the form of a phosphonate – ADP. Could MbtH proteins be involved in adding a 
second phosphate group, similar to phosphoglycerate mutases, to produce a more 
reactive, lower activation energy or more suitable substrate for adenylation? If you 
subscribe to the ‘addition-elimination’ mechanism of phosphoryl transfer, MbtH- like 
proteins could partake in a similar reaction to its similar PGM proteins. Working as a 
catalyst to produce a pentavalent intermediate during adenylation activity, acting as a 
nucleophile resulting in a species which occupies an energy valley – pushing the 
forward adenylation reaction (Fig. 86c). Although completely hypothetical, this could 
explain why adenylation domain activity is lowered/terminated when their MbtH 
counterparts are not present; it does not, however, explain their effect on A-domain 
solubility. This information, along with further homology searches may give further 
insight into the role these elusive proteins play. MbtH-like proteins may have been 
subjected to a similar bottle-neck affect as described here in NRPS systems – strict 
confines on what symbolises an NRPS protein has hindered novel enzyme 
discovery. The same could be said for MbtH-like proteins – using stringent homology 
searches to identify other MbtH proteins we may be inadvertently selecting against 
the discovery of those which represent early diverging proteins – those dissimilar to 
what we consider MbtH-like, but descriptive of a putative function, such as PGM. To 
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harness NRPS specific novelty, these essential enzymes and their function require 
increased investigation and their similarity to PGM enzymes represents a suitable 
starting point. It is widely accepted, since the genome sequencing revolution, that 
microbes possess the ability to produce infinity more SM and other biologically active 
compounds than once predicted; the approach outlined here presents an innovative 
means of identifying these unresolved clusters and hence, harnessing their activity.  
 
5.6 Application of findings – Native Cas exploitation from editing target 
species 
 
Gene editing using the CRISPR/Cas system was reported here for the first time in 
the Micromonosporaceae family of Actinomycetes; this proof of application study 
demonstrated the effective deletion of the pigment conferring genes present in 
Verrucosispora sp. str. MG37. Although successful for this particular phenotypically 
observable gene, problems regarding off-target Cas activity resulting in the widely 
reported ‘cas toxicity’, prevented further application of the technique in 
Verrucosispora spp., for more precise gene editing attempts. As previously discussed 
in Chapter 4, one way of rectifying this issue would be to exploit the CRISPR/cas9 
system found in the organism which is the target for gene editing. This is based on 
the theory that this native system must have acquired a mechanism to avoid affecting 
host DNA. The potential development of this approach would allow the application of 
a CRISPR/cas system with increased fidelity for specific use in non-model, 
genetically complex organisms, such as Verrucosispora species.  
 
5.6.1 Native CRISPR/Cas exploitation  
The Verrucosispora maris AB18-032 genome presents only a single area displaying 
characteristic features of a CRISPR/Cas loci, denoted in Uniprot as 
VAB18032_16190 – VAB108032_16250 (UniProt, 2017). This region contains 
multiple Cas-related genes spanning Cas I-III families; previous native application of 
this system is represented by 41 foreign spacers. The Cas proteins present show no 
conserved identity with spCas9 (<8%), the Cas protein most widely exploited for 
CRISPR/Cas applications, this divergence suggests that Verrucosispora spp. Cas 
(vmCas) proteins have evolved a level of specialization to this high GC, complex 
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Figure 87.  Potential exploitation of native CRISPR/Cas systems for more efficient 
gene editing. (a) Multiple sequence alignment of Cas genes from both type I and II 
systems, from Micromonosporaceae family in comparison to the model Cas protein – 
spCas9, showing the high variance. (b) Workflow of native cas genes for gene editing: 
they still rely on the synthesis of a synthetic guide RNA (blue arrows) but differ from 
other approaches as they (i) increase the expression of native cas genes or (ii) add the 
native cas genes on a plasmid under the control of a strong promoter. Alternatively, if 
native systems fail to work, (iii) the closest relative which is identified as an alien species 
should be used – this could be determined by identifying the species already present in 
the CRISPR loci.  
(a) 
(b) 
 266 
species. This is supported by work shown here, as when sgCas9 is employed in V. 
maris AB18-032 it results in Cas9 induced toxicity. To further understand the 
evolution of novel cas genes, those present in Verrucosispora spp., and other 
Micromonosporaceae family members were compared to that of spCas (Fig. 87a); 
this demonstrated a very high level of sequence divergence in regions known to be 
involved in Cas activities. This was demonstrated in Cas genes even in the same 
subclass as spCas9. From this we can predict that the high level of cas toxicity 
exhibited in Verrucosispora spp., is due to the lack of native pathways which 
recognise the foreign spCas9 protein to allow prevention of off-target endonuclease 
activity. To circumvent this, one approach would be to lower the overall concentration 
of heterologous Cas proteins, however this would, although favourably lowering off-
target Cas activity, also detrimentally affect targeted endonuclease action and hence, 
gene editing efficiency. Because of this paradox, I outline here a novel method in 
Figure 87b, of utilising the hosts own Cas proteins, in addition to synthetic 
components such as sgRNA, to allow efficient gene editing with the expectation that 
native Cas proteins will not act on host DNA to such an extent due to DNA protection 
pathways. This would require identifying the native cas genes within the host, then 
either increasing their expression by altering their promoter control or by placing it on 
a CRISPR/Cas designed plasmid in place of the spCas9 gene. One potential issue 
emerges when developing this application: native DNA protection pathways may be 
so effective that the native Cas protein will not act again its own DNA. To resolve 
this, there are two potential approaches: (i) identifying the closest relative included in 
the foreign DNA regions present in the CRISPR array as this demonstrates that the 
host recognises this as foreign and hence it must be dissimilar; or (ii) more simply, 
find the closest relative with a type-II cas gene characterised, and test for activity to 
confirm they have diverged enough. Although laborious to set the system up, once 
established this could be applied to all gene editing research in a given bacterial 
family or species, depending on the level of divergence. I propose this idea of finding 
‘the sweet spot’ between reduced Cas toxicity as a result of off-target DNA 
degradation, and maintaining Cas endonuclease activity towards similar/native DNA. 
I think that this novel approach is worth investigation to further the somewhat lacking 
research into bacterial CRISPR/Cas application.  
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5.7 Conclusions  
 
The requirement for biologically active novel chemistry compounds has never been 
greater; this exerts a pressure on scientific fields to begin yielding potential antibiotic 
drugs on a large scale. To accomplish this, we must pool all current technological 
innovations to ensure that the most efficient and effective approaches are being 
utilised. Microorganisms have developed the ability to defend themselves against 
competitors, utilising compounds refined over millennia of evolution; previously, they 
have been the source of much of what we consider modern medical compounds. 
Over time, attention on these compounds has dwindled due to apparently more 
financially lucrative research avenues which have yielded very little. Increased 
emphasis on returning to the search of novel compounds of microbial origins, has 
occurred, differing from previous approaches in the utilisation of modern techniques 
to develop the process. 
 
Here, we demonstrate a facile pipeline starting from the potentially clinically 
interesting NRPS-secondary metabolite, to whole genome sequencing, assembly 
and annotation to allow the identification and characterisation of the responsible 
metabolic pathway. In doing this, novel enzymology was discovered, demonstrating a 
contradiction to the previously established confines dictating NRPS A-domain 
activity. To the best of our knowledge, no other A-domain has the ability to activate a 
2,4-disubstituted heterocycle group as shown by Ppb120; likely owing to the non-
conventional core residue, namely the absence of A5, present in know activity 
conferring domains. The significance of this research is two-fold: (i) it demonstrates 
the ability to sequence, assembly and annotate a microbial genome, along with novel 
SMC identification, in a small scale, academic environment effectively showing that 
these research applications can be put in the hands of small laboratories; in addition 
to outlining and refining a freely accessible bioinformatical pipeline for this application 
(ii) the identification and characterisation of a truly novel adenylation protein which 
has the ability to be involved in production of almost unlimited novel chemistry 
containing novel compounds. By assessing the applicability of NGS platforms, and 
their associated data handling shortcomings, in an academic setting and its ability to 
yield attractive findings, will hopefully inform other similar research in this area. The 
approach used here, as well as all the future application of these findings, present an 
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easily employable approach to the much required clinically important compounds 
discovery. It has already been established that microbes are likely the best source of 
this, requiring refinement of current sequencing and assembly methodology tailored 
to this application; here we outline such an approach. The subsequent research 
focusing on NRPS pathway resolution provides a framework for future similar work; 
these enzymatic clusters have already shown their ability to yield clinically important 
compounds and represent a suitable primary target when whittling down the many 
SMCs revealed following WGS, to yield a cache of likely the most interesting, to 
investigate. Approaches described here, including the luciferase assay for A-domain 
activity and MbtH-guided NRPS identification, could represent important 
developments to catalyse this approach to new antibiotic discovery, into large scale 
implementation.  
 
Natures ability to produce compounds with completely novel chemistry and biological 
action is unparalleled; it will always greatly surpass man’s power and capability to do 
the same. Combinatorial chemistry approaches have failed: we do not possess the 
ability to conjure up a solution to the looming antibiotic crisis, instead focus must 
begin to exploit these microbial foes which pose such a great risk to our medically 
competent civilizations. The research here represents the first step in this endeavour, 
a path which, optimistically, other research groups and the pharmaceutical giants will 
follow in, before antimicrobial resistance thrives to a level currently on the horizon, of 
no return.   
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Appendix D 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1. Overview of integrated steps used during assembly of reads by 
SPAdes. SPAdes is a combination of two programs – BayeHammer and SPAdes. 
BayesHammer is integrated to allow further error-correction and quality assessment of 
reads. Other QC and trimming programs were used separately, for sake of inclusivity the 
processing steps undertaken by this integrated program is stated.  
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Figure F1. Michaelis-Menten kinetic parameters of Ppb120_AT catalysed 
adenylation of pyrrole derivatives – compound 4 and 6. Error bars represent SE.  
